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ABSTRACT 
 
REBECCA ANNE HUNTER: Electrochemical Detection of Nitric Oxide  
from Biological Systems 
(Under the direction of Mark H. Schoenfisch) 
 
 Nitric oxide (NO) is known to be involved in a number of physiological processes, 
including the immune response. As such, its role in severe infection and sepsis has been 
investigated, but previous measurement techniques have relied on complicated 
instrumentation or the quantification of NO byproducts (e.g., nitrate and nitrite). Herein, the 
fabrication of a microfluidic amperometric sensor for the direct detection of NO in whole 
blood is described. These sensors were used to evaluate the potential of NO and nitrosothiols 
(a stable transporter) as prognostic and/or diagnostic biomarkers for infection and sepsis. 
 The microfluidic devices facilitated the selective electrochemical measurement of NO 
in small volumes of blood at the point-of-care, with adequate sensitivity and limits of 
detection achieved in buffer, wound fluid, and whole blood. A green (530 nm) light-emitting 
diode was coupled to the device to enable photolysis of S-nitrosothiol species with 
subsequent NO detection. While inefficient photolysis prevented the measurement of 
nitrosothiols in whole blood, detection in serum was achieved. 
 A porcine model of sepsis permitted monitoring of temporal changes in NO and 
nitrosothiols throughout disease progression. While increases in NO were observed 
concurrently with other indicators (e.g., increased 
 iv 
accumulation of nitrosothiols was observed hours prior to the onset of other symptoms, 
despite a dramatic drop in the circulating white blood cells that produce NO. 
 A murine model of sepsis was utilized to understand the effects of bacterial virulence 
and immune suppression on NO during an infection. A non-lethal pneumonia with 
Pseudomonas aeruginosa resulted in elevated NO levels at 72 h that returned to baseline 
concentrations after 1 wk. A more virulent bacterium, Klebsiella pneumoniae, resulted in 
much greater increases in NO, reflecting its pathogenicity. Conversely, in a murine model of 
post-burn immune suppression and infection, blood NO concentrations remained unchanged 
relative to uninfected animals despite increased infection severity. 
 Nitric oxide-selective microelectrodes were also used to study NO release at the 
single cell level, from both immune cells and neurons. Upregulation of carbon monoxide 
production by the macrophages was demonstrated to inhibit their ability to release NO 
following immune stimulation. Additionally, the concentration and kinetics of NO release 
from neurons were determined. 
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CHAPTER 1. PHYSIOLOGICAL SIGNIFICANCE OF NITRIC OXIDE AND ITS 
MEASUREMENT WITHIN BIOLOGICAL SYSTEMS 
 
1.1 The ubiquitous roles of nitric oxide 
Investigation into the physiological roles of nitric oxide (NO) has expanded 
immensely since the realization that the endothelial derived relaxation factor was, in fact, 
likely to be NO.1 Since that time, the pivotal role of this gaseous free radical species has been 
recognized in numerous biological processes including the immune response to infection,2-4 
vasodilation,5 would healing,6,7 and cancer biology.8 Nitric oxide is known to impart 
physiological activity through binding to the heme center of soluble guanylyl cyclase (sGC), 
an enzyme involved in the formation of the second messenger cyclic guanosine 
monophosphate (cGMP). A multitude of physiological processes are linked to cGMP, 
including vascular smooth muscle relaxation, platelet activation, and protein kinase signaling 
cascades.9 As such, the physiological roles of NO are far-reaching. 
Despite the breadth of knowledge that has been gained since its discovery, much 
remains unknown about NO, especially with regard to absolute concentrations, its role in 
specific disease states, and how its dysfunction can be corrected for. As such, new detection 
methodologies are sought after to further the understanding of this small but immensely 
important free radical species. 
 2 
1.1.1 Nitric oxide in the immune system 
Within the immune system, NO is produced by specific cells (i.e., 
monocytes/macrophages, neutrophils, eosinophils) by the inducible isoform of nitric oxide 
synthase (iNOS), an enzyme whose expression is regulated by complex cascades of 
cytokines from different immune cells.4,10 All isoforms of NOS (i.e., inducible, endothelial, 
neuronal) produce NO from L-arginine, which is oxidized to produce N-hydroxy-L-arginine. 
Further oxidation of this intermediate yields both L-citrulline and NO. Stimulation of iNOS 
by cytokines or components of the bacterial cell wall allows for continuous release of NO for 
up to 5 d, as long as the stimuli remains present and the intracellular L-arginine supply is not 
depleted.4 When released by these cells, NO acts as a signaling molecule and may have 
antimicrobial/anti-tumor (pro-inflammatory) activity or immunosuppressive (anti-
inflammatory) effects, depending on the concentration released. For example, the presence of 
bacteria within the body will signal an upregulation in iNOS production and subsequent 
release of NO from immune cells will cause killing of nearby microbial organisms.3,4,11-13 
The bactericidal properties of NO are attributed to both nitrosative and oxidative stress.14 For 
example, the reaction of NO with oxygen produces toxic byproducts such as dinitrogen 
trioxide, which initiates nitrosation of protein thiols and DNA deamination. Nitric oxide may 
also react with superoxide (a radical product of normal cell respiration) to yield peroxynitrite. 
Buildup of peroxynitrite results in lipid peroxidation and membrane damage.15-17 While 
eukaryotic cells have evolved mechanisms for preventing buildup of such toxic byproducts 
(e.g., production of superoxide dismutase to scavenge superoxide and limit peroxynitrite 
accumulation), excessive inflammation and NO release may still damage host tissue. For this 
reason, NO is believed to play an important role in disease states that are caused by severe 
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infection and/or injury.18,19 While NO may be elevated to dangerous levels in the presence of 
high concentrations of bacteria, low NO concentration may indicate immune suppression 
and/or an insufficient response to infection.  
Nitric oxide may also serve an opposing role in the immune system as an anti-
inflammatory molecule or immune suppressant, providing a mechanism to defend the host 
from itself. For example, NO suppresses T helper cell proliferation and cytokine production, 
thus limiting the chronic immune response.20 Neutrophils, which are involved in the body’s 
non-specific response to infection, while stimulated by low NO concentrations, may 
experience inhibited adhesion to endothelial cells when exposed to high concentrations of 
NO, thus hindering their ability to traverse the vascular wall and migrate to local sites of 
infection.21 Further, NO has been observed to inhibit mast cell degranulation.22 While these 
negative feedback mechanisms help to prevent potentially dangerous chronic inflammatory 
states, immune dysfunction is still prevalent in severe diseases such as sepsis. 
1.1.2 Nitric oxide in the nervous and cardiovascular systems 
Unlike the immune system, NO in the nervous and cardiovascular systems is 
generally not produced by an inducible NOS isoform. Instead, it is generated by NOS 
isoforms that are triggered by increases in intracellular calcium: endothelial (eNOS) and 
neuronal (nNOS) nitric oxide synthase for the cardiovascular and nervous systems, 
respectively.23-25 Small, transient increases in intracellular calcium concentrations will thus 
cause short-lived production of NO (nM amounts within 10 min),26 in contrast to the 
sustained production resulting from iNOS stimulation. 
The physiological importance of NO was first realized within the cardiovascular 
system, where it is now known to regulate vascular tone and prevent platelet and leukocyte 
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adhesion.5,23,27,28 Due to its function as a blood pressure regulator, reduced bioavailability of 
NO may be of importance in a number of cardiovascular diseases.29 Naseem reported that 
reduced NO release from the endothelium may lead to more rapid progression of diseases 
such as atherosclerosis, where adhesion of platelets and leukocytes contribute to buildup and 
blockage along the vascular wall.29 Additionally, hindered NO production could lead to 
decreased angiogenesis. Conversely, overproduction of NO would cause dangerous systemic 
vasodilation. 
Within the central nervous system, NO is involved with general neurotransmission, 
thermal regulation, hormone release, and sleep cycles.30-33 Nitric oxide is also known to play 
a key role in long-term potentiation (memory formation).34 Studies by Rehder et al. have 
indicated the importance of NO in neuronal development, as it regulates the extension of 
neuronal growth cone filopodia.35,36 Nitric oxide produced by nNOS within the peripheral 
nervous system is also involved with smooth muscle relaxation.25 Similar to the 
cardiovascular and immune systems, dysfunctional NO production within the nervous system 
can contribute to disease. Inflammation and the resulting NO production contributes to 
numerous neurodegenerative diseases, including Alzheimer’s, Parkinson’s, amyotrophic 
lateral sclerosis, and multiple sclerosis.37 
1.2 Nitrosothiols as physiological transporters of nitric oxide 
Nitric oxide is a free radical gaseous species with a half-life ranging from 
milliseconds to seconds depending upon its concentration and the medium in which it 
exists.38 As such, its lifetime in the body, most notably in blood, is believed to be as short as 
2 msec due to the presence of scavengers (i.e., proteins and oxygen).39 Conversely, S-
nitrosothiol species, originally known as thionitrites, are more stable biological transporters 
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of NO and transducers of NO bioactivity. Nitrosothiols have been shown to exhibit effects 
similar to NO in vivo, including smooth muscle relaxation40 and reduced platelet adhesion.41 
Unlike free NO radicals, nitrosothiols do not react directly with metalloproteins (e.g., 
hemoglobin) or other radical species (e.g., superoxide), thus increasing their lifetime and 
preventing the buildup of toxic species such as peroxynitrite. 
S-nitrosothiols are synthesized on the bench top via a reaction between thiols and 
species such as nitrous acid, dinitrogen trioxide, dinitrogen tetraoxide, or nitrosyl chloride.42 
In vivo, nitrosothiols may be formed via multiple reactions involving NO and/or its 
byproducts with the thiols of proteins (e.g., albumin and hemoglobin), amino acids (e.g., L-
cysteine), and other small molecules (e.g., glutathione).43 Blood plasma alone contains ~600 
µM thiol “groups”, including ~500 µM albumin and 20–45 µM low molecular weight thiols 
(i.e., L-cysteine and glutathione).44 Despite it’s greater size and abundance, albumin contains 
only one free cysteine residue at which nitrosothiols form. Though once considered a major 
scavenger of NO, Stamler et al. demonstrated the ability of hemoglobin to accommodate 
nitrosation of its β-93-cysteine group, thus conserving the biological reactivity of NO by 
forming S-nitrosohemoglobin.45 Nitric oxide stored in this manner may later be released by 
multiple mechanisms, most notably under hypoxic conditions.46-48  
As shown in Figure 1.1, a common route of nitrosothiol formation requires a mixture 
of NO, oxygen (O2), and a thiol.49 One of many nitrosothiol formation pathways relies on the 
oxidation of NO by O2, where a peroxynitrite radical is generated and then further reacts with 
NO to produce nitrogen dioxide (•NO2). At normal physiological concentrations of NO (i.e., 
<100 nM), this reaction is unlikely as it may take hours to proceed.50 In the event that this 
reaction does occur, •NO2 reacts directly with a thiol to form a thiyl radical, which can 
 6 
subsequently combine with NO to form nitrosothiol. Alternatively, •NO2 may react with 
another molecule of NO to form dinitrogen trioxide (N2O3), which directly nitrosates a thiol 
species. In the event that NO autooxidation does not take place, NO reacts directly with a 
thiol, forming an aminoxyl radical that can be oxidized to form nitrosothiol. Evidence 
suggests that copper and iron ions can also generate S-nitrosothiols. The proposed 
mechanisms involve either a one-electron oxidation of a thiol (with subsequent reaction of 
the thiyl radical with NO) or the formation of a complex between NO and the metal.51,52 This 
mechanism is complicated by the fact that these same metals also initiate nitrosothiol 
decomposition. Within cellular compartments, transnitrosation is important in the formation 
and function of S-nitrosothiols.53 In this reaction, a thiolate anion attacks a nitroso nitrogen, 
allowing for transfer of the S-nitroso functional group as shown below: 
RS- + Rʹ′SNO ⇌ RSNO + Rʹ′S- 
Of note, transnitrosation rates are not equal between all thiols, and may vary between 0.1 and 
500 M-1s-1.50  
While S-nitrosothiols species are considered stable relative to the lifetime of free NO 
in vivo, numerous mechanisms exist by which nitrosothiols decompose to release NO. As 
shown in Figure 1.2, thermal and photolytic cleavage are two decomposition mechanisms 
that result in hemolytic cleavage of the S–N bond, generating a thiyl radical and gaseous 
NO.54 While trace metals such as copper have been implicated in the formation of 
nitrosothiols in vivo, they are also closely linked with their catalytic decomposition. 
Copper(II) may be reduced by trace thiolate, with the resulting copper(I) reacting with 
nitrosothiols to liberate NO upon returning to its oxidized state. 54 As mentioned previously,  
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Figure 1.1 Routes of nitrosothiol formation in vivo requiring nitric oxide, oxygen, and 
glutathione. 
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Figure 1.2 Routes of decomposition of nitrosothiols. 
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transnitrosation between a nitrosothiol and free thiols is an alternative and biologically 
relevant route of decomposition. 
As the formation and decomposition of nitrosothiols in vivo are so closely linked with 
NO-dependent pathways, a major goal has been to study their concentrations within cells and 
tissues. Within mouse macrophage cells (RAW 264.7), S-nitrosothiol levels are reported to 
be ~5 pmol mg-1 protein.55 Reported basal concentrations of nitrosothiols in blood plasma 
range widely, from 1 nM in rats56 to µM levels in humans, depending on the measurement 
technique utilized.57 Certain disease states lead to even greater levels of nitrosothiol 
formation and accumulation. In one example, nitrosothiol levels were observed to increase 
from 300 nM in healthy subjects to 4 µM in pneumonia patients.58 
While the roles of both NO and nitrosothiols in the body are apparent, much remains 
unknown regarding specific pathways and mechanisms of action. As such, techniques to 
accurately monitor small concentration changes and pinpoint specific protein targets are 
critical for future studies. 
 
1.3 Detection of nitric oxide and nitrosothiols 
1.3.1 Spectroscopic detection of nitric oxide 
To date, NO can be measured in a number of ways, each with distinct advantages. 
Spectroscopic methods (i.e., absorbance, fluorescence, chemiluminescence, and electron 
paramagnetic resonance) rely on the indirect detection of NO via byproducts of reactions 
with other chemicals or adducts formed between NO and other compounds.59 First described 
in 1864,60  the Griess assay, formally know as the diazotization assay, allows for the 
quantification of total NO concentrations via nitrite analysis. Nitrite is a stable byproduct of 
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the reaction of NO with oxygen in aqueous media, and upon reaction with sulfanilamide and 
N-(1-napthyl)ethylenediamine an azo dye is formed. Absorbance spectroscopy is then used to 
relate the concentration of dye to the concentration of nitrite (and thus NO that was in 
solution). Although inexpensive and easily obtained commercially, the Griess assay only 
provides a limit of detection of ~0.5 µM in buffer solution and is mainly useful for 
determination of NO totals.59,61,62 The lack of real-time information and poor limit of 
detection of this assay preclude its use for analysis of biological solutions. 
In contrast, chemiluminescence detection, a more costly method due to 
instrumentation requirements, measures NO directly via reaction with ozone.63 This reaction 
produces an excited state nitrogen dioxide, which emits a photon upon relaxation to the 
ground state. Nitric oxide-release kinetics may be determined directly from materials in 
solution, as the NO is immediately transported from solution to the detector by an inert 
carrier gas. As an alternative, nitrate and nitrite in solution can be measured following their 
reduction to NO. These spectroscopic techniques generally require complex instrumentation 
and thus are not amenable to in vivo applications. Additionally, their use with biological 
media (e.g., cell culture solutions and blood/serum) is limited due the need to purge solutions 
of oxygen. 
1.3.2 Real-time amperometric detection of nitric oxide 
Due to NO’s redox activity, electrochemistry is also commonly used to quantify NO 
in a variety of formats (e.g., direct oxidation via amperometry) and even at the single cell 
level due to the ability to miniaturize sensors.62 Currently, electrochemical methods for 
detecting NO remain the most pliable for biological applications given their adaptability and 
capacity to measure real-time release. Compared to other techniques, the electrochemical 
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measurement of NO provides some distinct advantages, including superior spatial and 
temporal resolution, the potential for low limits of detection, and the ability to tune 
selectivity and sensitivity by changing the potential applied or modifying the electrode with a 
catalyst and/or permselective membrane.59,64 Electrode platforms of varied shapes and sizes 
can be fabricated for the amperometric detection of NO, providing excellent spatial 
resolution when required. 
 Despite the simplicity of this measurement technique, a number of important 
considerations must be made to carry out accurate physiological measurements. The 
sensitivity, limit of detection (LOD), and linear response range of the sensor are especially 
important given the varied, but generally small concentrations of NO (i.e., picomolar to 
micromolar) that exist physiologically. For an amperometric measurement, selectivity is 
equally important given the number of potential electroactive interferents that may be present 
in vivo (e.g., nitrite, nitrate, hydrogen sulfide, ascorbic acid, dopamine). Due to its reactive 
nature, not all the NO released from a system may reach the electrode surface to be detected. 
As such, the size and shape of the electrode must be carefully considered for each 
application. For example, measurement of NO from a single cell adhered to a surface would 
best be achieved by placing a small electrode (similar in size to the cell) directly above the 
cell, thus limiting the distance traveled and the amount of NO that is allowed to diffuse 
and/or react without being detected. Despite such operational challenges, a number of sensor 
systems have been developed and demonstrated to accurately measure physiological levels of 
NO. 
Regardless of sensor design, each transducer must include a surface at which to 
oxidize or reduce NO and a means of excluding potential interferents (i.e., species that are 
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oxidized/reduced at a similar potential). The most common electrodes are platinum,2 carbon 
fiber,65 glassy carbon,66 and gold.67 Platinum is perhaps most widely utilized as it can be 
coated with small platinum black particles to increase microscopic surface area, thus 
significantly improving sensitivity and detection limits.68-70  
Amperometric measurements in biological systems are made even more challenging 
by a number of interferents that may be present in whole blood, plasma/serum, or 
cell/bacteria culture medium. Such species are electroactive at working potentials similar to 
or lower than NO (i.e., +0.7–1.0 V for oxidation). Common biological interferents and their 
concentrations are given in Table 1.1. The membranes utilized for enhancing selectivity 
toward NO vary significantly depending on other sensor characteristics. Most selective 
membranes rely on exclusion of interferents based on size and/or charge. For example, 
Nafion® is a widely used hydrophobic, cation exchange fluoropolymer that is applied via a 
dip-coating process and excludes interferents based on charge.71 While applied in a manner 
similar to Nafion®, xerogel-based permselective membranes allow for greater control of 
hydrophobicity and porosity. Shin et al. first described the use of xerogels derived from 
fluorinated alkylalkoxysilane precursors to maximize selectivity of electrodes toward 
NO.72,73 Additionally, xerogels may be applied to any sensor geometry (i.e., disk type, 
conical, planar) via dip coating, casting, or spray coating application of the sol.74 To exclude 
interferents based on size, Ferreira et al. electropolymerized o-phenylenediamine (o-PD) onto 
carbon film electrodes that had previously been dip coated with Nafion®.75 This treatment 
allowed for a 30:1 selectivity for NO over interferents tested (e.g., nitrite and ascorbic acid), 
but was not particularly effective against small cationic species (e.g., dopamine and 
serotonin). In another study, Kato et al. utilized cross-linked Langmuir-Blodgett (LB) 
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Table 1.1 Common biological interferents and their basal concentrations in vivo. 
Interferent In vivo concentration Tissue/media Reference 
Hydrogen sulfide < 100 nM blood 76 
Ammonium (pH 7.4) 30 µM blood 77 
Nitrite 176 nM blood 78 
Uric acid 254 µM serum 79 
Ascorbic acid 43 µM serum 80 
Acetaminophen 130 µM plasma 81 
Ammonia (pH 11) 35 pM blood 77 
Peroxynitrite 
(ONOOH/ONOO-) 30 pM endothelium 82 
Carbon monoxide 0.5–1.5 µM mouse kidney 83 
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films of oligo(dimethyl-siloxane) copolymer as permselective coatings, allowing for a 25:1 
selectivity for NO over nitrite while maintaining sensitivities to NO that were similar to bare 
electrodes.84 An alternative means of enhancing selectivity without coatings is the use of 
nanopore electrodes. Shim et al. developed a nanopore-platinized platinum electrode for NO 
detection by electrochemically etching a platinum nanodisk and subsequently depositing 
layers of porous platinum black onto the disk.85 The inside of the pore was then silanized to 
increase hydrophobicity and further enhance sensitivity and selectivity.  
While all electrochemical NO sensors utilize a specific working electrode material 
and selective membrane, varied sensor styles can also be considered depending on the 
application. The Shibuki-style sensor, based on the original oxygen electrode developed by 
Clark et al.,86 is comprised of a micropipette which contains both the working (platinum) and 
reference (silver) electrodes. This micropipette is then sealed with a gas-permeable 
membrane and filled with electrolyte solution.87 As the construction of the Shibuki sensor 
limits its amenability to miniaturization, new sensors were designed to avoid the requirement 
of an internal filling solution. Solid permselective electrodes allow for direct modification of 
the electroactive area with a hydrophobic membrane, typically via a simple dip coating or 
casting process. This advancement accommodates the use of electrodes of varied shapes and 
size. Designed in a manner similar to the solid permselective electrodes, solid catalytic 
sensors were created to improve the efficiency of the oxidation or reduction of NO at the 
electrode surface and/or allow for a reduction in the working potential. Such electrodes 
usually include a mediator capable of catalyzing the electrochemical process directly on the 
electrode surface or within a permselective membrane.88  
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Each of the aforementioned sensor designs is capable of detecting NO via its 
oxidation or reduction. While electrooxidation is primarily used, some reports of NO 
measurement via electroreduction exist.89-91 This reaction proceeds via the following two 
electron process at potentials ranging from -0.5 to -1.4 V vs. Ag/AgCl:88 
2NO + 2e- ! N2O2- 
Of note, oxygen is a major interferent in this process as it is also reduced at -0.6 V vs. 
Ag/AgCl via the process given below: 
O2 + 4H+ + 4e- ! 2H2O 
While most other interfering species are avoided when utilizing electroreduction, reduced 
sensitivity is a caveat. Furthermore, electroreductive NO sensors do not operate efficiently at 
physiological pH and are characterized by poor detection limits (i.e., µM range).92 Improved 
sensitivity is possible by coating electrodes with complexes that catalyze the reduction of NO 
(e.g., chromium complexes,93 hemoglobin94). Despite these few reports of NO detection via 
electroreduction, oxidation of NO remains the most common means of detecting NO 
electrochemically. 
Nitric oxide is readily oxidized at potentials ranging from +700–900 mV vs. Ag/AgCl 
reference via the three-electron process below:95,96 
NO ! NO+ + e- 
NO+ + OH- ! HNO2 
HNO2 + H2O ! NO3- + 2e- +3H+ 
Conversion of the nitrosonium cation (NO+) to nitrite is irreversible.64 Due to the 
aforementioned presence of interferents (Table 1.1) and the relatively high working potential, 
the use of a selective membrane is required for sensors that utilize this process to detect NO. 
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Catalytic oxidation of NO allows for enhancement of both selectivity and sensitivity 
by reducing the potential at which NO is oxidized, thus limiting the effect of interfering 
species. Recently reported electrode modifications include metalloporphyrins, 
metallophthalocyanines, self-assembled monolayers (SAMs), and protein catalysts. For 
example, Hrbáč et al. utilized the electropolymerization of nickel porphyin onto carbon fiber 
microelectrodes to achieve a 6-fold increase in sensitivity while also enhancing selectivity.97 
Unfortunately, metalloporphyrins degrade rapidly, so metallophthalocyanines have been 
adopted as a more stable alternative electrocatalytic layer.98 Self-assembled monolayers form 
highly stable chemical bonds with glassy carbon electrodes, making them useful as 
electrocatalysts for compounds with relatively high oxidation potentials (e.g., NO). 
Sivanesan et al. utilized SAMs of 1,8,15,22-tetraaminophthalocyanatocobalt(II) to decrease 
NO’s oxidation potential by 310 mV while simultaneously increasing the oxidation current 
produced.99 
Electrochemical detection continues to be one of the most promising methods for NO 
measurement, especially from biological systems. Further enhancements in sensitivity and 
selectivity, as well as new sensor configurations (e.g., microfluidic devices) will allow for 
greater understanding of the many essential roles of NO in vivo. 
1.3.3 Detection of nitrosothiols 
To date, the techniques most commonly utilized for nitrosothiol analysis exploit 
indirect detection schemes.100 Indirect detection of S-nitrosothiols is achieved via 
decomposition and detection of the resulting products (i.e., NO, NO+).62,100 Despite their 
relative stability, nitrosothiol species will decompose via multiple pathways (i.e., heat, light, 
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and chemical reduction) as shown in Figure 1.2. The figures of merit for the most commonly 
utilized methods for nitrosothiol detection are outlined in Table 1.2. 
The Saville assay is a colorimetric assay modeled after the Griess assay.101 Mercuric 
ions (Hg2+) are used to cleave the S–NO bond. The NO+ generated from this cleavage then 
reacts with O2 to form nitrite (NO2-). The reaction then proceeds in the same manner as the 
Griess assay, where nitrite is reacted with acidic sulfanilamide and N-(1-
naphthyl)ethylenediamine to form an azo dye which is detected spectrophotometrically.60 
Despite the simplicity of this assay, in vivo nitrite concentrations are usually much greater 
than that of nitrosothiols, making accurate quantification of nitrosothiols challenging. Indeed, 
the limit of detection for the Saville assay is ~500 nM in buffer solution. Analogous to the 
Saville assay, nitrite generated from nitrosothiols can be reacted with 2,3-
diaminonaphthalene to form the fluorescent 2,3-naphthotriazole (λexcitation = 365 nm, λemission 
= 405 nm) for in situ detection.102 As a more selective alternative, 4,5-diaminofluorescein can 
be used to react directly with NO released from nitrosothiols.103 However, while the UV 
photolysis utilized to decompose nitrosothiols is efficient, it also causes NO generation from 
nitrate, leading to artificially elevated NO totals.78 Chemiluminescence NO detection has also 
been combined with reductive or photolytic cleavage of nitrosothiols.104 Detection limits 
have been reported in the nM range with various reducing agents employed depending on the 
application (e.g., Cu+/cysteine, iodine/triiodide).105,106 Although less common due to cost, 
high performance liquid chromatography (HPLC) has been used to separate and detect 
different classes of nitrosothiols. Specifically, Marzinzig et al. coupled reverse phase HPLC 
with electrochemical or fluorescence detection to separate and quantify mixtures of low 
molecular weight nitrosothiols.107 While reductive cleavage of the S–NO bond would  
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Table 1.2 Summary of predominant analytical methods for detecting S-nitrosothiols in 
biological samples. 
 
Method Detected species LOD RSNOs analyzed Sample 
Saville assay Azo dye 500 nM LMW1 Plasma 
Chemiluminescence NO2* pM LMW + AlbSNO 
Blood 
Plasma 
Serum 
Fluorimetry Fluorescent adduct nM LMW + AlbSNO Blood 
Electrochemistry NO 10 nM LMW + AlbSNO 
Plasma 
Serum 
Diluted blood 
1LMW: low molecular weight nitrosothiols 
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theoretically allow for a means of direct nitrosothiol detection via electrochemistry, this 
method would suffer from O2 interference and not accommodate selective detection of 
different types of nitrosothiols due to the similar reduction potentials required. As such, 
indirect electrochemical detection of nitrosothiols is achieved in a manner similar to other 
nitrosothiol assays, where NO detection (via electrochemical oxidation) follows nitrosothiol 
decomposition. 
Compared to other techniques, detection of nitrosothiols via electrochemistry 
provides superior spatial and temporal resolution without the requirement of complex or 
costly instrumentation. S-nitrosothiol decomposition to NO may be achieved in a manner 
identical to other techniques, including chemical reduction and photolysis. Copper catalyzed 
reduction is one such method and whereby the addition of copper chloride salt or the addition 
of copper(II) in the presence of an additional reducing agent (e.g., glutathione, L-cysteine, 
ascorbate) breaks down the nitrosothiols to NO. Despite the facile nature of this method, NO 
generation (and thus nitrosothiol amount detected) varies significantly based on the amount 
of Cu+ or the ratio of Cu2+ to reducing agent.108-110 Furthermore, the addition of catalyst 
solutions to small biological samples is inconvenient and has the potential to dilute already 
small quantities of nitrosothiols to undetectable levels. To deal with these shortcomings, 
Meyerhoff et al. developed immobilized catalysts for the decomposition of NO and 
incorporated them into electrochemical NO sensors. A number of catalysts (e.g., copper, 
organoselenium, organotelluride) were immobilized into sensor membranes that coated the 
tip of the working electrode to facilitate nitrosothiol decomposition with immediate NO 
detection.111-114 Organoselenium-based sensors generated superoxide upon reaction of 
oxygen with the catalyst, and thus their utility was limited by NO scavenging.115 
 20 
Nevertheless, these devices were utilized to estimate levels of both low and high molecular 
weight nitrosothiols in biological samples. Meyerhoff et al. also developed nitrosothiols 
sensors that entrapped glutathione peroxidase behind a NO-selective PTFE membrane. 
Exploiting a similar idea, Bedioui et al. designed a ring-disk ultramicroelectrode where the 
center disk oxidized electrodeposited Cu(0) to Cu(I).116 The Cu(I) released facilitated 
nitrosothiol decomposition and the outer ring was used to detect the resulting NO. The same 
group also demonstrated the utility of this method using both dual disk-disk and band-band 
electrode configurations.116 
Alternatively, nitrosothiol decomposition may be triggered by light, specifically in the 
wavelength ranges of 290–270 nm and 505–625 nm.117 Decomposition via photolysis occurs 
by direct homolytic cleavage of the S–NO bond without involvement of side reactions.117 
Coupling this decomposition pathway with electrochemical detection of NO is particularly 
appealing as the light intensity (and thus NO generation) is highly tunable. Light sources can 
easily be adapted to a variety of electrochemical configurations, including small microfluidic 
devices. Additionally, this method does not require the addition of chemicals to samples, 
which is especially important if the sample volume is small and/or when measurements must 
be made rapidly. Riccio et al. described the combination of visible photolysis and 
amperometric detection of S-nitrosothiols.118 Visible light (532 nm) was chosen to avoid 
electrochemical interference, as ultraviolet (UV) light generates NO from nitrite in solution, 
and would thus overestimate nitrosothiol concentrations.78 Despite slightly decreased 
sensitivity relative to copper catalysts, this work demonstrated how tuning the properties of a 
light source (e.g., varying light intensity) could change the rate and amount of NO generation 
from both low and high molecular weight nitrosothiols in phosphate buffered saline and 
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blood plasma. Despite these advantages, the measurement required deoxygenation of the 
sample to overcome NO scavenging by oxygen. Additionally, relatively large sample 
volumes (~20 mL) were required for analysis. While these shortcomings limit the current 
clinical utility of this measurement technique, a light source could easily be coupled with 
numerous sensor configurations. For example, incorporation into a microfluidic device would 
allow for improved sample irradiation with enhanced sensitivities and detection limits. 
Additionally, a microfluidic device is more amenable to the small sample volumes required 
for future clinical analysis applications. 
 
1.4 Nitric oxide and nitrosothiols in sepsis 
 The general understanding of sepsis within the medical community has varied greatly 
throughout the years. During the sixteenth century, what we now understand to be sepsis was 
referred to as “hectic fever.”119 Even then, Machiavelli understood that this mysterious 
malady was easy to treat but difficult to detect at its inception, while later becoming simple 
to recognize but challenging to cure.119 More recently, sepsis was simply considered to be a 
systemic host response to infection.120 A more detailed, concrete definition of sepsis was not 
outlined until 1992, when the American College of Chest Physicians and the Society of 
Critical Care Medicine convened and came to a consensus on the differences between the 
spectrum of syndromes related to the body’s response to infection.121 As outlined in Table 
1.3, this spectrum includes systemic inflammatory response syndrome, sepsis, severe sepsis, 
and septic shock, each presenting with different symptoms.122 To date, these definitions have 
not been modified. 
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Table 1.3 Definition of systemic inflammatory response syndrome, sepsis, severe sepsis, 
and septic shock in humans.   
 
Syndrome Definition 
Systemic inflammatory response syndrome 
(SIRS) 
2 or more of the following:  
- Body temperature >38°C or <36°C 
- Heart rate >90 beats per minute 
- Respiration >20 breaths per minute or 
PaCO2 <32 mmHg 
- White blood cell count >12,000 mm-3 or 
<4,000 mm-3 
  
Sepsis SIRS caused by suspected or confirmed 
infection 
  
Severe sepsis Sepsis with acute organ dysfunction, 
hypotension, or hypoperfusion 
  
Septic shock Sepsis with hypotension/hypoperfusion 
despite adequate fluid resuscitation 
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 The current framework for classifying patients with sepsis is extremely important 
given its severity, the challenge of diagnosis, and associated treatment strategies. A recent 
epidemiological study examined trends in sepsis from 1979 through 2000, revealing that 
>750,000 cases of sepsis occur annually in the United States, accounting for 1.3% of all 
hospitalizations.123 While mortality has decreased over the years and currently ranges from 
18–30%, sepsis remains the leading cause of death in critically-ill patients. Recent statistics 
indicate sepsis-related incidences are increasing by 8.7% annually. In the United States 
alone, healthcare costs for treating sepsis exceed $16 billion.124 Clearly the need for 
improved understanding, diagnosis, and treatment of the disease and its underlying causes is 
highly warranted. 
1.4.1 Sepsis disease progression 
 The immune response to pathogens broadly is a normal physiological response and is 
usually tightly regulated. During a typical infection by a limited number of bacteria, the 
innate immune response is initiated upon detection of the invading organisms and the 
polarization of local macrophages to the M1 (pro-inflammatory) phenotype.125 Detection of 
foreign pathogens can occur through a number of mechanisms, although the best understood 
are pathogen-recognition receptors (e.g., Toll-like receptors) that identify bacterial cell wall 
components (e.g., lipopolysaccharide). The resulting “activated” macrophages (along with 
other immune cells) phagocytose the invading organisms and produce pro-inflammatory 
cytokines (e.g., tumor necrosis factor, IL-6, and IL-8) in order to recruit other circulating 
white blood cells (e.g., neutrophils, lymphocytes, monocytes) to assist. Following uptake of 
the bacteria by the macrophage, it becomes entrapped within the phagolysosome, where the 
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combination of reduced pH, proteases, and other antimicrobial agents (including NO) cause 
rapid killing and clearance of the invading species.  
Sepsis, being a systemic inflammatory response, occurs when this normal response to 
infection becomes so severe or dysfunctional that it causes harm to the host. Such action may 
be caused when the bacterial load present is too large for the body to handle, when the 
infection is due to a particularly virulent strain, or when the immune system is not 
functioning properly. This dysfunction will cause a number of physiological changes, both at 
the cellular and systemic levels, leading to severe and dangerous symptoms. During the later 
stages of sepsis, the body enters an immunosuppressive phase, termed the compensatory anti-
inflammatory response syndrome (CARS).126 This phase of the disease is particularly 
dangerous, as it increases patient susceptibility to secondary infections and death. Figure 1.3 
illustrates this changing immune response over time during the progression of sepsis. 
During the first phase of sepsis, a dramatic increase in production of pro-
inflammatory cytokines is observed. This phenomenon, know as the “cytokine storm,” allows 
the innate immune system (i.e., macrophages and neutrophils) to communicate with the 
body’s adaptive immune system.127,128 This overstimulation also causes a significant 
upregulation of the expression of iNOS129-131 and certain cell surface markers (e.g., CD80 
and CD86), which permit juxtacrine signaling between phagocytes and T cells.132,133  
Cell death is another major hallmark of sepsis, including both necrosis and apoptosis. 
Necrosis, which usually occurs following an ischemic injury and results in slow death due to 
lack of nutrient supply, causes leakage of caustic enzymes which may also damage 
surrounding tissue.134,135 Conversely, apoptosis is a programmed cell death that can occur via 
binding of proteins to specific receptors or a mitochondrial-mediated pathway. This process  
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Figure 1.3 Changes in immune response during the progression of sepsis in human 
patients. Adapted from Hotchkiss et al.136 
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is a normal part of cellular proliferation, but occurs to an extreme and detrimental extent 
during sepsis. Of note, apoptosis is more pronounced in lymphocytes and gastrointestinal 
epithelial cells during sepsis.137,138 Lymphocyte death is linked to the CARS that is observed 
in later stages of sepsis.139,140 Under normal circumstances, the intestine has an unusually 
high cell turnover rate, making it particularly sensitive to changes in apoptosis.141 In contrast 
to this increased cell death, neutrophils often undergo delayed apoptosis during sepsis, 
leading to further damage to tissue by the release of toxic antimicrobial products.142 
1.4.2 Clinical manifestations of sepsis 
 These phenotypic and chemical changes at the cellular level manifest a number of 
systemic physiological changes that may be monitored in the hospital setting. As provided in 
Table 1.3, physicians consider a set of symptoms that define sepsis within a spectrum of 
disorders. In addition to these basic physiological metrics, a number of potential biomarkers 
for sepsis have been proposed for diagnostic and/or prognostic use. Due to the shear number 
of physiological processes involved in sepsis and its systemic nature, the quantity of 
biomarkers that have been evaluated to date is immense, with at least 178 independent 
biomarkers since 2010 alone.143 Most biomarkers have been tested for their prognostic 
ability, but of greater importance may be the ability to improve the diagnosis of sepsis, as 
early and appropriate treatment is known to improve patient outcomes.144-147 The most 
commonly studied categories of biomarkers include cytokines/chemokines and acute phase 
proteins. A number of cells (most notably immune cells) release cytokines and chemokines in 
order to mediate the pathophysiology of sepsis. For example, pro-inflammatory cytokines 
such as tumor necrosis factor148,149 and various interleukins150-169 are released at high levels 
in response to infection. Similarly, anti-inflammatory cytokines and chemokines may be 
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examined to monitor the immunosuppressive phase of sepsis.170 While clinical and 
experimental studies have revealed that these biomarkers are elevated in sepsis and may 
predict survival,171 they are neither sensitive nor specific enough to be clinically useful. 
Acute phase proteins such as C-reactive protein may aid in predicting a patient’s response to 
therapy, but serve no diagnostic value.172-174 Other categories of molecules that have been 
studied for their diagnostic and/or prognostic value include cell surface markers, coagulation 
biomarkers, vasodilation biomarkers, organ dysfunction biomarkers, vascular endothelial 
damage biomarkers, and receptor biomarkers.143 However, no one biomarker to date has 
proven both sensitive and specific enough to become routinely implemented in sepsis 
monitoring. Future approaches must include the evaluation of new potential biomarkers as 
well as multi-biomarker panels for more accurate diagnosis.170 
1.4.3 Nitric oxide and nitrosothiols as prognostic/diagnostic biomarkers 
Due to the well-established roles of NO in the immune system and inflammation, as 
well as its role in blood pressure maintenance, many have hypothesized that endogenous NO 
levels may become erratic during the development and progression of sepsis. For example, 
multiple studies have indicated increases in iNOS during progression of sepsis.129,131,175,176 
Regulation of iNOS has been examined to determine whether its up- or down-regulation may 
be beneficial for the treatment of sepsis, but the results have been mixed. For example, some 
findings have indicated that inhibition of iNOS provides a protective effect and thus 
improves outcomes.177-179 In contrast, others have reported that NO scavenging or iNOS 
deficiencies actually worsen outcomes, likely due to the role of NO in mediation of 
infection.180,181 Such conflicting results indicate a delicate balance and the need for methods 
that more directly determine circulating NO and nitrosothiol levels in vivo. To date, a 
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number of studies have examined changes in metabolites of NO (i.e., nitrate, nitrite, and 
nitrosothiols) more directly during sepsis in humans and other animal species, most 
frequently utilizing chemiluminescence and colorimetric detection methods. The results of 
select studies have been summarized in Table 1.4. While the reported concentrations vary 
widely, an increase in endogenous NO relative to controls was observed in almost all cases. 
One notable exception was reported by Jacob et al., who observed a decrease in plasma 
nitrate/nitrite levels in patients with trauma and infection relative to control (no trauma or 
infection) patients.182 Despite this trend, an increase was observed relative to patients with 
trauma but without infection. The ability to measure NO and nitrosothiols directly in whole 
blood and/or plasma would provide a clearer understanding of the mechanisms involved in 
this immune dysfunction. 
1.4.4 Animal models of sepsis 
 Outcomes for sepsis may only be further improved through advancements in 
understanding mechanisms of disease pathophysiology and the development of new 
therapeutics. Well-controlled and reproducible studies to achieve such an outcome are only 
possible through the use of animal models.183 Preclinical (i.e., animal) studies are especially 
necessary for testing of potential therapeutic agents prior to human clinical trials. The main 
concern in planning such studies is that the model accurately replicates the complex 
physiological state of human sepsis, in which the inflammatory response develops over days 
and leads to multi-organ failure when not treated promptly. 
While mimicking human sepsis remains a priority,184,185 the use of nonhuman 
primates in sepsis research is rare, due in part to ethical objections.186 Large animal species—
including dogs, sheep, and pigs—are often used and share some similar disease pathways  
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Table 1.4 Summary of reported changes in NO and its metabolites during sepsis. 
Species Analyte Medium Detection Method Control  Septic Reference 
Human NOXa Plasma 
Capillary 
electrophoresis 
20 ± 3 µM 144 ± 39 µM 130 
Human NOX Plasma 
Reduction/ 
chemiluminescence 
 133 ± 48 µM 187 
Human NOX Plasma Griess assay 29 ± 4 µM 72 ± 9 µM 19 
Human NOX Plasma Griess assay  90–150 µM 188 
Human NOX Serum Griess assay 43 ± 24 µM 118–145 µM 189 
Human RSNO Blood 
Reduction/ 
chemiluminescence 
 1.2–6.25 µM 190 
Mouse RSNO Plasma 
Reduction/ 
chemiluminescence 
5 × 10-6 SNOb 
per heme 
4 × 10-5 SNO 
per heme 
191 
Rat RSNO Plasma 
Reduction/ 
chemiluminescence 
108 ± 23 nM 
1335 ± 423 
nM 
192 
Pig NOX Plasma 
Reduction/ 
chemiluminescence 
No difference, but did observe 
upregulated iNOS during sepsis 
175 
 
a NOX refers to byproducts of NO oxidation, nitrate and nitrite. 
b SNO refers to a nitrosothiol moiety. 
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with humans. These species also allow for clinical monitoring (e.g., heart rate, cardiac 
output, blood gasses) that is similar to an intensive care unit setting. Despite these 
advantages, the use of large animals are often cost prohibitive. As such, their use in studying 
sepsis is less prevalent than rodent models (i.e., mice and rats). Unlike other models for 
sepsis, rodent models afford the ability to study disease mechanisms in greater detail, 
especially with the use of genetically engineered knockouts. Due to low total blood volumes 
(~2 mL in mice) however, serial sampling in a mouse is not possible without the induction of 
hypovolemic shock.185 Of note, each of these species has a varied timeframe for sepsis 
development and mortality, as well as differing sensitivities to bacteria and endotoxin.185 
Another important consideration in terms of relevance of this model is animal age. While 
most human patients who develop sepsis are >65 years of age,193 animals used for modeling 
sepsis and other diseases are generally juvenile, leading to significantly decreased 
mortality.194,195 
Once the appropriate species has been chosen, one must consider the means of 
inducing sepsis. Three main categories of sepsis models exist: administration of a toxin (e.g., 
lipopolysaccharide), administration of a viable pathogen (e.g., bacteria), and surgical 
alteration of a protective barrier (e.g., bowel perforation). Each method has its own distinct 
advantages and caveats, as outlined in Table 1.5. Direct administration of live bacteria is 
another means of inducing sepsis in animal models that can be useful for studying specific 
mechanisms of host response to infection by particular bacteria. The two main routes of 
infection include direct administration into the blood or peritoneum, and intra-tracheal 
administration for lung infection. Direct inoculation of the blood will have a rapid effect on 
the cardiovascular system, while a lung or peritoneal infection will first induce immune cell 
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Table 1.5 Advantages and caveats of various animal models of sepsis. Adapted from 
Buras et al.196 and Zanotti-Cavazzoni et al.185 
Model Advantages Caveats Variable Parameters 
    
Endotoxemia 
- well-controlled 
- easy to perform 
- changes in 
cardiovascular state and 
cytokine levels 
- single toxin dissimilar 
to human sepsis 
- variable response 
depending on species 
- variable response 
depending on dose 
- type of toxin 
- route of administration 
- dose 
- animal species 
    
    
Bacterial infection 
- allows measurement of 
host response to 
pathogen 
- response tunable with 
bacteria load 
- single pathogen does 
not always mimic 
human sepsis 
- requires prior bacteria 
quantification 
- genetic background 
affects host response 
- bacterial strain 
- compartment of 
infection 
- timing of infusion 
- antibiotics 
- animal species 
    
    
CLP and CASP 
- polymicrobial sepsis 
-  most closely mimics 
human disease states 
(hemodynamic, 
metabolic, and immune) 
- polymicrobial sepsis 
leads to variability 
between animals 
- uncontrolled bacterial 
load (CLP model) 
- abscess formation in 
CLP model 
- age variability  
 
- size of puncture (CLP) 
or stent (CASP) 
- number of perforations 
- antibiotics 
- animal species 
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differentiation and migration.197 Other important considerations for this model include 
bacterial strain and load.198 This method is also desirable because the strain causing the 
infection is known, allowing for the assessment of specific targeted treatments. 
The host-barrier disruption model of sepsis usually involves perforation of the bowel. 
Cecal ligation and puncture (CLP), considered the “gold standard” in sepsis research, is 
meant to mimic ruptured appendicitis in humans.199-201 The bowel perforation created using 
this model allows for fecal leakage into the abdomen, creating a polymicrobial infection and 
necrotic tissue.202,203 Disease severity is usually adjusted by changing the puncture size or 
number of punctures.199 This model is especially clinically relevant as it mimics the 
hemodynamic, metabolic, and immune responses most often observed in humans during 
sepsis.199,204 However, disease severity and progression is more difficult to control, as the 
load of fecal material and bacteria is variable. Similar to CLP, the colon ascendens stent 
peritonitis (CASP) model also creates bowel leakage into the abdomen, but seepage is 
prolonged due to stent placement. As a result, increases in systemic cytokine and bacteria 
levels are generally higher in the CASP model.196 Disease severity can be modified by 
altering the size of the stent placed. This model is typically used to study the acute phase of 
septic peritonitis. 
 Choosing an appropriate model and means of inducing sepsis relies greatly on the 
desired result of a given experiment. While no model is perfect, careful selection of 
parameters can provide data that is relevant and translatable to human subjects.  
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1.5 Summary of dissertation research 
The focus of my dissertation research was to develop improved methods for detecting 
NO and nitrosothiols from a variety of complex biological systems. To accomplish this, I 
made use of electrochemical detection of NO and nitrosothiols using an assortment of 
platforms suited for each individual measurement environment. The specific aims of my 
research included the: 
1) understanding of commonly utilized methods for detection NO, including their 
advantages and shortcomings, specifically in complex biological media; 
2) design and evaluation of a microfluidic electrochemical NO sensor specifically 
suited for detection of NO in small volumes of blood; 
3) adaption and evaluation of the microfluidic sensor to accommodate on-chip 
photolytic cleavage and amperometric detection of S-nitrosothiols in 
physiological fluids; 
4) utilization of the microfluidic sensor to evaluate NO as a diagnostic and/or 
prognostic biomarker for sepsis using controlled animal models; 
5) use of a microsensor for understanding the dynamics of NO release from single 
cell systems including neurons and macrophage cells. 
The goal of this introductory chapter was to provide an overview of the current 
understanding of the physiological roles of NO and S-nitrosothiols, including their role in 
sepsis, and how electrochemistry can be utilized for both NO and nitrosothiol detection in 
complex biological systems. In Chapter 2, a more thorough evaluation of the most common 
NO detection schemes (i.e., Griess assay, chemiluminescence, and electrochemistry) in 
multiple types of biological media will be provided. Chapters 3 and 4 will focus on the 
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development of a microfluidic sensor to facilitate NO measurement in small volumes of 
physiological fluid and its adaption to allow for photolysis and amperometric detection of S-
nitrosothiols. The study of NO and nitrosothiols as potential diagnostic/prognostic 
biomarkers for sepsis in two animal models (i.e., mice and pigs) will be detailed in Chapter 5. 
In Chapter 6, the use of a microelectrode to study NO release from single cell systems (i.e., 
macrophages and neurons) will be discussed. Finally, a summary of my work along with a 
description of future studies will be provided in Chapter 7.  
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CHAPTER 2: CHALLENGES OF NITRIC OXIDE MEASUREMENT FROM 
BIOLOGICAL SYSTEMS2 
 
2.1 Introduction 
Nitric oxide (NO), an endogenous free radical produced by a collection of enzymes 
known as NO synthases (NOS), is a physiological mediator of the cardiovascular, immune 
and nervous systems.1 For example, NO produced in the vasculature by endothelial NOS 
serves as a vasodilator and blood pressure regulator.2,3 The immune system produces NO at 
high concentrations via inducible NOS to serve as a signaling molecule4,5 and potent 
antimicrobial agent.6 In the brain, NO produced by neuronal NOS functions as a 
neurotransmitter and is involved in memory formation.7 The physiological significance of 
NO has led to increased research on NO and NO-releasing scaffolds as potential 
therapeutics.8-12 Given that the location and concentration of NO governs its biological effect, 
the release characteristics of NO-based therapies often influence their success. Consequently, 
developing and assessing methods for the accurate quantitative measurement of NO is 
critical. 
While understanding NO’s behavior in vivo is obviously important, this task is far 
from trivial. Nitric oxide is highly reactive with a lifetime on the order of seconds in most 
biological media.13 Additionally, the diffusion of NO is rapid, with diffusion coefficients 
                                                
2 This chapter previously appeared as a manuscript in Analytical Chemistry. The original citation is 
as follows: Hunter, R. A.; Storm, W. L.; Coneski, P. N.; Schoenfisch, M. H. "Inaccuracies of nitric 
oxide measurement methods in biological media." Analytical Chemistry 2013, 85, 1957-1963. 
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approaching 3300 µm2 s-1 in physiological buffer.14,15 Complicating matters further, 
physiological concentrations of NO span six orders of magnitude (pM to µM),16 requiring 
sensitive measurement techniques over wide dynamic ranges.17 To date, three analytical 
techniques account for the majority of NO measurements in the literature.12,18  
First described in 1864,19  the Griess assay, formally know as the diazotization assay, 
allows for the quantification of total NO concentrations via nitrite analysis. Nitrite is a stable 
byproduct of the reaction of NO with oxygen in aqueous media, and upon reaction with 
sulfanilamide and N-(1-napthyl)ethylenediamine an azo dye is formed. Absorbance 
spectroscopy is then used to relate the concentration of dye to the concentration of nitrite 
(and thus NO that was released into solution). Although inexpensive and easily obtained 
commercially, the Griess assay only provides a limit of detection around 0.5 µM and is 
mainly useful for determination of NO totals.12,20,21  
In contrast, chemiluminescence detection, a more costly method due to 
instrumentation requirements, measures NO directly via reaction with ozone.22 This reaction 
produces and excited state nitrogen dioxide, which emits a photon upon relaxation to the 
ground state. Nitric oxide-release kinetics may be determined directly from materials in 
solution, as the NO is immediately purged from solution to the detector. As an alternative, 
nitrate and nitrite in solution can be measured following their reduction to NO. 
Due to NO’s redox activity, electrochemistry is also commonly used to quantify NO 
in a variety of formats (e.g., direct oxidation via amperometry) and even the single cell level 
due to sensor miniaturization.21 This detection scheme is especially advantageous for in vivo 
and in situ application due to the spatial and temporal resolution provided by the 
measurement technique. 
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While each of these techniques has inherent advantages for measuring NO, it is 
important to consider the environment in which the NO is measured. Since NO readily reacts 
with thiols, other free radical species (e.g., superoxide, thiyl radicals, and lipid peroxyls), and 
metal-containing proteins (e.g., hemoglobin) in situ, the available (i.e., free) NO will vary 
depending on the sample medium.23-25 While a number of reviews have focused on 
describing the available methodologies for biological measurement of NO, 21,22,26-33 a 
systematic study of the effects of biological media on the validity of such methods is lacking. 
Herein, we evaluate the accuracy of NO analysis with respect to measuring NO in 
physiological buffers and fluids, cell culture media, and bacterial broth using the Griess 
assay, a chemiluminescence analyzer, and an amperometric sensor. 
 
2.2 Materials and Methods 
(Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) was purchased 
from Gelest (Morrisville, PA). Methyltrimethoxysilane (MTMOS) was purchased from Fluka 
(Buchs, Switzerland). Griess assay reagents were purchased from Promega (Madison, WI). 
Tryptic soy broth (TSB) and brain heart infusion (BHI) broth were purchased from BD 
Biosciences (San Jose, CA). Dulbecco’s Modified Eagle Medium (DMEM), McCoy’s 
Medium 5A Modified, fetal bovine serum (FBS), dipotassium ethylenediaminetetraacetic 
acid (K2EDTA), nicotinamide adenine dinucleotide phosphate (NADPH), and nitrate 
reductase (from Aspergillus niger) were purchased from Sigma (St. Louis, MO). Opti-MEM 
I (a reduced serum medium) was purchased from Life Technologies (Grand Isle, NY). 
Leibovitz medium (L-15; a carbon dioxide-free cell culture medium) was purchased from 
Lonza (Basel, Switzerland). Porcine blood was obtained from the Francis Owen Blood 
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Research Laboratory (University of North Carolina; Chapel Hill, NC). Blood serum was 
obtained by collecting porcine blood without the addition of anticoagulant. After allowing 
the blood to clot, it was centrifuged at 2500 rpm for 15 min and the supernatant (i.e., serum) 
was removed. To obtain blood plasma, porcine blood was drawn into a tube with K2EDTA 
(~1.8 mg mL-1), mixed immediately, and then centrifuged at 2500 rpm for 15 min. After 
centrifugation, three layers were present (from top to bottom: plasma, leukocytes, and 
erythrocytes); the top layer was removed. A Millipore Milli-Q UV Gradient A10 System 
(Bedford, MA) was used to purify distilled water to a final resistivity of 18.2 MΩ·cm and a 
total organic content of ≤6 ppb. Nitrogen and argon gases were purchased from AirGas 
National Welders (Raleigh, NC). Nitric oxide gas was purchased from Praxair (Danbury, 
CT).  Other solvents and chemicals were analytical-reagent grade and used as received.   
2.2.1 Preparation of physiological media 
Artificial saliva solution was prepared as described by Arvidson et al.34 via the 
addition of the following components to 500 mL of Milli-Q water: 279 mg monopotassium 
phosphate, 284 mg sodium phosphate dibasic, 1.24 g potassium bicarbonate, 482 mg sodium 
chloride, 254 mg magnesium chloride, 184 mg calcium chloride, and 394 mg citric acid.  The 
pH of the solution was subsequently adjusted to 6.7.  A 500 mL solution of artificial normal 
human urine was prepared according to Kark et al.35 by adding the following to Milli-Q 
water: 2.40 g sodium phosphate, 2.25 g potassium chloride, 3.75 mg sodium chloride, and 
9.1 g urea.  After the pH of this solution was adjusted to 5.9, 25 mg bovine serum albumin 
and 1.0 g creatinine were added.  For a 500 mL solution of physiosol in Milli-Q water the 
following were added: 2.63 g sodium chloride, 185 mg potassium chloride, 150 mg 
magnesium chloride, 1.11 g sodium gluconate, and 2.51 g sodium acetate.36  The pH of the 
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solution was then adjusted to 6.0. A saturated NO solution (1.9 mM NO) was made by 
purging ~20 mL of PBS with argon for 30 min to remove oxygen, followed by NO gas for 20 
min.   
2.2.2 Synthesis of PROLI/NO 
N-diazeniumdiolated L-proline (PROLI/NO) was prepared following a previously 
published protocol.37 Briefly, L-proline (2.05 g) was dissolved in a solution of methanol (25 
mL) and sodium methoxide (2.00 g). The solution was then placed in a stainless steel 
reaction vessel and flushed with Ar six times (three in succession, three for 10 min each), 
then charged with NO at a pressure of 10 atm for 3 d with constant stirring. Six additional Ar 
purges were performed after 3 d. The solution was then precipitated by the addition of diethyl 
ether (150 mL) at −20 °C for 4 h. The white precipitate was isolated by vacuum filtration and 
dried in vacuo to yield PROLI/NO, which was stored at −20 °C until use. Ultraviolet spectra 
of a 14.9 μg·mL–1 solution of the product (in 1.0 M sodium hydroxide) were acquired on a 
Thermo Scientific evolution array UV–visible spectrophotometer (Figure 2.1). The molecular 
weight of pure PROLI/NO was taken to be 251 g·mol–1. 
2.2.3 Griess assay 
To quantify NO via the Griess assay,38 50 µL of a 2 mg mL-1 solution of PROLI/NO 
in 100 mM sodium hydroxide (NaOH) was added to 15 mL of desired media and incubated 
at room temperature for at least 24 h. Aliquots (50 µL) of this sample were added to a 
sulfanilamide solution (50 µL) and incubated in the dark at room temperature for 5 min. 
Naphthylethylenediamine (50 µL) was added to the mixture to form a colorimetric product 
with concomitant absorbance measured in each well at 540 nm using a LabSystems 
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MultiSkan RC microplate reader (Helsinki, Finland). Sodium nitrite standards were used to 
normalize the assay reactivity and associated absorbance. 
For analysis of blood constituents (i.e., plasma and serum), NADPH (25 µL) and 
nitrate reductase (2 µL) were added to the samples and allowed to incubate for at least 30 min 
prior to the addition of the Griess reagents. 
2.2.4 Chemiluminescence detection 
Real-time NO release was monitored using a Sievers 280 Chemiluminescent NO 
Analyzer (Boulder, CO). The instrument was calibrated with a 25.6 ppm gas standard 
(balance N2) and an atmospheric sample that had been passed through a NO zero filter. 
Samples were prepared by adding 10 µL of a 2 mg mL-1 solution of PROLI/NO in 100 mM 
NaOH to 30 mL of desired media that had been degassed in a sample vessel for at least 20 
min. Nitric oxide produced in the vessel was carried to the NO analyzer by a stream of 
nitrogen gas bubbled into the solution (80 mL min-1) across the headspace of the flask (120 
mL min-1), equivalent to 200 mL min-1 flow to the instrument. 
2.2.5 Electrochemical detection 
Inlaid 2 mm diameter polycrystalline platinum (Pt) disk electrodes sealed in Kel-F 
(CH Instruments; Austin, TX) were mechanically polished with successively finer grades of 
deagglomerated alumina slurries down to 0.05 µm particles (Buehler; Lake Bluff, IL). 
Residual alumina was removed using an ultrasonic cleaner (in water) and the electrodes were 
dried with nitrogen.  A fluorinated NO selective xerogel membrane was applied to the 
electrode as previously described to minimize response to common interferents.39,40 Briefly, a 
silane solution was prepared by mixing MTMOS (60 µL) in ethanol (300 µL). To this 
solution, 17FTMS (15 µL) was added, resulting in a 20% v/v fluoroalkoxysilane (balance 
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MTMOS) mixture. The silane solution was subsequently mixed with water (80 µL) and 0.5 
M HCl (5 µL) for 1 h. The resulting sol (1.5 µL) was cast onto Pt working electrodes and 
allowed to cure for 24 h under ambient conditions. To evaluate the analytical performance of 
the NO sensors, amperometric measurements were performed using a CH Instruments 730B 
bipotentiostat (Austin, TX). The electrode assembly (3-electrode configuration) consisted of 
the xerogel-modified Pt working electrode, a Pt-coiled counter electrode, and a Ag/AgCl 
reference electrode (3.0 M KCl; CH Instruments). Electrooxidation currents were recorded at 
an applied potential of +700 mV (vs. Ag/AgCl). To measure NO release in the various media 
using PROLI/NO as the NO source, a 2 mg mL-1 solution of the NO donor was added to a 
constantly stirring bulk solution (30 mL) for a final concentration of 0.1 mg mL-1. Of note, 
the larger volume of media was necessary to accommodate the working, reference, and 
counter electrodes in the flask. 
 
2.3 Results and Discussion 
Diverse biological media were chosen for these experiments to properly represent 
environments in which NO measurements are relevant (e.g., in vivo, cell/tissue culture, 
bacteria culture). Solutions included simple physiological buffers (PBS and physiosol), 
simulated biological fluids (saliva, urine, and wound fluid), cell culture media (DMEM, 
McCoy’s, L-15, and Opti-MEM), bacterial broth (TSB and BHI), whole blood, plasma, and 
serum.  The salt, amino acid, protein, and vitamin content of these media vary significantly 
(Tables 2.1–2.4) and thus likely impact the validity of NO measurement data. 
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2.3.1 Nitric oxide determination via Griess 
The Griess assay allows for indirect measurement of NO via nitrite, NO’s reaction 
product in oxygenated media (eqs 1–3): 
2NO + O2 ! 2NO2    (1) 
NO + NO2 ! N2O3    (2) 
N2O3 + H2O ! 2NO2- + 2H+    (3) 
The resulting nitrite is reacted with the sulfanilamide and N-(1-naphyl)ethylenediamine 
producing an azo dye with an absorbance maximum at 540 nm. To accurately quantify NO, 
calibration curves are constructed with a standard nitrite solution in the sample medium.38 
In theory, 1 molecule of PROLI/NO decomposes to release 2 molecules of NO, for a 
theoretical total NO release of 7.9 μmol·mg–1.37 Following synthesis, PROLI/NO was 
characterized by UV/vis spectroscopy (Figure 2.1). An observed λmax at 252 nm confirmed N-
diazeniumdiolate formation from the L-proline precursor, consistent with prior reports.37 A 
14.9 μg·mL–1 solution was prepared in 1.0 M sodium hydroxide and the molar absorptivity 
coefficient (ε) reported previously by Saavedra et al.37 at 252 nm (8.4 mM–1·cm–1) was used 
to determine a PROLI/NO concentration of 55.7 μM. If total purity were assumed, the 
concentration of this solution would be 59.5 μM, implying a relative purity of 93.5%. This 
value is also supported by the chemiluminescent NO release totals in buffers lacking 
scavenging components (i.e., PBS). 
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Figure 2.1 UV-visible spectra of 14.9 µg mL-1 PROLI/NO in 1.0 M sodium hydroxide. 
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Table 2.1 Salt concentrations (g L-1) and pH of common biological media.   
 
Media 
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* 
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B
H
I 4
7  
pH 7.4 6.0 6.7 5.9 7.4 7.3 7.4 7.3 7.5 7.4 
CaCl2   0.37  0.20 0.14 0.14# 0.10   
MgCl2  0.30# 0.51    0.094    
Fe(NO3)3     0.0001      
MgSO4     0.98# 0.98# 0.098#    
KCl 0.20 0.37  4.5 0.40 0.40 0.40    
KH2PO4 0.54  0.56    0.060  2.5  
NaHCO3   2.5  3.7 2.2  X   
NaCl 8.1 5.3 0.96 7.5 6.4 6.5 8.0  5.0 5.0 
Na2HPO4 0.87#  0.57# 4.8# 0.11# 0.50# 0.19#   2.5# 
Citric acid   0.79        
Sodium 
gluconate  2.2         
Sodium 
acetate  5.0         
*The complete Opti-MEM formulation is proprietary, so not all components and their 
concentrations are available (those known to be present are denoted with an X).  #Denotes 
anhydrous form of salt. 
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Table 2.2 Amino acid concentrations (g L-1) of common biological media.  
*The complete Opti-MEM formulation is proprietary, so not all components and their 
concentrations are available (those known to be present are denoted with an X).  #Amino acid 
content derived from tryptone and peptone.  ‡ Amino acid content derived from brain heart 
infusion.  
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L-Alanine      0.013 0.45  0.82 0.39 
L-Arginine •HCl     0.084 0.042 0.50  0.63 0.19 
L-Asparagine •H2O      0.045 0.25  0.11 0.024 
Aspartic acid         0.58 0.23 
L-Cysteine •HCl     0.063 0.024 0.12  0.051 0.03 
L-Glutamine     0.58   X 0.0085 0.0060 
Glutamic acid      0.022   2.8 0.38 
Glycine     0.030 0.0075 0.20  0.77 0.22 
L-Histidine •HCl •H2O     0.042 0.021 0.25  0.35 0.072 
Hydroxy-L-proline      0.020     
L-Isoleucine     0.11 0.39 0.25  1.0 0.14 
L-Leucine     0.11 0.39 0.13  1.4 0.26 
L-Lysine •HCl     0.15 0.037 0.075  1.2 0.25 
L-Methionine     0.030 0.015 0.15  0.38 0.060 
L-Phenylalanine     0.066 0.017 0.25  0.97 0.14 
L-Proline      0.017   1.4 0.20 
L-Serine     0.042 0.026 0.20  0.42 0.018 
L-Threonine     0.095 0.018 0.60  0.34 0.042 
L-Tryptophan     0.016 0.0031 0.020  0.15 0.018 
L-Tyrosine •2Na •2H2O     0.10 0.026 0.37  0.24 0.072 
L-Valine     0.094 0.018 0.20  1.1 0.19 
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Table 2.3 Vitamin concentrations (mg L-1) of common biological media.   
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Ascorbic acid      0.60     
D-Biotin      0.20     
Choline chloride     4.0 5.0 1.0    
Riboflavin 
mononucleotide       
0.1
0    
Folic acid     4.0 10 1.0    
Inositol     7.2 36 2.0    
Nicotinamide     4.0 0.50 1.0    
p-Aminobenzoic 
acid       1.0     
Niacin (B3)      0.50     
D-Pantothenic acid 
(B5) 
    4.0 0.20 1.0    
Pyridoxine •HCl 
(B6) 
    4.0 0.50 1.0    
Pyridoxal •HCl 
(B6) 
     0.50     
Riboflavin (B2)     
0.4
0 0.20     
Thiamine •HCl     4.0 0.20     
Thiamine 
monophosphate       1.0    
Cobalamin (B12)      2.0     
*The complete Opti-MEM formulation is proprietary, so not all components and their 
concentrations are available.   
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Table 2.4 Concentrations (g L-1) of other additives in common biological media.   
 
Media 
PB
S 
Ph
ys
io
so
l 
Sa
liv
a 
U
rin
e 
D
M
EM
 41
,4
2  
M
cC
oy
’s
 42
-4
4  
L-
15
 45
 
O
pt
i-M
EM
 
46
* 
TS
B
 47
 
B
H
I 4
7  
D-Glucose     4.5 3.0  X 2.5  
D+Galactose       0.90    
Creatinine    2.0       
Dextrose          3.0 
Urea    18.2       
HEPES        X   
Hypoxanthine        X   
Thymidine        X   
Phenol red •Na     0.016 0.011 0.010 X   
Pyruvic acid •Na     0.11  0.55 X   
Tyrptone         17  
Peptone      0.60   3.0  
Glutathione      0.00050     
Insulin        X   
Transferrin        X   
*The complete Opti-MEM formulation is proprietary, so not all components and their 
concentrations are available (those known to be present are denoted with an X).  #BHI also 
contains infusion from brain and heart (6.0 g L-1), peptic digest of animal tissue (6.0 g L-1), 
and pancreatic digest of gelatin (14.5 g L-1).   
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Estimated NO release totals derived from the total nitrite present in each type of media are 
given in Figure 2.2 along with totals derived from chemiluminescence detection. The total 
NO measured in PBS via the Griess assay was only 5.67 ± 0.27 µmol mg-1, ~30% lower than 
the theoretical amount and that detected via the chemiluminescence method (7.24 ± 0.04 
µmol mg-1). Of note, care was taken to add fresh PROLI/NO solution to the media quickly. 
In addition, multiple samples were analyzed to obtain standard deviations. Similar depressed 
NO levels were observed in all of the media types tested by Griess. We attribute the 
deviation between Griess and theoretical to lost (e.g., escaped) NO gas (from solution) that 
subsequently was not accounted for in the total nitrite levels. Indeed, when the headspace in a 
20 mL scintillation vial was reduced by adding 20 mL of PBS versus 15 mL, the total nitrite 
detected was increased by 44% ± 12%. Conversely, when the total buffer volume was 
decreased to 10 mL, the total nitrite recovered was reduced by 32% ± 21% (data not shown). 
The most significant decreases in measured NO levels were observed for bacterial broth (i.e., 
TSB and BHI), certain cell culture media (i.e., McCoy’s and L-15), and blood constituents 
(i.e., plasma and serum), likely the result of NO’s reaction with proteinaceous components in 
the media. Both cell culture and bacterial growth media consist of complex mixtures of 
amino acids, proteins, sugars, and vitamins of various concentrations (Tables 2.1–4). Proteins 
and other additives present in some media have been shown to interfere with the Griess assay 
previously,48-50 acting as either positive or negative interferents. For example, positive 
interferents such as NOS and hemoglobin also absorb light around 540 nm.  A number of 
other interferents including cysteine, tyrosine, ascorbate, and NADPH react with nitrite to 
negatively skew NO totals. Although interfering proteins could be removed by chemical 
precipitation or ultrafiltration,26 such solution conditioning is tedious and would be at the 
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expense of biological relevance.  As anticipated, NO release in whole blood was not 
quantifiable via Griess due to both the opacity of blood and the presence of interfering 
proteins.49 Additionally, NO and nitrite are rapidly oxidized to nitrate in whole blood.51,52 
Nevertheless, nitrite levels were measureable from plasma and serum samples extracted from 
the blood with the caveat that nitrate reductase and NADPH were used to revert any nitrate 
that formed back to nitrite. In both plasma and serum, the totals of NO detected were >15% 
lower (4.75 ± 1.1 µmol mg-1 and 4.18 ± 0.85 µmol mg-1, respectively) than that in PBS, 
indicating the challenge of using the Griess assay to determine NO levels in blood 
constituents. Indeed, NADPH has been indicated as an interferent for Griess. Furthermore, 
nitrite recovery is highly variable and dependent on enzyme activity.26,31,53 
The accurate detection of NO via the Griess assay is also concentration-dependent in 
certain types of media. While no significant differences were observed for non-proteinaceous 
media, detection in the more complex media (i.e., cell culture media and bacterial broth) 
varied significantly depending on the amount of PROLI/NO added to solution (Figure 2.3). 
For example, while the addition of a low PROLI/NO concentration (0.67 µg·mL–1) in 
DMEM yielded nitrite totals that were only 48% ± 9% of those achieved at the highest 
concentration of PROLI/NO (67 µg·mL–1), an intermediate concentration (67 µg·mL–1) 
yielded nitrite amounts that nearly matched the highest concentration (97% ± 1%). The same 
trend held true for the bacterial broth TSB. This can be attributed to the effect of scavenging, 
as the concentration of such scavengers in a given medium is constant, so adding more NO 
allows this effect to be overcome to some extent. 
Given these results, the use of Griess for quantifying NO in most biological media 
leads to questionable results. Nevertheless, the potential for high-throughput analysis via 
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microtiter plates and readers makes Griess useful for initial screening of NO-release 
materials in less complex media (e.g., PBS) so long as such data are supplemented with more 
rigorous analysis in relevant milieu prior to drawing conclusions regarding clinical utility. In 
addition, some kinetic data are obtainable via Griess by taking aliquots from a sample 
solution at set periods or moving bulk (i.e., larger) substrates (e.g., polymer-coated slides) in 
and out of a soak solution and subsequently sampling those solutions. For example, AHAP 
films soaked in select media yielded totals similar to those obtained under the same 
conditions by chemiluminescent detection (Table 2.5) after 1 week. Although the low levels 
of NO release were undetectable with chemiluminescence after 2 weeks, the accumulation of 
nitrite was still measurable by the Griess assay and indicated a continued release of NO from 
the substrates. 
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Figure 2.2 Total NO released from PROLI/NO in several types of biological media 
determined via Griess assay (solid) and chemiluminescence (striped).  Theoretical NO 
release from PROLI/NO is 7.9 µmol mg-1.  *Denotes a significant difference (p <0.05) 
relative to PBS. 
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Figure 2.3 Concentration dependence trends of PROLI/NO in different types of media 
for each technique. For the Griess assay and electrochemistry the final concentrations of 
PROLI/NO were 0.67, 6.7, and 67 µmol mg-1. For chemiluminescence analysis, the 
concentrations used were 0.167, 1.67, and 16.7 µmol mg-1. Chemiluminescence analysis 
could not be performed in bacterial broth due to frothing. Results were normalized to the 
highest concentration used for each. *Denotes a significant difference (p<0.05). 
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Table 2.5 Total NO release from AHAP xerogel films in various media at 1 and 2 weeks 
as determined using nitrite concentrations via the Griess assay. Total NO as determined using 
chemiluminescence was 1.29 µmol cm-2 in PBS at 1 week. 
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2.3.2 Chemiluminescence nitric oxide analyzer 
To facilitate real-time measurement with improved (lower) limits of detection relative 
to the Griess assay, chemiluminescence has become an important tool for solution-based NO 
analysis.18 Comparable to Griess, the measurement principles for chemiluminescence are 
straightforward. Nitric oxide is reacted with ozone in an instrument separate from the 
solution/sample vessel to form an excited-state nitrogen dioxide species that emits a photon 
upon relaxation back to the ground state. This light (600–875 nm) is detected by a 
photomultiplier tube. The reaction is both specific for and sensitive to NO with a detection 
limit approaching 0.5 ppb (0.66 pM in 100 mL) in PBS.12 
Analogous to Griess experiments, samples of PROLI/NO (0.67 µg mL-1) were 
introduced into a solution, but analyzed using chemiluminescence detection to quantify NO 
release. The media compatible with this method was limited to solutions that did not foam as 
a result of purging with nitrogen gas. Foaming due to nitrogen bubbling was most prominent 
for culture media, bacterial broth solutions, and blood (i.e., whole, plasma, serum) due to 
their high protein content.54 Unfortunately, purging the sample is necessary to both 
deoxygenate the media (to reduce autooxidation) and carry NO to the instrument, making this 
technique incompatible with samples containing high concentrations of proteins. Nitric oxide 
release totals for the compatible media are shown in Figure 2.2, allowing for direct 
comparison of total NO detected with the Griess assay as a function of media type. Of note, 
the 7.24 ± 0.04 µmol NO mg-1 measured in PBS via chemiluminescence was near the 
predicted NO payload for PROLI/NO and further confirmed the integrity of our NO donor as 
synthesized. Surprisingly, no significant differences in NO totals were observed for low 
protein content media using chemiluminescence, indicating the high accuracy of this 
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technique for measuring total NO. While L-15 cell culture media contains biomolecular 
components that may scavenge NO as described above, such reactivity was limited as 
nitrogen rapidly carried the NO from the sample vessel to the instrument upon formation.  
Another advantage of chemiluminescence detection is the ability to extract kinetic 
information about the NO release. For example, the maximum NO flux, time to the 
maximum release (tmax) and NO release half-lives (t1/2) may be determined for a particular 
NO source (e.g., macromolecular scaffold) in addition to NO totals. The kinetic NO release 
profiles from PROLI/NO in PBS, physiosol, artificial saliva, and L-15 are provided in Table 
2.6. Little variation in the NO release kinetics for PROLI/NO in these media was noted using 
chemiluminescence, with two exceptions. In artificial saliva, the maximum NO release was 
significantly lower than that in PBS (73,360 ± 1,100 vs. 86,200 ± 3,700 pmol s-1 mg-1, 
respectively).  This behavior may be attributed to a lower pH compared to PBS (6.7 vs. 7.4, 
respectively). The pH effects on NO release from N-diazeniumdiolate NO donors are well 
known.9 Likewise, the half-life of PROLI/NO was reduced by ~8 s in L-15 cell culture 
media. These variances are not surprising given the complex and varying nature of biological 
media (Tables 2.1–2.4). 
Despite the advantage of providing real-time NO-release kinetic information, the 
instrumental setup for chemiluminescence remains problematic for performing measurements 
in biological samples (e.g., undesirable frothing). In addition, the reaction vessel should be 
free of oxygen to minimize side reactions that would result in decreased NO detection.12,22 
Unfortunately, most NO-producing cells require an oxygenated environment (for survival), 
thus precluding chemiluminescence for measuring long-term, real-time cellular NO release.   
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Table 2.6 Kinetic parameters of NO release from PROLI/NO in PBS, physiosol, L-15, 
and artificial saliva. *Denotes a significant difference (p <0.05) relative to PBS. 
 
 
 tmax (s) 
max NO release 
(pmol s-1 mg-1) t1/2 (s) 
PBS 42 ± 1.9 86,200 ± 3,700 65 ± 3.0 
Physiosol 40 ± 1.7 81,200 ± 36 64 ± 1.1 
L-15 40 ± 1.2 96,600 ± 3,100 57 ± 0.7* 
Saliva 47 ± 5.2 73,400 ± 1,100* 74 ± 3.5 
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2.3.3 Amperometric nitric oxide sensor 
In contrast to other NO measurement approaches, electrochemical sensors allow for 
the measurement of NO in almost any biological setting, including at the single cell level.55-57 
The advantages of electrochemical detection of NO include superior spatial and temporal 
resolution, excellent limits of detection and dynamic ranges, and the potential for 
miniaturization. In addition, both the selectivity and sensitivity of the sensor are tunable by 
changing the applied potential to the working electrode and modifying the working electrode 
with a catalyst and/or permselective membrane.12,58 Due to these inherent advantages, 
amperometric sensors have been used extensively to examine both endogenous11,56,57,59-62 and 
exogenous63-65 NO production. In particular, constant potential amperometry is most often 
utilized for NO detection as it allows for sub second temporal resolution,56 and produces a 
current proportional to NO concentration upon the oxidation of NO via a three-electron 
process (eqs 4–6): 
NO ! NO+ + e-   (4) 
NO+ + OH- ! HNO2   (5) 
HNO2 + H2O ! NO3- + 2e- + 3H+   (6) 
A NO-selective fluorosilane-based xerogel-coated platinum working electrode39 was 
used to measure the electrooxidation of NO as current at an applied potential of +700 mV vs. 
Ag/AgCl reference electrode in a well-stirred solution. Total NO release was determined by 
integrating the current vs. time response of each sample, since the charge at the electrode 
surface is proportional to the moles of analyte oxidized. The integrated totals obtained 
yielded NO concentrations significantly lower than the theoretical amount of NO released 
from PROLI/NO regardless of media. These results were not surprising since the electrode is 
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only able to oxidize a portion of the NO liberated in its vicinity due to its small size. 
Consequently, the total NO release calculated is not representative of the actual total amount 
of NO produced by PROLI/NO in bulk solution. This effect may be further compounded in 
biological media where several sinks for NO exist (e.g., proteins). While electrochemical 
sensors are clearly less suitable for characterization of potential NO donors, useful 
information may be deduced upon comparison of relative NO totals in different media and 
certainly when quantifying localized NO release (e.g., from a surface or single cell). As 
shown in Figure 2.4, the greatest total NO detected for oxygenated media was in PBS at 16 ± 
1.4 × 10-4 µmol mg-1. Unsurprisingly, the NO release from PROLI/NO in oxygenated 
physiosol was not significantly different than PBS due to their similarity; only their salt 
concentration and pH differ slightly. Nitric oxide release totals in oxygenated L-15 and Opti-
MEM cell culture media were also similar to those in PBS despite significant protein content.  
However, L-15 and Opti-MEM did not contain added fetal bovine serum (FBS) as do 
DMEM and McCoy’s, the latter resulting in NO scavenging via the presence of sulfhydryl-
containing proteins (e.g. albumin, fibrinogen, macroglobulins, glycoproteins).66,67 For 
example, the amount of NO measured in simulated wound fluid (10% v/v FBS in water) was 
significantly lower (60.4 ± 7.4 × 10-5 µmol mg-1).  In whole blood, undoubtedly the most 
complex of all the media tested, the measured NO total was the lowest (17.3 ± 4.8 × 10-7 
µmol mg-1), due to the expected reaction of NO with numerous blood proteins including 
oxyhemoglobin.68 Despite the low total NO measured in whole blood, it was still quantifiable 
using the amperometric sensor.  Nitric oxide totals in blood constituents (i.e., plasma and 
serum) were also determined with the amperometric sensor.  Due to the reduced hemoglobin 
 80 
concentration in these samples, the NO totals were greater than those in blood (4.02 ± 1.3 × 
10-4 µmol mg-1 and 1.63 ± 0.67 × 10-4 µmol mg-1 for plasma and serum, respectively).  
While testing of deoxygenated media was limited to solutions that did not foam, NO 
levels were larger after the removal of oxygen (Figure 2.4). These results were expected 
since oxygen reacts readily with NO.69,70 In blood and other media containing high protein 
content or cells, fouling due to protein/cell adsorption may also impact the analytical 
accuracy of the measurement for electrochemical sensors.71-74 Of note, such fouling for 
sensors used in the short experiments described herein only accounted for a 3–5% decrease in 
sensitivity (data not shown), and therefore did not contribute significantly to the differences 
observed in NO totals.  
Analogous to the Griess assay and chemiluminescent detection, the accurate 
electrochemical detection of NO was also dependent on the concentration of the NO donor. 
However, a concentration-dependent effect was observed in all media (Figure 2.3). We 
attribute this effect to the finite surface area of the working electrode, whereby greater 
concentrations of the NO donor readily alter the local NO concentrations. 
As the amount of NO donor near the electrode surface influences the concomitant NO 
measured, the electrode distance from an NO source should have a similar effect on NO 
measurement. To examine this methodically, a NO-selective electrode was placed 25, 50, and 
100 µm above a NO-releasing surface (xerogel polymer cast on glass) under ambient 
conditions in PBS. The amperometric signal (current) obtained when the working electrode 
was placed 50 µm above the surface at 95 min was 45% of that recorded at 25 µm (Figure 
2.5). Similarly, the signal was reduced by 73% at 100 µm above the surface (relative to the 
25 µm working electrode placement). While such NO source/electrode distance dependence 
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will clearly impact the analytical accuracy of a measurement, it may be useful for measuring 
the diffusion of NO from surfaces or cells as a function of biological medium. 
Despite the overall low NO totals that would be quantified electrochemically, the use 
of amperometric sensors remains beneficial due to unequalled spatial and temporal 
resolutions. As such, electrochemistry has proven to be quite useful for the characterization 
of cellular NO release11,56,57,59-62 and may prove useful for measurements from small NO-
releasing surfaces. However, electrochemical NO analysis is generally the least robust of the 
methods described herein, requiring frequent calibration and performance testing to maintain 
data integrity.   
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Figure 2.4 Nitric oxide totals measured using PROLI/NO as the NO source in several 
types of biological media as determined via amperometry in oxygenated (solid) and 
deoxygenated (striped) solutions.  Theoretical NO release from PROLI/NO is 7.9 µmol mg-1.  
*Significant difference (p <0.05) relative to PBS.  #Significant difference (p <0.05) relative 
to deoxygenated solution. 
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Figure 2.5 Distance-dependent NO release from xerogel membranes in PBS detected via 
constant potential amperometry. 
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2.4 Conclusions 
The analytical measurement of NO is complex,12 requiring careful scrutiny of both 
the analysis method and its performance as a function of solution milieu. While prior work 
has described the utility of the Griess assay, chemiluminescence analyzers, and 
electrochemical sensors for measuring NO in solution, performance discrepancies as a 
function of sample type have been disregarded. The data reported here clearly demonstrate 
the significant variations between analysis technique and sample composition. As such, the 
caveats of the analytical method employed must be carefully considered with respect to 
sample, desired data (e.g., NO totals, flux, kinetics and bioavailability), and result integrity. 
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CHAPTER 3: MICROFLUIDIC DEVICE FOR AMPEROMETRIC NITRIC OXIDE 
DETECTION IN BIOLOGICAL MEDIA3 
 
3.1 Introduction 
Nitric oxide (NO), a diatomic free radical endogenously produced by a class of 
enzymes known as nitric oxide synthases (NOS),1-9 plays a role in a number of physiological 
processes including wound healing,10-12 angiogenesis,13-16 and the immune response.6,17,18 As 
might be expected, the detection and quantification of NO in vivo and from NO donor 
scaffolds has been the subject of intense research.19-25 Measuring NO in biological systems is 
challenging due to NO’s reactivity (i.e., short half-life), wide concentration range (pM to 
µM),1-3,9 and sample complexity.19 Despite such challenges, direct and indirect methods for 
measuring NO are routinely employed to determine its concentration in biological samples.26 
Often, NO is most easily quantified by measuring its oxidative byproducts (e.g., nitrite and 
nitrate). In this respect, absorbance or fluorescence may be used to quantify NO upon its 
reaction with an assay reagent after oxidation to nitrite or nitrate (i.e., NOX).3,27-29 Depending 
on the sample, pre-existing NOX species could be measured simultaneously and thus must be 
considered when determining the signal from solely NO.  For example, the Griess assay is 
widely used to quantify NO indirectly as nitrite in solution. Nitrite and nitrate levels fluctuate 
                                                
3 This chapter previously appeared as a manuscript in Analytical Chemistry. The original citation is 
as follows: Hunter, R. A.; Privett, B. J.; Henley, W. H.; Breed, E. R.; Liang, Z.; Mittal, R.; Yoseph, 
B. P.; McDunn, J. E.; Burd, E. M.; Coopersmith, C. M.; Ramsey, J. M.; Schoenfisch, M. H. 
"Microfluidic amperometric sensor for analysis of nitric oxide in whole blood." Analytical 
Chemistry 2013, 85, 6066-6072. 
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in physiological milieu,1-3,9 making real-time NO concentration determination complex.3 
Strategies for measuring NO more directly include chemiluminescence,30,31 electron 
paramagnetic resonance (EPR) spectroscopy,30,32,33 and the use of electrochemical sensors.19, 
26 Although measurement of NO by chemiluminescence or EPR allows for sensitive and 
direct analysis, the required instrumentation for these methods is expensive, requires 
extensive user training, and is difficult to adapt for analysis of challenging biological 
matrices such as whole blood.26,34 In contrast, electrochemistry allows for real-time 
measurement of NO in physiological media using a sensor platform that is tunable (i.e., 
sensor style, geometry, material, and size) based on the application at a generally low 
cost.19,20,22,26,32,35-48 For biomedical use, electrochemical sensors are amenable to 
miniaturization and thus can facilitate both in vivo and ex vivo analysis.19,20,49,50  
A notable obstacle for measuring NO accurately in biological milieu via amperometry 
is the presence of interfering species such as nitrite, acetaminophen, ascorbic acid, uric acid, 
hydrogen sulfide and ammonium/ammonia that may also be redox active at the working 
electrode potential required for NO analysis.19,51,52 Almost all effective NO sensor designs 
include a membrane-modified working electrode to eliminate or reduce the diffusion of 
interferents and concomitant erroneous sensor response. For example, working electrodes 
have been modified with Teflon,® Nafion,® and silicon rubber membranes to restrict the 
diffusion of nitrite and larger molecules such as dopamine and ascorbic acid to the electrode 
surface, relative to NO.43,44,50,53 To simplify NO sensor fabrication, we have employed 
xerogel sensor membranes that enable straightforward modification of a number of electrode 
geometries via dip coating or casting of a sol solution.45,46 The ensuing xerogel-modified 
 94 
sensors are characterized by superior analytical performance (i.e., sensitivity and selectivity 
for NO). 
The style of electrode platform (i.e., needle-type, planar, microfluidic) is dependent 
on the intended measuring environment. For example, needle-type sensors provide adequate 
NO sensitivity for single cell analysis.42,47 The sensor design requirements for blood analysis 
are more complex. Malinski et al. reported the fabrication of a Teflon®-coated NO 
microsensor (5 µm tip diameter) to measure NO intravascularly in human subjects before and 
after the administration of bradykinin.47 However, the clinical utility of such in vivo devices 
proved poor primarily due to biofouling (i.e., protein adsorption, platelet adhesion, and clot 
formation) that leads to erratic or unreliable sensor response.54 While ex vivo measurements 
are possible, the most common sensor designs require large sample volumes (>1 mL) and 
convection that increases background noise and negatively impacts analytical performance. 
In contrast to stand-alone sensors, the use of microfluidics allows for reduced sample 
volume and handling (e.g., elimination of mechanical convection), thus addressing the 
shortcomings of prior devices and analytical methodology required for clinical analysis.55,56 
With respect to NO, Spence et al. combined microfluidics with planar carbon ink electrodes 
to measure NO from stimulated endothelial cells.57 The device was fabricated using 
polydimethylsiloxane (PDMS) channel walls. Recognizing that NO and other gases may 
diffuse through PDMS, Cha et al. reported the fabrication of a catalytic gold/indium tin oxide 
microfluidic NO sensor using polyethylene tetraphthalate/polyurethane channels to minimize 
loss of NO.58 Despite suitable analytical performance in phosphate buffered saline (PBS; 10 
pA nM-1 NO), the design of this device was complex, requiring hand assembly.   
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Herein, we report the use of sol-gel chemistry and standard photolithographic 
techniques amenable to rapid, reproducible, and inexpensive fabrication of microfluidic NO 
sensors. The analytical performance of the device is demonstrated in simulated wound fluid 
and whole blood, indicating the ability to measure NO in complex media. Toward more 
clinical applications, the device is used to monitor NO concentrations in a murine model of 
sepsis confirming that NO levels increase during a systemic inflammatory response to 
infection.2,3 
 
3.2 Materials and Methods 
 (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) was 
purchased from Gelest (Tullytown, PA). Methyltrimethoxysilane (MTMOS), (3-
aminopropyl)triethoxysilane (APTES), ascorbic acid, acetaminophen, sodium sulfide and 
sodium nitrite were purchased from Sigma (St. Louis, MO).  Ammonium hydroxide solution 
(14.8 M) was purchased from Fisher Scientific (Hampton, NH).  Nitric oxide gas (99.5%) 
was purchased from Praxair (Danbury, CT).  Nitrogen and argon gases were purchased from 
National Welders Supply (Raleigh, NC). Other solvents and chemicals were analytical-
reagent grade and used as received. A Millipore Milli-Q UV Gradient A10 System (Bedford, 
MA) was used to purify distilled water to a final resistivity of 18.2 MΩ·cm and a total 
organic content of <6 ppb. Simulated wound fluid was produced by diluting fetal bovine 
serum (FBS) obtained from Sigma in distilled water (1:10, v:v). Whole porcine blood was 
drawn into 1:10 (v:v) 40 mM ethylenediaminetetraacetic acid (EDTA) from healthy pigs at 
the Francis Owen Blood Lab (University of North Carolina, Chapel Hill, NC).  
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3.2.1 Preparation of working electrodes 
Planar platinum (Pt) electrodes were patterned onto on a 0.9 mm thick SCHOTT 
B270 glass substrate (Telic Company; Valencia, CA) via photolithography and evaporative 
metal deposition. Glass substrates (100 × 100 mm) were cleaned with distilled water, 
isopropanol, nitrogen gas, and then dried at 95 °C for 5 min. After cooling to room 
temperature, Microposit S1813 photoresist (Microchem Corp.; Newton, MA) was deposited 
via spincoating at 3000 rpm for 45 s.  The substrate was then soft-baked at 115 °C for 2 min. 
An electrode pattern was exposed through a polyester film/emulsion photomask (Infinite 
Graphics Incorporated; Minneapolis, MN) for 10 s using a Karl SÜSS MA6/BA6 mask 
aligner (hard contact, 100 µm gap) equipped with a 350 W UV lamp (SÜSS Microtec; 
Garching, Germany). The pattern was developed in an AZ400 alkaline developer (1:3 
dilution in water) for 1 min, rinsed with distilled water, dried with nitrogen gas, and then 
baked on a hotplate at 115 °C for 2 min. The exposed glass surface was oxygen plasma 
cleaned at 100 W for 1 min. To fabricate working electrodes, 10 nm Ti and 150 nm Pt were 
deposited in a Kurt J. Lesker PVD 75 magnetron sputtering system (Clairton, PA). The 
substrate was soaked in acetone to liftoff the remaining photoresist and excess metal 
resulting in 100 µm wide patterned Pt electrodes on glass. 
3.2.2 Membrane synthesis and deposition 
Working electrode-modified glass substrates were rinsed with distilled water, dried 
with nitrogen, and heated to 95 °C for 5 min.  Substrates were then oxygen plasma cleaned at 
100 W for 1 min. The membrane deposition regions were masked by evenly applying 1002F-
50 photoresist (prepared as previously described59) by spin-coating at 500 rpm for 10 s, 3000 
rpm for 40 s, and heating at 95 °C for 1 h on a hot plate. The electrode pattern was exposed 
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through a chrome mask for 80 s using the mask aligner. Following exposure, the substrate 
was baked on a hot plate at 95 °C for 10 min. The pattern was developed in SU-8 developer 
(Microchem Corp.; Newton, MA) for 6 min, rinsed with isopropanol, dried with nitrogen, 
and baked on a hotplate at 115 °C for an additional 10 min. An adhesion layer of APTES was 
deposited via three 5 mL injections at 130 °C using a LabKote vapor deposition system 
(Yield Engineering Systems; Lawrence, CA). The fluoroalkoxysilane membrane solution 
was prepared via the acid catalyzed hydrolysis and condensation of 17FTMS and MTMOS as 
reported previously.45 Briefly, 600 µL absolute ethanol, 120 µL MTMOS, 30 µL 17FTMS, 
160 µL distilled water, and 10 µL 0.5 M HCl were added sequentially to a 1.5 mL micro 
centrifuge tube with vigorous mixing between the addition of each component. This solution 
was then vortexed for 1 h. Working with 16 electrode batches, 30 µL of the sol solution was 
spread-cast across the working electrodes using a pipette tip for 1 min to ensure even coating.  
The xerogel-coated substrate was then dried overnight under ambient conditions to facilitate 
adequate curing. The 1002F-50 photoresist was removed by soaking the substrate for 1 h in 
distilled water. Membrane thickness was characterized using a P15 Profilometer (KLA-
Tencor Corp.; San Jose, CA). 
3.2.3 Microfluidic device fabrication 
Reference electrodes were fabricated on separate glass microscope slides. The slides 
were oxygen plasma cleaned (100 W, 5 min) and masked with tape so that only the middle 
third of each slide remained exposed. Reference electrodes were deposited in this region by 
first sputtering a 10 nm Ti adhesion layer followed by a ~1 µm Ag layer in the magnetron 
sputtering system. To form channel walls, two parallel strips of 6.3 mm double-sided 
Kapton® polyimide tape (90 µm thick, KaptonTape.com) were applied ~3 mm apart and 
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perpendicular to the Pt electrodes on the working electrode substrate. The reference electrode 
slide was then bonded to the working electrode substrate (reference electrode facing down) 
by aligning and clamping the components together with spring clamps and heating at 100 °C 
for 5 min. After the ends of the channel were sealed, 8 mm diameter inlet/outlet reservoirs 
were affixed to the device using a high-strength, chemical-resistant epoxy (Loctite® 
Professional Heavy Duty 5 min; Westlake, OH). Electrical wires were soldered directly to 
the solder-on pads of each electrode facilitating an electrical connection to the potentiostat. 
Prior to using the device to measure NO, the Ag electrode was chemically oxidized by 
reaction in 50 mM ferric chloride for 10 s to create a pseudo-reference/counter electrode. 
Following this process, the device channel was rinsed with distilled water. 
3.2.4 Microfluidic device characterization 
To evaluate the performance of the microfluidic device, the working and 
reference/counter electrodes were connected to a CH Instruments 1030A 8-channel 
potentiostat (Austin, TX).  Gravity solution flow (~100 µL min-1) was employed to move 
sample through the device by attaching a 40 mm piece of Tygon® tubing to the inlet 
reservoir. This location served as the introduction site. Prior to sample analysis, the device 
was polarized at 700 mV vs. the AgCl pseudo-reference/counter electrode for up to 1 h in 
PBS. To calibrate the device, a saturated NO standard solution (prepared by purging 
deaerated PBS with NO gas for ~10 min resulting in a 1.9 mM solution of NO) was diluted 
with PBS and introduced into the inlet reservoir. To assess the selectivity of the sensor for 
NO, separate solutions of nitrite, acetaminophen, ascorbic acid, uric acid, hydrogen sulfide, 
ammonia/ammonium, and peroxynitrite (protonated and deprotonated) were injected into the 
device. The sensitivity of the microfluidic sensor to NO was also tested in both simulated 
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wound fluid (10% v/v fetal bovine serum in water) and anti-coagulated porcine whole blood. 
In these experiments, select volumes of the saturated NO solution were added to 2 mL 
aliquots of blood, mixed briefly, and added to the sample reservoir. For wound fluid testing, 
increasing volumes of saturated NO were added to 30 mL of wound fluid, mixed, and added 
to the sample reservoir.  
3.2.5 Animals 
Murine sepsis experiments were performed using C57Bl6/J mice that had free access 
to food and water, and were maintained on a 12 h light/dark schedule.  Animal studies were 
performed in accordance with National Institutes of Health Guidelines and approved by the 
Emory University Institutional Animal Care and Use Committee (IACUC). To initiate 
pneumonia-induced sepsis, mice were anesthetized using isoflurane and then received a mid-
line cervical incision. A total of 40 µL of Pseudomonas aeruginosa (ATCC 27853) 
suspended in normal saline was then introduced by direct intratracheal installation using a 
28-gauge needle, corresponding to 2–4 x 107 colony-forming units.60,61 To enhance delivery 
of the bacteria into the lungs, mice were held vertically for 10 s. All mice received a 
subcutaneous injection of saline (1 mL) post-operatively to compensate for insensible fluid 
losses. For NO measurement, 250 µL of blood was obtained via cardiac puncture (while the 
animals were under anesthesia) at the time of sacrifice. The blood was immediately 
transferred to an EDTA tube, mixed, and injected onto the sample port of the microfluidic 
device. Blood samples from control mice in the absence of bacteria exposure were used as 
the 0 h time point for NO analysis and were run throughout the experiment. Additionally, all 
sensors were calibrated before, during, and after animal experiments. 
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3.2.6 Statistical analysis 
Murine sepsis data were analyzed using OriginPro 7.0 (OriginLab; Northampton, 
MA) and presented as mean ± standard error of the mean. Comparisons between groups were 
performed using the Wilcoxon rank-sum test with P < 0.05 considered to be statistically 
significant. 
 
3.3 Results and Discussion 
Working electrode compositions for NO analysis have spanned many materials 
including carbon ink,57 gold/indium tin oxide,62 and platinum.46,63 Platinum (Pt) working 
electrodes were utilized for this study due to availability, compatibility with our 
microfabrication equipment, and inherent robustness for sensor applications. Working 
electrodes were deposited by metal evaporation using standard photolithographic techniques. 
Clean glass was first modified with a thin (10 nm) layer of Ti to improve the adhesion of Pt 
at the desired thickness (150 nm), with metal thickness monitored using a quartz crystal 
microbalance. 
Prior to xerogel modification, an ethanol-resistant photoresist (1002F-50) mask was 
applied over the entire substrate to enable selective deposition of the membrane solution over 
only the working electrodes after UV exposure and processing.  To ensure selectivity for NO 
over interfering species, a 20% (v/v) 17FTMS-MTMOS fluorinated alkoxysilane xerogel 
membrane was deposited onto the microfabricated working electrodes. Selectivity for NO 
using xerogel sensor membranes was modified slightly from what we reported previously for 
Pt-coated tungsten conical wire electrodes.45 Of note, spread-casting of the sol was necessary 
to enable reproducible coating of the planar Pt electrodes; dip-coating of this substrate (in 
sol) did not allow for sufficient control over the ensuing xerogel thickness. The spread-
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casting process consistently produced xerogel membranes that were 129 ± 59 nm thick, 
robust (i.e., scratch resistant) and capable of withstanding subsequent solution immersion (for 
use as sensors) without delamination or cracking of the films. 
Before microfluidic device fabrication, the xerogel-coated Pt electrodes were 
characterized with respect to NO sensitivity and selectivity over common interferents in a 
stirred solution of PBS.  An unforeseen benefit of the cast NO-selective membrane was 
reduced background signal and noise while making measurements. While the sensitivity of 
the membrane-coated Pt electrodes to NO was reduced by ~10% relative to bare electrodes 
(2.2 to 2.0 pA nM-1 NO, respectively), the decreased noise allowed for an improved limit of 
detection (260 vs. 6 nM NO for bare vs. xerogel-coated, respectively). Analogous to our 
previous wire-based electrodes,45 the sensitivity of the xerogel-modified electrodes to NO 
was ~4 orders of magnitude greater than any of the interferents tested (nitrite, ascorbic acid, 
acetaminophen, uric acid, hydrogen sulfide, ammonia/ammonium). 
A microfluidic device was fabricated by placing a glass substrate patterned with a Ag 
reference electrode on top of a ~3 mm wide microfluidic channel formed by applying two 
strips of double-sided Kapton® polyimide tape (~90 µm thick) across the working electrode 
substrate.  A cutaway illustration of the device fabricated in the manner is shown in Figure 
3.1, with a cross-section given in Figure 3.2. A deep, wide channel was chosen for this 
design to allow for adequate flow of more viscous biological fluids like blood or plasma. The 
addition and removal of sample were accomplished by fixing glass (8 mm diameter) 
reservoirs over the inlet and outlet vias with epoxy.  
The fully assembled device was characterized using constant potential amperometry 
at a working electrode potential of +700 mV vs. Ag/AgCl pseudo-reference/counter 
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electrode. To achieve a steady baseline current, the device was polarized in PBS for ~1 h 
prior to testing. Nitric oxide calibration curves were constructed by adding 1.6 µL aliquots of 
saturated NO to a PBS solution and transferring ~1 mL of this solution to the sample inlet 
reservoir of the device. Measurements were recorded upon stabilization of the oxidation 
current. The NO solution in the reservoir was then replaced with another NO solution of a 
different concentration. As shown in Figure 3.3, the response to NO for bare and membrane-
coated electrodes in the microfluidic device geometry was 2.0 and 1.4 pA nM-1 NO, 
respectively. As would be expected, the xerogel-coated electrode was characterized by a 
lower sensitivity than the bare electrode due to slowed NO diffusion across the membrane to 
the electrode surface. In addition, sensor response to NO for both the bare and coated 
electrodes was lower for the microfluidic devices relative to the entire glass substrate 
(described previously) because the channel exposes only a portion of the actual working 
electrode area patterned onto the glass. 
Despite lower sensitivity when encased within the microfluidic device, the limit of 
detection for both the bare and coated microfluidic electrodes were 880 and 840 pM NO, 
roughly 1 log lower than the same electrodes prior to device fabrication. The improved limit 
of detection is attributed to lower noise due to the elimination of bulk convection and 
oscillating magnetic field from the stir plate. Furthermore, the use of gravity flow avoids 
pulsatile noise common to peristaltic pumps. For the device configuration described, volumes 
as low as 250 µL were adequate for successful NO analysis. By integrating a pulsatile-free 
flow control device (e.g., a venturi or syringe pump) and/or reducing channel width, even 
smaller volumes are conceivable. The response of the xerogel-coated electrode to nitrite, 
ascorbic acid, acetaminophen, uric acid, hydrogen sulfide, ammonium, ammonia, and   
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Figure 3.1 A) Cutaway illustration of electrode locations and channel construction; and, 
B) fully assembled device with inlet and outlet reservoirs. 
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Figure 3.2 Illustration of device cross-section (not shown to scale). 
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Figure 3.3 Typical sensor response of bare (dotted red line) and xerogel-coated (solid 
black line) electrodes in microfluidic geometry to NO in PBS flowing at 15 µL/min. Inset 
shows NO calibration curves for bare (●) and xerogel-coated (▲) sensors. 
  
400 600 800 1000 1200
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0 100 200 300 400 500
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
R
es
po
ns
e 
(n
A
)
Time (sec)
100 nM NO
500 nM NO
PBS
R
es
po
ns
e 
(n
A
)
[NO] (nM)
 106 
 
Interferent  
Selectivity 
(coated) 
Selectivity 
(bare) 
Hydrogen sulfide < -6.0 -0.5 
Ammonium -5.8 -5.6 
Nitrite -5.3 -4.2 
Uric acid -5.0 -2.8 
Ascorbic acid -4.2 -2.4 
Acetaminophen -4.0 -2.7 
Ammonia -3.8 -3.8 
Peroxynitrite (ONOO-) -4.0 -2.7 
Peroxynitrite (ONOOH) -1.5 -0.5 
Table 3.1 Selectivity coefficients of common interferents for both bare and xerogel-
coated platinum working electrodes 
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peroxynitrite (both protonated and deprotonated) was exceptionally low. The difference in 
selectivity between bare and xerogel-coated platinum electrodes is given in Table 3.1. Of 
note, an improvement in selectivity over most interferents was observed with the addition of 
the xerogel membrane. One exception to the selectivity improvement was ammonia, which is 
not a concern as it wouldn’t be present in high concentrations at physiological pH (7.4). 
3.3.1 Microfluidic nitric oxide sensor response in physiological fluids 
The analytical performance (i.e., sensitivity and selectivity) of the microfluidic NO 
sensor was characterized in wound fluid and whole blood to determine clinical analysis 
potential. Despite the presence of proteins, the microfluidic NO sensor proved capable of 
measuring NO in simulated wound fluid (10% FBS in water, v/v, based on the composition 
of interstitial fluid), a clinically relevant sample for which NO analysis may prove useful due 
to NO’s role in wound healing.10-12,64 Boykin recently suggested that NO could be used as a 
prognostic biomarker for assessing wound healing if easily measured in wound extracts.64 
The microfluidic sensor responded to NO additions in the simulated wound fluid sample with 
a LOD of 18 nM, roughly 20 times higher than in PBS.  The increased NO detection limit is 
attributed to NO scavenging, as would be expected for proteinaceous solutions. Indeed, the 
LOD was increased further in whole blood. 
Measurement of NO in whole blood is believed to be difficult due to NO scavengers 
such as hemoglobin and oxygen.65-67 To calibrate NO sensitivity accurately, aliquots of a 
saturated NO solution were added to 1 mL samples of porcine blood prior to transfer into the 
microfluidic device.  As shown in Figure 3.4, the addition of saturated NO solution was 
readily measurable, producing currents proportional to the amount of NO spiked into the 
blood up to 100 µM. Of note, care was taken to minimize the period between NO injection 
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into the blood and the analysis to avoid degradation of the NO signal due to reaction with 
scavenging species present in the blood.  As shown in Figure 3.4, the signal did decay over 
time (within ~100 s), indicating the prevalence of, and problems associated with, NO 
scavenging/loss. 
Although the sensitivity to NO in blood was decreased relative to PBS (0.0035 vs. 1.4 
pA nM-1 NO), the reduced noise characteristic of the microfluidic device configuration still 
enabled a satisfactory LOD (472 nM NO).  A LOD of ~500 nM is likely sufficient for 
studying a number of NO-mediated disease states where NO concentrations have been 
reported in the µM range.2,3,36,68-71 Of note, slightly higher sensitivities (0.0125 vs. 0.0035 pA 
nM-1 NO) were observed for higher NO concentration ranges (i.e., 20–100 µM NO), likely 
attributed to the greater concentration of NO relative to potential scavengers in blood. 
3.3.2 Nitric oxide levels in sepsis 
Sepsis is a systemic inflammatory response caused by severe infection and 
characterized by a multifaceted immunologic response consisting of an initial 
hyperinflammatory phase and subsequent immunosuppression.72-75 Due to NO’s role in the 
immune response to pathogens,6,17,18 previous studies have monitored plasma concentrations 
of nitrate and nitrite—both stable end products of NO oxidation in vivo—using the Griess 
assay to assess their role as biomarkers of sepsis. As expected, large concentration changes 
were observed for severely septic patients.2,3,76 While indirect NO monitoring via the Griess 
assay may provide some insight into changes in NO dynamics throughout the progression of 
disease, blood sample processing and poor LOD preclude bedside monitoring and/or sepsis 
risk assessment (at pre-severe disease levels). In contrast, the microfluidic NO sensor 
described herein may represent a strategy for point-of-care monitoring of NO directly in 
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whole blood. To evaluate the ability to assess sepsis progression, we infected mice with a 
single but lethal (96% mortality within 48 h) dose of P. aeruginosa (2–4 x 107 colony-
forming units). A group of unmanipulated control animals (n=8) was used as the 0 h-time 
point to represent healthy or baseline blood NO concentrations. Blood was sampled from 
infected mice at 2, 6, and 24 h (n = 8, 10, and 13 animals per group, respectively) throughout 
the course of sepsis progression. As expected, blood NO concentration changes over 2, 6, and 
up to 24 h after introduction of bacteria were statistically significant, reaching 82 ± 12 µM at 
24 h (Figure 3.5). This 8-fold increase agrees with those reported previously by indirect 
detection of NOX species.2,3,76 For example, Strand et al. reported a 7-fold increase in average 
NOX concentration in human patients with sepsis (144 ± 39 µM) relative to healthy patients 
(20 ± 3 µM).2 The observed large increase in blood NO in this study is not surprising given 
the lethal bacterial dose administered. Future experiments will employ a lower, less lethal 
dose of P. aeruginosa and smaller measurement intervals, if necessary, to study the onset of 
sepsis. Additionally, the effects of other bacterial strains and antibiotic treatment on blood 
NO levels will be assessed to more fully gauge the suitability of NO as a sepsis biomarker 
and prognosis indicator upon treatment.  
 
 110 
 
 
Figure 3.4 Typical microfluidic sensor response to 1 µM increases in NO concentration 
(A) and full dynamic range (B) in porcine whole blood.  
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Figure 3.5 Temporal changes in blood NO concentrations during the progression of 
sepsis in a pneumonia murine model of sepsis. Each data point represents the average ± 
standard error of the mean for a group of mice of n ≥ 8. *denotes a significant difference in 
blood NO relative to the 0 h unmanipulated group (p < 0.05). 
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3.4 Conclusions 
Herein we describe the use of standard photolithographic microfabrication techniques 
to construct a microfluidic NO sensor.  The use of a NO-selective working electrode and 
microfluidic geometry enable highly sensitive detection of NO in both PBS and more 
challenging biological matrices including simulated wound fluid and whole blood. The 
analytical performance of the microfluidic sensor was dependent on sample milieu, with 
excellent sensitivity and selectivity for NO in PBS.  As expected, the response of the device 
to NO in biological fluids was attenuated due to scavenging of NO by proteins.  
Nevertheless, the 472 nM LOD in blood is the lowest reported to date using direct 
electrochemical detection.  The microfluidic device configuration enables rapid analysis of 
NO at low concentrations and in small (~250 µL) sample volumes that may prove useful for 
studying NO’s action as a potential disease biomarker and/or therapeutic. As an example, 
whole blood NO levels changed dramatically in a pneumonia mouse model of infection 
indicating NO’s potential as a biomarker for sepsis. 
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CHAPTER 4: IMPROVED DETECTION OF S-NITROSOTHIOLS VIA VISIBLE 
PHOTOLYSIS AND AMPEROMETRIC DETECTION IN A MICROFLUIDIC 
DEVICE 
 
4.1 Introduction 
Nitric oxide (NO), a seemingly ubiquitous endogenous free radical, is intricately 
involved in a number of physiological processes including wound healing,1-4 angiogenesis,5-8 
and the immune response.9-12 As such, the detection and quantification of NO and its 
metabolites is the subject of intense investigation, especially in biological environments.13-21 
S-nitrosothiols (RSNOs), present in both low molecular weight (e.g., S-nitrosoglutathione 
and S-nitrosocysteine) and macromolecular (e.g., S-nitrosoalbumin) forms in vivo,22-29 are a 
class of metabolites believed to be the primary endogenous reservoirs and transporters of NO 
due to the nitrosation of thiols within blood plasma (which contains ~600 µM free thiols), 
cells, and tissues.30 Futhermore, RSNO concentrations have been identified as important in a 
number of disease states, including sepsis, asthma, and tuberculosis.25,31-33 While some 
RSNOs have even been employed for clinical applications (e.g., S-nitroso-N-acetyl-
penicillamine as a vasodilator),27,34 further understanding of the formation, decomposition, 
and circulating concentrations of these species in both healthy and disease states is vital as 
future therapeutic uses emerge. 
To date, nearly all RSNO measurement strategies are based on chemiluminescence, 
fluorescence, or electrochemistry.13,18,35-37 These methods rely on the indirect quantification 
of RSNOs via homolytic cleavage of the S—N bond with subsequent NO release and 
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detection. Reductive catalytic bond cleavage can be achieved via copper or other reducing 
agents (e.g., ascorbate), but requires the addition of external reagents or the immobilization 
of a catalyst.38-45 Photolysis is an alternative means of achieving S—N bond cleavage that is 
easily coupled to a detection platform. In such experiments, the frequency of light has been 
proven to be an important parameter. For example, the use of visible over ultraviolet light 
allows for efficient photolysis while avoiding the possibility of overestimation of RSNOs due 
to the generation of NO from nitrate.46-49 Riccio et al. previously reported on the use of 
visible photolysis and amperometric detection for the quantification of RSNOs in both 
phosphate buffered saline (PBS) and blood plasma.50 To achieve adequate limits of detection, 
this detection scheme required deoxygenation of samples to avoid the reaction of NO with 
oxygen. The requirement of large sample volumes (40 mL), further limited the clinical utility 
of the setup. 
In contrast, microfluidic devices permit the use of significantly reduced sample 
volumes, improving amenability to clinical analysis.51,52 The smaller sample volume also 
allows for more complete sample irradiation, thus increasing the RSNO to NO conversion 
efficiency of photolysis. Improvements in limits of detection and RSNO conversion to NO 
using a microfluidic platform have the potential for more accurate measurement of 
biologically relevant RSNO concentrations in physiological media (e.g., blood serum or 
plasma).  
Herein, we report the use of a modified microfluidic platform for enhanced visible 
photolysis and amperometric detection of S-nitrosothiols. The improved analytical 
performance of this device is demonstrated in both PBS and blood plasma. The device was 
also used to monitor the basal endogenous RSNO levels in healthy swine. 
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4.2 Materials and Methods 
  (Heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) was purchased 
from Gelest (Morrisville, PA). Methyltrimethoxysilane (MTMOS), (3-
aminopropyl)triethoxysilane (APTES), reduced l-glutathione (GSH), bovine serum albumin 
(BSA), l-cysteine-hydrochloride (Cys), and diethylene triamine pentaacetic acid (DTPA) 
were purchased from Sigma (St. Louis, MO). Nitric oxide gas (99.5% pure) was purchased 
from Praxair (Danbury, CT).  Nitrogen and argon gases were purchased from National 
Welders Supply (Raleigh, NC). A Millipore Milli-Q UV Gradient A10 System (Bedford, 
MA) was used to purify distilled water to a final resistivity of 18.2 MΩ·cm and a total 
organic content of <6 ppb. A high-power mounted 530 nm light-emitting diode (LED; model 
M530L2) and driver were purchased from Thorlabs Inc. (Newton, NJ). Other solvents and 
chemicals were analytical-reagent grade and used as received.  
4.2.1 Microfluidic device fabrication 
Devices were fabricated as previously described.15 Briefly, 150 nm thick planar 
platinum (Pt) electrodes with a 10 nm titanium seed layer were patterned onto a glass 
substrate via photolithography and evaporative metal deposition. The resulting Pt electrodes 
were 100 µm wide. To impart selectivity to NO, a xerogel membrane was applied to each 
working electrode. Following the deposition of a 1002F-50 photoresist mask, an adhesion 
layer of APTES (1% v/v in ethanol) was deposited via three passes with a spray coater. The 
substrate was then rinsed with water and dried in ambient conditions overnight. A 
fluoroalkoxysilane membrane solution was prepared via the acid catalyzed hydrolysis and 
condensation of (heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane (17FTMS) and 
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methyltrimethoxysilane (MTMOS) as reported previously.15,21 Briefly, 600 µL absolute 
ethanol, 120 µL MTMOS, 30 µL 17FTMS, 160 µL distilled water, and 10 µL 0.5 M HCl 
were added sequentially to a 1.5 mL microcentrifuge tube with vigorous mixing between the 
addition of each component. This solution was then vortexed for 1 h. The sol solution (30 
µL) was spread-cast across the working electrodes for 1 min using a pipette tip to ensure 
even coating.  The xerogel-coated substrate was then dried overnight under ambient 
conditions to facilitate adequate curing. The 1002F-50 photoresist was removed by soaking 
the substrate for 1 h in distilled water.  
Reference electrodes were fabricated on separate glass microscope slides by 
sputtering a 10 nm Ti adhesion layer followed by a ~1 µm Ag layer in the magnetron 
sputtering system. To form channel walls, two parallel strips of 6.3 mm wide double-sided 
Kapton® polyimide tape (90 µm thick) were applied ~1 mm apart and perpendicular to the Pt 
electrodes on the working electrode substrate. The reference electrode slide was then 
clamped to the working electrode substrate bonded by heating at 100 °C for 5 min. After the 
ends of the channel were sealed, 8 mm diameter inlet/outlet reservoirs were affixed to the 
device. Prior to using the device, the Ag electrode was chemically oxidized by reaction in 50 
mM ferric chloride for 10 s to create a pseudo-reference/counter electrode. Following this 
process, the device channel was rinsed with distilled water. 
4.2.2 Preparation of S-nitrosothiols 
Low molecular weight RSNOs were prepared using a previously reported procedure.50,53 
Nitrosation of thiols was achieved by mixing 5 mM GSH or Cys dissolved in 120 mM 
sulfuric acid with an equal volume of 5 mM sodium nitrite in 20 µM EDTA. S-
nitrosoalbumin (AlbSNO) was prepared by mixing a solution of BSA (200 mg mL-1 in water) 
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with 1.5 mM sodium nitrite in 0.5 M hydrochloric acid in the dark for 30 min.24 Final 
concentrations of the RSNO solutions were determined via their UV absorption maxima at 
335 nm (ε = 503, 586, and 3869 M–1 cm–1 for S-nitrosocysteine (CysNO), S-
nitrosoglutathione (GSNO), and AlbSNO, respectively).54 Nitrosothiol solutions were 
shielded from light and stored at 4 °C prior to use to prevent premature degradation. 
4.2.3 Electrochemical analysis of S-nitrosothiols 
The working and reference/counter electrodes of the microfluidic device were 
connected to a CH Instruments 1030A 8-channel potentiostat (Austin, TX). Prior to sample 
analysis, the device was polarized at +800 mV vs. the Ag/AgCl pseudo-reference/counter 
electrode for at least 1 h in PBS with 500 µM DTPA (required to chelate free copper ion and 
avoid undesirable RSNO degradation). The LED was placed 100 mm above the device and 
focused using an adjustable biconvex lens to tune the focus and resulting spot size of the light 
upon the channel. An LED driver was used to vary light intensity. To calibrate the device, a 
saturated NO standard solution (prepared by purging deaerated PBS with NO gas for ~10 
min to yield a 1.9 mM solution of NO) was diluted with PBS and introduced into the inlet 
reservoir. Nitrosothiol samples were introduced into the device in an identical manner. The 
light intensity of the LED at the device channel was measured at 530 nm using a Newport 
Model 840-C hand-held optical power meter (Irvine, CA). Plasma was prepared by collecting 
fresh blood into 3 mL EDTA-coated Vacutainer® tubes (Becton, Dickinson and Company; 
Franklin Lakes, NJ) and centrifugation of this sample at 4 °C (1300 ×g for 10 min). 
Following introduction of plasma into the device, aliquots of each RSNO were added to 
facilitate calibration. To determine the ability to detect RSNOs added to whole blood, a 
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similar calibration was performed where RSNOs were added to blood prior to centrifugation, 
with subsequent analysis of the resulting plasma. 
4.2.4 Determination of basal S-nitrosothiols levels in blood 
Arterial blood was collected from Yucatan™ miniature swine (n=4) into 3 mL 
EDTA-coated Vacutainer® tubes. The blood was immediately centrifuged at 4 °C (1300 ×g 
for 10 min) to isolate blood plasma. This sample was subsequently run through the 
microfluidic device. Following sample introduction, the LED was turned on to facilitate 
RSNO decomposition to NO. 
 
4.3 Results and Discussion 
The microfluidic NO sensor utilized herein has been previously characterized with 
respect to blood NO analysis.15 In other works, Riccio et al. established the effectiveness of 
green (500–550 nm) light for photolysis of RSNOs with subsequent amperometric detection 
of NO. As such, initial analyses focused on optimizing a light source for incorporation of 
visible photolysis and amperometric detection of RSNOs within the microfluidic device 
platform. A 530 nm high-power LED was chosen as the ideal source due to its small size and 
amenability to tuning position, focus, and light intensity. The LED was positioned directly 
over the microfluidic channel at a distance of 100 mm to ensure complete irradiation of the 
sample prior to reaching the working electrode while also avoiding sample heating. The total 
transit time from the device inlet to the NO selective electrode was ~5 s.  
4.3.1 Optimization of LED configuration 
Low molecular weight nitrosothiol GSNO in oxygenated PBS was used to evaluate 
the effect of light intensity and irradiation area/focus. When evaluating intensity, the LED 
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light was focused to a 10 mm diameter spot centered on the inlet channel. As indicated in 
Table 4.1, greater light intensity yielded a linear increase in sensitivity while improving the 
limit of detection (attributed to greater RSNO to NO conversion with the more intense 
source). Representative current traces as a function of light intensity are given in Figure 4.1. 
To evaluate the effect of irradiating a larger portion of the channel (the channel length from 
inlet to working electrode is ~20 mm), the focus of the light was altered to create a larger 
area of irradiation, centered along the length of the channel. Spot sizes of 5, 10, and 20 mm 
in diameter produced slightly varied output powers of 34, 40, and 27 mW, respectively. 
While a significant difference in sensitivity was observed between the 10 and 20 mm spot 
diameters (22.6 ± 1.6 and 12.3 ± 1.2 pA µM-1), all sensitivities became equal when 
normalized to output power (~0.5 pA µM-1 mW-1), indicating this difference resulted from 
the change in apparent light output instead of variation in irradiation area. The optimized 
configuration was used (focused 10 mm diameter light at 100% intensity) for subsequent 
experiments. 
4.3.2 Detection of common low molecular weight and macromolecular nitrosothiols 
In addition to GSNO, the utility of this device was evaluated for sensitivity to CysNO 
and AlbSNO in oxygenated PBS (to represent a physiologically relevant system). As 
indicated in Table 2, the device exhibited identical sensitivities for both low molecular 
weight RSNOs (i.e., GSNO and CysNO; 22.6 ± 1.6 and 25.5 ± 1.3 pA µM-1, respectively), 
an expected result due to comparable molar absorptivities (ε = 17.2 and 14.9 M-1 cm-1, 
respectively). The maximum current signal was obtained after only 100 s, with linear 
responses up to 150 µM, well beyond expected in vivo concentrations. Based on the 
oxidation current measured from dilutions of a saturated NO solution, utilizing visible 
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photolysis within the microfluidic device configuration allows for a ~40% conversion of 
RSNO to free NO. Compared to 7–11% conversion in a 25 mL deoxygenated solution 
reported by Riccio et al. (using chemiluminescence detection),50 this result represents a 
significant improvement compared to utilizing this method in bulk solution.  
The ability of the device to detect NO from nitrosated serum albumin (AlbSNO) was 
also evaluated, as nitrosated proteins make up the majority of RSNO species in vivo.23 Not 
surprisingly, an ~80% decrease in sensitivity was observed compared to low molecular 
weight RSNOs. The greater stability of AlbSNO relative to low molecular weight RSNOs is 
well known and attributed to the protection of the nitrosocysteine group within a 
hydrophobic pocket of the protein.22,23,29,55 Of note, albumin contains only a single free 
cysteine residue for nitrosothiol formation despite its greater size,23 making its theoretical 
NO storage/release equivalent to GSNO and CysNO. 
After normalizing for differences in irradiation power and electrode surface area, a 6–
8× improvement was observed for the low molecule weight RSNOs after 1 min irradiation, 
while the sensitivity for AlbSNO was improved by ~20×. In addition, the LOD for each was 
improved by at least 55%. Importantly, the results reported herein were obtained in 
oxygenated PBS. Further performance improvements would be expected in deoxygenated  
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Figure 4.1 Representative amperometric responses for CysNO detection at 100 (blue 
dashed-dotted, 40 mW), 75 (purple dotted, 25 mW), 50 (red dashed, 6 mW), and 25% (black 
solid, 2 mW) light intensity and 10 mm irradiation diameter.  
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Table 4.1 Effect of light intensity and irradiation area on S-nitrosoglutathione sensitivity 
in oxygenated phosphate buffered saline. Data represent the mean ± standard deviation (n≥3). 
 
Spot diameter 
(mm) 
Apparent power 
(mW) 
Sensitivity 
(pA µM-1) 
Limit of detection 
(nM) 
5 34 17.6 ± 0.9 80 
10 
40 22.6 ± 1.6 60 
25 11.7 ± 2.4 120 
6 5.0 ± 1.7 280 
2 2.9 ± 0.1 480 
0 0.6 ± 0.0 2500 
20 27 12.3 ± 1.2 110 
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solutions. Indeed, a 44% increase in current was noted for a sample of GSNO upon dilution 
in deoxygenated versus oxygenated PBS (data not shown). 
4.3.3 Detection in plasma 
To fully evaluate the utility of this device for the determination of RSNOs in 
biologically relevant systems, it was important to establish whether measurement in 
physiological milieu (i.e., whole blood and plasma) was possible. Despite the significantly 
reduced sample cross-section (~90 µm) and irradiated volume (~450 nL), detection of 
exogenous RSNOs added to whole blood was not possible, likely due to light scattering 
and/or absorbance by red blood cells. Based on complete blood cell counts obtained from 
these samples, 450 nL of blood contains an average of 2 × 106 red blood cells. Nevertheless, 
measurements of RSNOs in oxygenated plasma were possible using the microfluidic device 
whether plasma was spiked with RSNOs or the RSNOs were first added to whole blood with 
subsequent centrifugation to collect plasma.  
Compared to measurements carried out in PBS, the sensitivities and limits of 
detection in plasma were greatly reduced, with an ~80% decrease in sensitivity for all RSNO 
species evaluated as shown in Table 4-2. Identical responses were achieved regardless of 
how the RSNO was added to the samples (Figure 4-2). Samples that were frozen (−20 °C) 
and reanalyzed after 24 h exhibited a ~50% decrease in sensitivity (data not shown). Based 
on these sensitivities, theoretical limits of detection of 400, 240, and 2660 nM were achieved 
for GSNO, CysNO, and AlbSNO, respectively. This diminished response is somewhat 
expected due to the opacity of plasma relative to PBS, as well as NO scavenging and light 
scattering due to the presence of proteins.56,57 Indeed, the transmittance of 530 nm light in 
blood plasma is limited to 26%.  
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Table 4.2 Sensitivity and limit of detection of a range of S-nitrosothiol species in 
oxygenated phosphate buffered saline and plasma. Data represent the mean ± standard 
deviation (n≥3). 
 
 
PBS  Blood plasma 
RSNO 
type 
Sensitivity 
(pA µM-1) 
LOD 
(nM) 
 
Sensitivity  
(pA µM-1) 
Sensitivity 
decrease from 
PBS (%) 
LOD 
(nM) 
GSNO 22.6 ± 1.6 60  4.2 ± 1.8 82 400 
CysNO 25.5 ± 1.3 60  6.9 ± 3.2 73 240 
AlbSNO 5.0 ± 1.4 280  0.6 ± 0.2 87 2660 
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Figure 4.2 Representative amperometric responses for CysNO added directly to 
phosphate buffered saline (solid black), plasma (dashed red), and whole blood (dotted blue). 
Following addition to whole blood, the sample was centrifuged to separate plasma and 
immediately analyzed. 
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Despite the decreased sensitivity, this technique was used to determine endogenous 
RSNO levels in fresh plasma separated from blood obtained from healthy swine, with an 
average of 1.5 ± 1.0 µM determined (n=4). This concentration likely represents only low 
molecular weight RSNOs due to the elevated limit of detection for AlbSNO in plasma (2.7 
µM), yet falls within plasma RSNO concentrations determined by numerous other 
methodologies (up to 9 µM).37 
  
4.4 Conclusions 
The work presented herein represents a significant enhancement in the measurement 
of RSNO in physiological fluids using photolytic cleavage with amperometric detection of 
NO. By utilizing a microfluidic device to reduce the sample cross-section and volume, 
irradiation and resulting RSNO decomposition to NO were increased, thus improving the 
sensitivity and limit of detection for both low molecular weight and protein nitrosothiols. 
Additionally, the required analysis time was minimal (i.e., <2 min for sample irradiation and 
detection) was required. While detection of RSNOs directly in blood was not realized, 
analysis in the plasma separated from whole blood was possible with RSNO levels in healthy 
swine falling within previously reported ranges.37 Future studies should include the analysis 
of RSNO levels during disease states as well (e.g., sepsis) where both NO and RSNO 
concentrations are expected to rise.33,58-60 
Small LED sources can easily be coupled to future device designs, potentially 
allowing for simultaneous measurement of NO and RSNO in one sample. Light sources with 
greater intensity may permit the measurement of RSNO directly in whole blood, but care 
must be taken to avoid sample heating. Within whole blood, S-nitrosohemoglobin is an 
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especially relevant analyte of interest, as NO stored/transported in this form may be of 
importance to NO generation under hypoxic conditions.61-63 
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CHAPTER 5: TEMPORAL MONITORING OF NITRIC OXIDE AND 
NITROSOTHIOLS IN A PORCINE MODEL OF SEPSIS 
 
5.1 Introduction 
 Sepsis, a systemic inflammatory response syndrome (SIRS), occurs when the body’s 
normal response to infection becomes so severe or dysfunctional that it causes harm to the 
host. This dysfunction may initiate a number of physiological changes, both at the cellular 
and systemic levels, leading to severe symptoms including a dramatic increase in the 
production of pro-inflammatory cytokines. This “cytokine storm” has the potential to cause 
multiple organ dysfunction and death.1,2 A recent epidemiological study revealed that 
>750,000 cases of sepsis occur annually in the United States and account for 1.3% of all 
hospitalizations.3,4 While mortality has decreased and currently ranges from 18–30%, sepsis 
remains the leading cause of death in critically-ill patients. Recent statistics indicate that 
sepsis-related illness is increasing by 8.7% annually. In the United States alone, the cost for 
treating sepsis exceeds $16 billion per year.3,4 Clearly the need for improved understanding, 
diagnosis, and treatment of this disease and its underlying causes is highly warranted. 
Changes at the cellular level manifest a number of systemic physiological 
manifestations that may be monitored in the hospital setting. In addition to basic 
physiological metrics (e.g., lactate, base excess, heart rate), a number of potential biomarkers 
for sepsis have been proposed for diagnostic use. Indeed, the number of biomarkers 
evaluated to date is immense, with >178 independent biomarkers considered since 2010,5,6 
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due in part to the complex physiology associated with sepsis. Unfortunately, no single 
biomarker has proven both sensitive and specific enough to be routinely implemented for 
sepsis monitoring. Potential future approaches must include the evaluation of and new 
biomarkers and multi-biomarker panels for more accurate diagnosis.  
Much research has pointed to endogenous NO levels as a sepsis biomarker due to 
NO’s roles in the immune system, inflammation, and blood pressure maintenance. For 
example, many studies have indicated increased iNOS expression during the progression of 
sepsis.7-9 Additionally, a number of studies monitored changes in NO metabolites (i.e., 
nitrate, nitrite, and nitrosothiols) during sepsis using chemiluminescence or colorimetric 
detection methods.7,10-17 While reported “NO” concentrations vary and range up to ~150 µM, 
an increase in endogenous NO relative to controls has been observed in most cases. 7,15-18 
Similar to NO, nitrosothiols have been shown to induce smooth muscle relaxation19 and 
reduced platelet adhesion.20 Unlike free NO radicals, nitrosothiols do not react directly with 
metalloproteins (e.g., hemoglobin) or other radical species (e.g., superoxide), thus increasing 
their lifetime and preventing the buildup of toxic species such as peroxynitrite. The ability to 
directly measure NO and nitrosothiols in whole blood and/or plasma at the bedside may 
provide a clearer understanding of the mechanisms involved in this immune dysfunction 
given NO’s significant chemical reactivity.  
Herein, we describe the use of a microfluidic amperometric sensor to monitor 
temporal changes in NO throughout the progression of sepsis in a porcine model of cecal 
ligation and puncture (CLP). The changes in NO are compared to more traditionally 
monitored indicators in intensive care unit patients (e.g., lactate, mean arterial pressure) to 
determine the usefulness of NO as a prognostic and/or diagnostic biomarker for sepsis. In a 
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separate study, this device was fitted with a light-emitting diode (LED) to facilitate 
nitrosothiol and subsequent NO detection. Nitrosothiols levels during sepsis are directly 
compared to temporal changes in NO. 
 
5.2 Materials and Methods 
5.2.1 Microfluidic device fabrication and characterization 
Microfluidic NO sensors were fabricated as described previously.21 Briefly, 150 nm 
thick planar platinum (Pt) electrodes with a 10 nm titanium (Ti) seed layer were patterned 
onto a glass substrate via photolithography and evaporative metal deposition. The resulting 
Pt electrodes were 100 µm wide. To provide selectivity to NO, a xerogel membrane was 
applied to each working electrode. Following the deposition of 1002F-50 photoresist mask, 
an adhesion layer of (3-aminopropyl)triethoxysilane (1% v/v in ethanol) was deposited via 
three passes with a spray coater. The substrate was then rinsed with water and allowed to dry 
in ambient conditions overnight. The fluoroalkoxysilane membrane solution was prepared 
via the acid catalyzed hydrolysis and condensation of (heptadecafluoro-1,1,2,2-
tetrahydrodecyl)trimethoxysilane (17FTMS) and methyltrimethoxysilane (MTMOS).22,23 
Briefly, 600 µL absolute ethanol, 120 µL MTMOS, 30 µL 17FTMS, 160 µL distilled water, 
and 10 µL 0.5 M hydrochloric acid were added sequentially to a 1.5 mL microcentrifuge tube 
with vigorous mixing between the addition of each component. This solution was then 
vortexed for 1 h. The sol solution (30 µL) was spread-cast across the working electrodes 
using a pipette tip for 1 min to ensure even coating.  The xerogel-coated substrate was then 
dried overnight under ambient conditions to facilitate curing of the sensor membrane. The 
1002F-50 photoresist was removed by soaking the substrate for 1 h in distilled water.  
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Reference electrodes were fabricated on separate glass microscope slides by 
sputtering a 10 nm Ti adhesion layer followed by a ~1 µm Ag layer. To form channel walls, 
two parallel strips of 6.3 mm wide double-sided Kapton® polyimide tape (90 µm thick, 
KaptonTape.com) were applied ~1 mm apart and perpendicular to the Pt electrodes on the 
working electrode substrate. The reference electrode slide was then bonded to the working 
electrode substrate by clamping the components and heating at 100 °C for 5 min. After the 
ends of the channel were sealed, 8 mm diameter inlet/outlet reservoirs were affixed to the 
device. Prior to using the device, the Ag electrode was chemically oxidized by reaction in 50 
mM ferric chloride for 10 s to create a pseudo-reference/counter electrode. The device 
channel was rinsed with distilled water following this process. 
The working and reference/counter electrodes of each microfluidic device were 
connected to a CH Instruments 1030A 8-channel potentiostat (Austin, TX). Prior to sample 
analysis, the device was polarized at +800 mV vs. the Ag/AgCl pseudo-reference/counter 
electrode for at least 1 h in PBS. For nitrosothiol measurement, a 530 nm LED (Thorlabs 
Inc.; Newton, NJ) at 100% intensity was placed 100 mm above the device and focused on the 
microfluidic channel (just before the working electrode) using an adjustable biconvex lens. 
To calibrate the devices, a saturated NO standard solution (prepared by purging deaerated 
PBS with NO gas for ~10 min to yield a 1.9 mM solution of NO) was diluted with PBS and 
introduced into the inlet reservoir. For nitrosothiols, aliquots of nitrosothiols were added 
following introduction of serum into the device. 
5.2.2 Porcine model for sepsis 
All experiments were conducted in compliance with The University of North 
Carolina at Chapel Hill Institutional Animal Care and Use Committee. For temporal 
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monitoring of NO, twelve male swine were obtained from the North Carolina State 
University breeding colony in Raleigh, NC. Swine were subjected to overnight fasting prior 
to each experiment. Anesthesia was induced intramuscularly using a mixture of ketamine and 
buprenorphine (500 and 0.3 mg) and animals were administered isoflurane and intubated for 
mechanical ventilation. A femoral venous catheter was used for fluid maintenance 
throughout the duration of the study and femoral artery catheter allowed for hourly blood 
draws and constant monitoring of heart rate and mean arterial pressure. A midline 
laparotomy was performed following catheter placement. The cecum was ligated with suture 
and an incision was made to allow for removal of intestinal contents. The cecum contents 
were weighed and ~1 g fecal material per kg body weight (in 500 mL saline) was placed into 
the abdominal cavity. The cecum was then replaced in the abdominal cavity and the 
laparotomy incision was closed. Control animals (n=5) underwent a sham surgery consisting 
of a laparotomy with only cecal manipulation (i.e., no perforation). The time of cecal 
perforation was considered to be zero for the experiment. During the entire study duration, 
animals were maintained on isotonic fluids at a maintenance rate and buprenorphine was 
administered as necessary.  
For a follow-up study comparing temporal changes in NO and nitrosothiols, the 
Yucatan minipig was utilized. The CLP surgery and all other procedures were performed in 
the same manner as previously, but pain medication (i.e., buprenorphine) was administered at 
a constant low dose of 1.5 µg kg-1 h-1. 
Physiological monitoring 
Temperature, heart rate (HR), mean arterial pressure (MAP), central venous pressure 
(CVP), and electrocardiogram (ECG) were monitored throughout the duration of the 
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experiment (up to 26 h or until termination). Arterial blood (~3 mL) was drawn into 
ethylenediamine triacetic acid (EDTA)-coated Vacutainer® tubes hourly for standard 
monitoring of blood gasses and complete blood counts. For blood gas analysis, a Radiometer 
ABL800 Flex (Copenhagen, Denmark) was utilized. A Horiba scil Vet ABC hematology 
analyzer (Kyoto, Japan) was used to facilitate complete blood counts. Fresh volumes of 
blood (~500 µL) were used (immediately after collection) for the microfluidic NO analysis. 
The remaining blood was immediately centrifuged at 4 °C (1300 ×g for 10 min) to isolate 
blood serum. This sample was subsequently run through the microfluidic device. Following 
sample introduction, the LED was turned on to facilitate RSNO decomposition to NO. 
5.2.3 Statistical analysis 
Porcine sepsis data are presented as the mean ± standard error of the mean. 
Comparisons between groups and from basal levels were performed using the Wilcoxon 
rank-sum test with p <0.05 considered to be statistically significant. 
 
5.3 Results and Discussion 
The swine model was selected for this study because of their physiological similarity 
to humans compared to other models (e.g., rodents).24 In particular, their large size allows for 
routine physiological monitoring and serial blood draws. Cecal ligation and puncture was 
used to replicate the complex physiological state of human sepsis, as it mimics ruptured 
appendicitis and polymicrobial sepsis. Cecal ligation and puncture is often referred to as the 
“gold standard” in modeling sepsis because it mirrors the hemodynamic, metabolic, and 
immune responses observed in humans during sepsis.25-27  
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5.3.1 Physiological changes in a porcine model of sepsis and their effect on circulating 
nitric oxide concentrations 
 In the mixed-breed study, temporal changes in NO were monitored in order to 
compare its rate and magnitude of change to other physiological metrics. Of note, survival 
varied between control and septic groups, as shown in Figure 5.1. Similar to humans, sepsis 
in this swine model resulted in significant changes in hemodynamic and blood chemistry 
profiles. Within the control group, HR (Figure 5.2) and MAP (Figure 5.3) were maintained at 
~110 beats per minute (BPM) and ~100 mmHg, respectively. While the development of 
sepsis led to few significant changes in HR, disease progression resulted in decreased MAP 
at ~13 h post-surgery. Systemic hypotension and rapid HR are known outcomes of sepsis,28 
and others have suggested NO’s potential role in this process due to its role as a 
vasodilator.29 
Using the microfluidic NO sensor, we monitored blood NO concentrations hourly. 
Similar to previous reports using alternative detection schemes and NO metabolites (e.g., 
nitrate and nitrite), a significant increase in NO was observed over the course of the 
experiment and progression of sepsis. In general, the changes in blood NO were noted when 
other physiological metrics also began to change in favor of enhanced NO circulation. In 
contrast, NO levels in control animals decreased slightly over the 24 h experiment (Figure 
5.4). When averaged across all CLP animals (Figure 5.4A), significant increases in NO 
relative to controls were noted at 6 h. Amongst the CLP swine that survived the entire study 
duration (Figure 5.4B), a significant increase in NO relative to controls was first observed 8 h 
(40 ± 19% increase from baseline levels). Significant increases were also observed at 11, 14, 
15, and 20 h post-surgery.   
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Figure 5.1 Survival for control (solid black) versus cecal ligation and puncture (dashed 
red) swine over 24 h post-surgery. 
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Figure 5.2 Changes in heart rate of septic (") versus control (#) swine. Data are 
presented as the mean ± standard error of the mean. * denotes a significant difference relative 
to the control group at the given time point (p <0.05).  
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Figure 5.3 Changes in mean arterial pressure of septic (") versus control (#) swine. Data 
are presented as the mean ± standard error of the mean. * denotes a significant difference 
relative to the control group at the given time point (p <0.05). 
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As shown in Figure 5.4C, elevation of blood NO was even greater during severe sepsis, 
which was classified by early mortality (≤15 h survival). Within this group, a significant 
increase in NO relative to controls was apparent as early as 3 h (88 ± 33% increase from 
baseline levels). In addition to occurring earlier, this increase in blood NO was larger than 
the initial changes in survival CLP swine. At 14 (final time point), we measured a 6-fold 
increase in NO relative to baseline levels. This trend is similar to our observations in a lethal 
model of murine sepsis, where NO increased ~800% within 24 h, indicating that NO is a 
predictor of mortality.21 To more accurately compare all animals within both the control and 
septic groups, the final percent change in NO for each group was averaged, based on the last 
sample collected for each animal (Figure 5.4D). While the variation amongst CLP swine was 
large (415 ± 44% increase from baseline), NO increases were consistently greater than those 
observed for control animals (-23 ± 7% change from baseline). 
While full blood chemistry profiles (i.e., blood gasses and complete blood counts) 
were collected hourly for each animal following CLP surgery, lactate, average base excess 
(ABE), white blood cell (WBC) counts and hemoglobin concentrations were monitored most 
closely as these parameters are currently considered most relevant in the hospital setting. 
Nitric oxide production during sepsis is most often attributed to the robust immune response 
and stimulation of immune cells.14,16,30,31 Not surprisingly, the number of circulating WBCs 
increased by 133 ± 38% in control swine (Figure 5.5), peaking at 8 h following surgery. Such 
WBC behavior was expected as leukocytosis is a normal response to surgical trauma.32 
Despite the WBC surge, no increase in NO levels was noted for controls. In contrast, septic 
animals experienced an immediate and dramatic reduction in WBC counts, with counts   
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Figure 5.4 Percent change from baseline NO concentrations in septic (") versus control 
(#) swine. (A) Data from all animals; (B) Data from only animals that survived the 
experiment duration; (C) Averages of the septic animals that survived <15 h; and (D) The 
final end-of-life change for all animals. Data are presented as the mean ± standard error of 
the mean. * denotes a significant difference relative to the control group at the given time 
point (p <0.05).   
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decreasing from (13.5 ± 0.4) to (5.4 ± 1.1) × 103 cells mm-3 at the time of death for all septic 
animals. Leukopenia during sepsis has been well documented, and is not necessarily the 
result of apoptosis. Rather, studies in both rodents and swine have indicated the recruitment 
of WBC into the liver or infection loci during abdominal sepsis.33-35 While not circulating, 
these leukocytes still produce NO, and do so at concentrations up to 10-fold higher than cells 
obtained from sham animals.33 While unlikely that the NO produced from localized WBCs 
was able to circulate systemically and be detected by our device, buildup of other metabolites 
(nitrite, nitrate, nitrosothiols) is likely and the altered blood chemistry in a severely 
compromised physiological state may facilitate the regeneration of NO.36-39 
Similar to initial changes in NO levels, total hemoglobin concentrations also peaked at 5 h, 
with an increase of 63 ± 12% from baseline level in septic animals (Figure 5.6). Red blood 
cell counts increased by ~40% (data not shown), indicating hemolysis and a subsequent 
increase in free hemoglobin. Elevated concentrations of free hemoglobin (and thus heme), 
caused by the presence of blood borne pathogens,40 has been linked with an increased risk of 
mortality for patients with sepsis.41 Larsen et al. reported that mice lacking heme oxygenase-
1 had greater concentrations of circulating heme making them more susceptible to death 
following CLP-induced polymicrobial sepsis,42 attributed to the ability of heme to induce 
programmed cell death in the presence of other pro-inflammatory mediators, leading to 
multiple organ dysfunction.42,43 In addition, it is possible that increased circulating 
hemoglobin concentrations, in conjunction with the metabolic acidosis of severe sepsis, 
contributed to enhanced circulation of NO with concomitant systemic vasodilation. 
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Figure 5.5 Percent change from baseline white blood cell counts in septic (") versus 
control (#) swine. Data are presented as the mean ± standard error of the mean. * denotes a 
significant difference relative to the control group at the given time point (p <0.05).  
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Figure 5.6 Percent change from baseline hemoglobin concentrations in septic (") versus 
control (#) swine. Data are presented as the mean ± standard error of the mean. * denotes a 
significant difference relative to the control group at the given time point (p <0.05).  
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Lactate, a product of anaerobic cellular metabolism following glycolysis, becomes elevated 
during tissue hypoxia.44 Prior work has indicated that consistently increased lactate levels are 
predictive of poor patient outcomes.45,46 Base excess (or base deficit), calculated based on the 
measured carbon dioxide partial pressure (PCO2), blood pH, and bicarbonate concentration, 
has also been reported as a predictor of morbidity and mortality in patients with sepsis.46 
While the lactate and ABE levels remained consistent within the control group throughout 
the study, large changes were observed for both in the septic animals. Lactate was increased 
up to 175 ± 127% at 4 h post-CLP, reflective of the severity of this model (Figure 5.6). 
Similarly, changes in ABE were significant, with deviations from basal levels of up to -153 ± 
69% at 6 h post-surgery (Figure 5.7). Collectively, these fluctuations indicate ongoing tissue 
hypoxia and slight acidification of the blood, which may directly impact the circulating 
concentration of NO. Indeed, the lactate increase at 4 h correlated with NO increases between 
3–7 h. Lactic acidosis has previously been reported to stimulate inducible NO synthase47 and 
increases concentrations of the pro-inflammatory cytokine interleukin-6.48 Additionally, the 
slightly hypoxic conditions that contribute to increased lactate levels are optimal for the 
generation of NO from nitrite via reaction with hemoglobin.36-38 
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Figure 5.7 Percent change from baseline lactate concentrations in septic (") versus 
control (#) swine. Data are presented as the mean ± standard error of the mean. * denotes a 
significant difference relative to the control group at the given time point (p <0.05).  
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Figure 5.8 Percent change from baseline base excess in septic (") versus control (#) 
swine. Data are presented as the mean ± standard error of the mean. * denotes a significant 
difference relative to the control group at the given time point (p <0.05).  
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Table 5.1 Levels of nitric oxide, lactate, base excess, white blood cells, and hemoglobin 
at 0, 4, and 15 h post-surgery. Data are presented as the mean ± standard error of the mean. * 
denotes a significant difference relative to the control group at the given time point and ‡ 
denotes a significant difference from basal levels (p <0.05).  
 
  Time post-surgery (h) 
Analyte Group 0 4 15 
Nitric oxide 
(nM) 
Control 210 ± 40 150 ± 40 160 ± 10 
Septic 160 ± 20 350 ± 50 920 ± 250*‡ 
     
Lactate 
(mM) 
Control 1.9 ± 0.1 1.6 ± 0.2 0.7 ± 0.1‡ 
Septic 1.7 ± 0.1 2.7 ± 0.2* 4.6 ± 1.2* 
     
Average base excess 
(mM) 
Control 5.2 ± 0.1 6.0 ± 0.1 6.0 ± 0.2 
Septic 7.1 ± 0.2 4.3 ± 0.4‡ -0.8 ± 1.8*‡ 
     
White blood cells 
(103 mm-3) 
Control 13.2 ± 1.0 27.0 ± 1.9‡ 19.9 ± 1.8‡ 
Septic 13.5 ± 0.4 5.6 ± 0.5*‡ 5.4 ± 1.1*‡ 
     
Hemoglobin 
(g dL-1) 
Control 10.7 ± 0.2 11.2 ± 0.3 10.1 ± 0.3 
Septic 10.0 ± 0.1 16.0 ± 0.4*‡ 12.5 ± 1.1* 
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While nitrite was once considered a useless oxidation product of NO metabolism, 
new evidence suggests the possibility of nitrite recycling to NO under hypoxic and/or acidic 
conditions.39 Although the potential pathways/mechanisms are many and complex, the most 
likely scenarios involve the reaction of nitrite with deoxy-hemoglobin to regenerate NO 
directly or provide dinitrogen trioxide that subsequently reacts with thiol species to produce 
nitrosothiols. Nitric oxide can also form a complex with oxy-hemoglobin that may be 
oxidized to regenerate free NO in the presence of nitrogen dioxide radicals (formed via the 
reaction of nitrite with oxy-hemoglobin). Stamler et al. also demonstrated the ability of 
hemoglobin to accommodate nitrosation of its β-93-cysteine group, thus conserving the 
biological reactivity of NO by forming S-nitrosohemoglobin.49 Nitric oxide stored in this 
manner may be liberated via multiple mechanisms, most notably under hypoxic conditions.50-
52 The increased lactate and base deficit observed in our study indicate the development of 
tissue hypoxia and an increase in blood acidity, conditions that are ideal for the recycling of 
nitrite to NO. As shown in Figure 5.9, the fraction of oxy-hemoglobin decreased in the most 
severe cases of sepsis, and NO concentrations appeared to increase at a similar rate. These 
results suggest that dramatic increases in NO during the progression of sepsis are more likely 
due to nitrite accumulation and blood acidification and deoxygenation that favored the 
recycling of nitrite to NO, rather than directly from stimulated immune cells. The most 
dramatic NO elevations during severe sepsis correlate with significantly decreased MAP and 
thus mortality. 
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Figure 5.9 Correlation between changes in nitric oxide and fraction of oxyhemoglobin in 
blood for severely septic swine. 
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5.3.2 Nitrosothiols versus nitric oxide in a porcine model of sepsis 
The results from the mixed-breed swine model of sepsis indicated a possible buildup 
of byproducts of NO, which may include nitrite, nitrate, and/or nitrosothiols. As nitrosothiols 
have long been considered stable, physiological transporters of NO,19,53-56 we sought to 
monitor temporal changes in NO and nitrosothiols simultaneously. For this study, Yucatan 
miniature swine were utilized. This breed of swine is commonly used for laboratory studies 
due to decrease variability between animals.57 A previous study utilizing this breed for 
monitoring of peritoneal sepsis demonstrated the slow onset of disease over multiple days.35 
Overall, the severity of sepsis within a 24 h period was reduced in this breed of swine 
compared to the mixed-breed swine utilized in the first study. All animals in the Yucatan 
study survived the experiment (n=6 CLP, n=4 sham control). Figure 5.10 depicts the stark 
difference in NO changes between the two separate models of sepsis. While control groups 
were reproducible between studies, sepsis severity and NO levels varied greatly. Lactate 
concentrations did not increase significantly relative to controls until 20 h following CLP, 
with increases from baseline of only 35 ± 34% (Figure 5.11). In comparison, lactate levels 
were doubled at 6 h in the mixed-breed model. Increases in circulating NO concentrations 
(61 ± 14% from basal levels) also occurred at 20 h (Figure 5.12). As our mixed-breed study 
alluded to, measurable changes in circulating NO may be delayed due to the late shift in 
blood chemistry that occurred.  
Despite the delayed increase in NO, nitrosothiol levels began to increase as early at 8 
h following CLP (Figure 5.13) in the Yucatan study. At this time, serum nitrosothiol levels 
were 61 ± 21% greater than basal concentrations. An initial burst in NO produced by immune   
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Figure 5.10 Box-and-whisker plots depicting percent change in NO for control and septic 
animals in mixed-breed (A) and Yucatan (B) mini pigs. 
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Figure 5.11 Percent change from baseline lactate concentrations in septic (") versus 
control (#) Yucatan swine. Data are presented as the mean ± standard error of the mean. * 
denotes a significant difference relative to the control group at the given time point (p <0.05). 
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Figure 5.12 Percent change from baseline NO concentrations in septic (") versus control 
(#) Yucatan swine. Data are presented as the mean ± standard error of the mean. * denotes a 
significant difference relative to the control group at the given time point (p <0.05). 
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Figure 5.13 Percent change from baseline nitrosothiol concentrations in septic (") versus 
control (#) Yucatan swine. Data are presented as the mean ± standard error of the mean. * 
denotes a significant difference relative to the control group at the given time point (p <0.05). 
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cells may cause accumulation of nitrosothiols via a number of mechanisms. The most 
common routes of nitrosothiol formation requires a mixture of NO, oxygen (O2), and thiols.58 
One of many nitrosothiol formation pathways relies on the oxidation of NO by O2, where a 
peroxynitrite radical is generated that further reacts with NO to produce a nitrogen dioxide 
radical (•NO2). Nitrogen dioxide will react directly with a thiol to form a thiyl radical, that 
subsequently combines with NO to form nitrosothiol. Alternatively, •NO2 may react with 
another molecule of NO to form dinitrogen trioxide (N2O3) that directly nitrosates a thiol 
species. In the event that NO autooxidation does not take place, NO reacts directly with a 
thiol, forming an aminoxyl radical that can be oxidized to form a nitrosothiol. Following this 
initial increase in nitrosothiols concentration, their level remained relatively stable, indicating 
an early increase in NO generation. 
 
5.4 Conclusions 
 These two CLP studies using the mixed-breed and Yucatan swine indicate that NO 
and nitrosothiols play a key role in the onset, development, and outcome of sepsis. In less 
severe cases of sepsis (Yucatan swine model), nitrosothiols appear to accumulate in the blood 
12 h prior to the onset of other symptoms. While increased nitrosothiol levels do not appear 
to be linked directly to decreased blood pressure that can ultimately result in multiple organ 
dysfunction and death, the accumulation of these and other byproducts of NO production 
(e.g., nitrite) may prime the bloodstream for late-stage regeneration of NO as the blood 
chemistry becomes optimal (i.e., more acidic and hypoxic) for this process. Late production 
of large quantities of free NO was especially evident during severe sepsis, resulting in 
sizeable arterial pressure decreases and often death (n=4 animals). While NO is important for 
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the killing and clearance of bacterial pathogens during infection, its seemingly unregulated 
production in late-stage sepsis has the potential to cause significant physiological dysfuntion 
and death. 
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CHAPTER 6: NITRIC OXIDE MONITORING IN A MURINE MODEL OF 
SEPSIS—EFFECTS OF BURN INJURY AND BACTERIAL VIRULENCE 
 
6.1 Introduction 
Infection and resulting sepsis are especially common amongst patients in the 
intensive care unit due to their immunocompromised state. Pneumonia, often a ventilator-
associated infection, is the most common nosocomial (i.e., hospital acquired) infection, with 
an estimated annual incidence of 160,000 cases in the United States alone.1,2 While the 
immune response to pathogens is a normal physiological response to infection and is usually 
a tightly regulated cascade, sepsis results when the body’s response to infection becomes 
dysfunctional to the point of causing harm to tissues and organ systems. To date, sepsis 
remains the leading cause of mortality amongst critically-ill patients. In addition, the 
incidence of sepsis is increasing annually by 8.7%.3,4 As such, the significant healthcare 
burden of sepsis motivates the need for improved understanding, diagnosis, and treatment of 
sepsis and its underlying causes. 
While many types of bacteria have been implicated in nosocomial infection, 
Pseudomona aeruginosa and Klebsiella pneumonia are among the most prominent, 
particularly in ventilator-associated pneumonia.1,5,6 Infection severity may vary significantly 
depending on the virulence (i.e., degree of pathogenicity) of a particular bacterial strain.7 K. 
pneumoniae is known to be particularly virulent, sometimes resulting in immune paralysis.8 
In addition to other common virulence factors, this species of bacteria develops a thick, 
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acidic polysaccharide capsule, protecting it from phagocytosis and other immune defense 
mechanisms.9  
Physical trauma such as burn injury also causes severe immune dysfunction, 
increasing the risk of infection, sepsis, multiple organ dysfunction, and death.10 The immune 
response following trauma is characterized by an initial pro-inflammatory period and a 
subsequent anti-inflammatory phase.10,11 The early stage is similar to the systemic 
inflammatory response syndrome (SIRS) that occurs during severe infection and sepsis,12 
with the release of pro-inflammatory mediators (e.g., tumor necrosis factor, interferon 
gamma, interleukin-6, interleukin-1β).13 In the struggle to maintain homeostasis, a 
compensatory anti-inflammatory response syndrome (CARS) ensues following SIRS.11,14,15 
While limiting damage due to chronic inflammation, the CARS phase also increases a 
patient’s susceptibility to infection.6,14,16 Burn patients are especially prone to ventilator-
associated and wound infections,16,17 and the leading cause of death following burn injury is 
related to infection and sepsis.16,18  
The ability to monitor the immune response during and following trauma and 
infection is key for understanding the physiological changes that occur and evaluating 
treatment options. The measurement of endogenous nitric oxide (NO), a free radical species 
that is intricately involved with the innate immune response,19-34 may reflect the immune 
status of an organism. Indeed, the upregulation of inducible nitric oxide synthase (iNOS) 
during SIRS has been reported, in addition to the accumulation of NO byproducts in blood 
and tissue.6,20,25,35-39 Conversely, Jacob et al. reported decreased serum concentrations of 
nitrate and nitrite in trauma patients, indicating suppressed NO production resulting from 
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CARS.40 Cairns et al. reported that burn injury induced a late decrease in expression of Toll-
like receptor (TLR),41 a macrophage receptor linked with the induction of iNOS.42-44  
Until recently, direct detection of NO in whole blood was not possible, but instead 
required the measurement of its byproducts (i.e., nitrate and nitrate) or the use of complex 
instrumentation (i.e., electron paramagnetic resonance spectroscopy).45 As described in 
Chapter 3, a microfluidic amperometric sensor was developed to enable the measurement of 
NO in small volumes of blood.36 To date, the effects of bacterial virulence and trauma-
induced CARS on NO levels during infection have not been elucidated, and thus this device 
was used to study blood NO changes in a murine model of sepsis. Small animal (e.g., rodent) 
models of sepsis are particularly attractive as they permit the study of more fundamental 
mechanisms of sepsis due the availability of genetic variants and routes of infection (e.g., 
CLP, pneumonia).46-49 Direct administration of live bacteria into the trachea or nasal passage 
produces severe pneumonia that represents ventilator-associated infection.47,49,50 The effect of 
virulence is studied by comparing two separate strains of bacteria (i.e., P. aeruginosa and K. 
pneumoniae) with known pathogenicity variation. Lastly, we used a murine model of burn 
injury to examine the effect of trauma on NO levels during a late-stage infection. 
 
6.2 Materials and Methods 
6.2.1 Microfluidic device fabrication and characterization 
Devices were fabricated as described previously.36 Briefly, 150 nm thick planar 
platinum (Pt) electrodes with a 10 nm titanium (Ti) seed layer were patterned onto a glass 
substrate via photolithography and evaporative metal deposition. The resulting Pt electrodes 
were 100 µm wide. To provide selectivity to NO, a xerogel membrane was applied to each 
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working electrode. Following the deposition of 1002F-50 photoresist mask, an adhesion layer 
of (3-aminopropyl)triethoxysilane (1% v/v in ethanol) was deposited via three passes with a 
spray coater. The substrate was then rinsed with water and allowed to dry under ambient 
conditions overnight. The fluoroalkoxysilane membrane solution was prepared via the acid 
catalyzed hydrolysis and condensation of (heptadecafluoro-1,1,2,2-
tetrahydrodecyl)trimethoxysilane (17FTMS) and methyltrimethoxysilane (MTMOS) as 
reported previously.51,52 Briefly, 600 µL absolute ethanol, 120 µL MTMOS, 30 µL 17FTMS, 
160 µL distilled water, and 10 µL 0.5 M hydrochloric acid were added sequentially to a 1.5 
mL microcentrifuge tube with vigorous mixing between the addition of each component. 
This solution was then vortexed for 1 h. The sol solution (30 µL) was spread-cast across the 
working electrodes using a pipette tip for 1 min to ensure even coating.  The xerogel-coated 
substrate was then dried overnight under ambient conditions to facilitate adequate curing. 
The 1002F-50 photoresist was removed by soaking the substrate for 1 h in distilled water.  
Reference electrodes were fabricated on separate glass microscope slides by 
sputtering a 10 nm Ti adhesion layer followed by the deposition of a ~1 µm Ag layer. To 
form channel walls, two parallel strips of 6.3 mm wide double-sided Kapton® polyimide tape 
(90 µm thick) were applied ~1 mm apart and perpendicular to the Pt electrodes on the 
working electrode substrate. The reference electrode slide was then bonded to the working 
electrode substrate by clamping the components together and heating at 100 °C for 5 min. 
After the ends of the channel were sealed, 8 mm diameter inlet/outlet reservoirs were affixed 
to the device. Prior to using the device, the Ag electrode was chemically oxidized by reaction 
in 50 mM ferric chloride for 10 s to create a pseudo-reference/counter electrode. Following 
this process, the device channel was rinsed with distilled water. 
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The working and reference/counter electrodes of the microfluidic device were 
connected to a CH Instruments 1030A 8-channel potentiostat (Austin, TX). Prior to sample 
analysis, the device was polarized at +800 mV vs. the Ag/AgCl pseudo-reference/counter 
electrode for at least to 1 h in PBS. Prior to use, a saturated NO standard solution (prepared 
by purging deaerated PBS with NO gas for ~10 min to yield a 1.9 mM solution of NO) was 
diluted with PBS and used to calibrate the device. 
6.2.2 Murine model of infection with Klebsiella pneumonia and Pseudomonas aeruginosa 
To evaluate the effect of bacterial virulence, two strains were used to induce 
pneumonia: 1) intratracheal administration of 50 µL P. aeruginosa (PAK strain, 1 × 106 
colony forming units mL-1) or 2) intranasal administration of 20 µL K. pneumoniae (2 × 105 
colony forming units mL-1). Uninfected groups were administered identical volumes of 
phosphate buffered saline (PBS) containing protease peptone. At select times following 
infection, ~300 µL blood was drawn into ethylenediaminetetraacetic acid (EDTA)-coated 
microcentrifuge tubes via submandibular puncture. This blood was immediately (within 10 s) 
injected into the microfluidic device and analyzed amperometrically to determine NO 
concentrations. 
6.2.3 Murine model for sepsis and burn injury 
All protocols were performed in accordance with the National Institutes of Health 
guidelines and approved by the University of North Carolina at Chapel Hill Institutional 
Animal Care and Use Committee. Nine week-old female C57BL/6 mice weighing ~18 g 
underwent a 20% total body surface area (TBSA) burn injury as previously described.53 
Briefly, mice were anesthetized with gaseous isofluorane, their dorsal flanks shaved, and 
they received a subcutaneous injection of morphine sulphate prior to receiving a full-
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thickness burn with 4 applications of a copper rod heated in boiling water. Following burn 
injury, mice were resuscitated via an intraperitoneal injection of lactated Ringer’s solution. 
Throughout the experiment duration, mice were monitored and received morphine in their 
drinking water (0.02 mg mL-1; 4 mg kg-1 body weight per day) ad libitum. Sham (0% TBSA) 
mice also underwent these treatments as described, except the application of the copper rod. 
Rapamycin-treated mice received an intraperitoneal injection of rapamycin (4 mg kg-1) 5 d 
prior to burn injury, with continued daily treatment following injury. 
At 14 d following burn injury, pneumonia was induced via the intratracheal 
administration of 50 µL Pseudomonas aeruginosa (PAK strain, 1 × 106 colony forming units 
mL-1) following sedation via Avertin. Uninfected groups were administered 50 µL PBS with 
protease peptone in the same manner. At 48 h following infection, ~300 µL blood was drawn 
into EDTA-coated microcentrifuge tubes via submandibular puncture. This blood was 
immediately injected into the microfluidic device and analyzed amperometrically to 
determine NO concentrations. 
6.2.4 Statistical analysis 
An unpaired, two-sided Student’s t-test was used to determine statistical significant 
between groups, with p <0.05 considered to be significant. 
 
6.3 Results and Discussion 
6.3.1 Nitric oxide levels during systemic infection and the effect of virulence 
 Following infection with P. aeruginosa, blood NO levels were monitored at 1, 3, and 
7 d. At the dose of bacteria administered (1 × 106 colony forming units mL-1), mice were 
expected to clear the infection and fully recover without treatment. Conversely, the virulence 
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associated with K. pneumoniae in mice often leads to mortality within 72 h following 
infection54 and thus blood was drawn to monitor NO concentrations at 12, 24, and 72 h 
following infection. As shown in Figures 6.1—6.3, the blood NO levels remained relatively 
unchanged for uninfected mice in both experiments. In contrast, both infections resulted in 
greater circulating NO concentrations, although there were differences in the magnitude of 
change. Indeed, an infection of P. aeruginosa resulted in significant increases in NO at 72 h 
following infection, with a 90 ± 50% change relative to uninfected mice (Figure 6.4). By 7 d 
after the initial infection, NO concentrations returned to basal levels (Figure 6.5). For the 
more virulent K. pneumoniae, the most substantial increases in NO also occurred at 72 h 
following infection, with a much greater magnitude than that observed for P. aeruginosa at 
the same time point. Relative to uninfected mice, NO concentrations were increased by 600 ± 
110% at 72 h. These mice do not generally recover from K. pneumoniae infection,54 and the 
large increase in NO is likely attributable to the infection severity. The increase in NO 
observed in this model is similar to fatal infections that we previously reported on in both 
murine and porcine models of sepsis.36 Given these results, it is clear that circulating NO 
concentrations reflect the severity of an infection, with infections by more pathogenic 
bacteria resulting in the generation of more NO. 
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Figure 6.1 Change in blood NO concentrations for uninfected (#) and Pseudomonas 
aeruginosa infected mice ("). Data are given as mean ± standard error of the mean. For each 
time point, n = 4 for uninfected and n = 6 for infected.  
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Figure 6.2 Change in blood NO concentrations for uninfected (#) and Klebsiella 
pneumoniae infected mice (").Data are given as mean ± standard error of the mean. For each 
time point, n = 2–3.  
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Figure 6.3 Change in blood NO concentrations over time during Pseudomonas 
aeruginosa (") and Klebsiella pneumoniae (!) infections in a murine model. Shown relative 
to uninfected mice (#). Data are given as mean ± standard error of the mean. 
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Figure 6.4 Percent change in murine blood NO concentrations relative to uninfected 
animals during infections with Pseudomonas aeruginosa (green) and Klebsiella pneumoniae 
(blue).  
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Figure 6.5 Percent change in murine blood NO concentrations relative to basal levels 
during infections with Pseudomonas aeruginosa (blue) and Klebsiella pneumoniae 
(magenta). Shown relative to uninfected mice for P. aeruginosa (green) and K. pneumoniae 
(cyan). 
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6.3.2 Nitric oxide during the compensatory anti-inflammatory response syndrome following 
burn injury 
While these studies have made the link between NO and SIRS evident, the effect of 
CARS on systemic NO concentrations remains unknown. As burn injury elicits late-stage 
CARS,14,55,56 a murine burn model was used to evaluate changes in NO production during 
periods of immune suppression. A previous report by Cairns et al. demonstrated that while 
burn injury induced upregulated expression of Toll-like receptor (TLR) by macrophages 
early (3 d) following trauma, decreased TLR expression occurred at later time points (14 d).41 
Other studies have linked TLR with the induction of iNOS and concomitant release of NO by 
innate immune cells (e.g., macrophages).42-44 Indeed, TLR is directly involved in microbe 
recognition by innate immune cells (TLR2 for Gram-positive peptidoglycan and TLR4 for 
Gram-negative lipopolysaccharide) and thus mediates subsequent inflammatory signals, 
including NO.57 As shown in Figure 6.6, blood NO levels were significantly increased during 
a P. aeruginosa infection without previous trauma. At 48 h following infection, NO 
concentrations were 810 ± 180 and 370 ± 40 nM for infected and uninfected mice, 
respectively. This deviation is not surprising, as NO is known to be produced in response to 
bacteria,58 with increased endogenous NO levels having been observed during systemic 
infection.36 However, similarly increased NO levels were not observed during P. aeruginosa 
infection occurring 14 d following burn injury. Nitric oxide concentrations were 410 ± 110 
and 290 ± 80 nM for uninfected and infected mice, respectively. The differences between the 
infected and uninfected groups with burn injury were insignificant and indicate a late-stage 
effect of trauma on immune function (i.e., immune suppression) and NO production   
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Figure 6.6 Nitric oxide levels 48 h following P. aeruginosa infection in a murine model 
of sepsis, both with and without prior burn injury. Data are given as mean ± standard error of 
the mean. For each treatment, n = 3–4 and 4–6 for uninfected and infected groups, 
respectively. Statistical significance is indicated by * based on p <0.05.  
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during an infection. Of note, the NO concentrations observed in burn mice (both infected and 
uninfected) were equivalent to those in the uninfected sham mice. The dysfunctional immune 
response following burn injury has been well documented,11 with CARS frequently observed 
late after burn injury. Multiple studies have suggested that early hyperactivity of macrophage 
cells contributes to the development of immune suppression.59-61 The observed decrease in 
NO production is not surprising given the numerous immune defense systems linked to TLR, 
including the induction of iNOS.57 Reduction in NO production by innate immune cells, 
along with other aspects of immune suppression (e.g., shifts in T cell phenotype,61 altered 
cytokine profiles62), contribute to the increased infection susceptibility of burn patients. 
 Similar to burn injury, treatment with rapamycin also led to decreased NO levels 
despite infection. Rapamycin is well known for its immunosuppressive action by its blockage 
of the mammalian target of rapamycin (mTOR), which is believed to regulate the innate 
immune response.63 In particular, inhibition of mTOR has been proven to decrease NO 
production by lipopolysaccharide-stimulated macrophage cells, possibly due to decreased 
secretion of interferon-β.64 As shown in Figure 6.7, rapamycin treatment negated the 
expected NO upregulation relative to uninfected animals, both with and without prior burn 
injury. A study by Malik et al. has also demonstrated the ability of rapamycin treatment to 
inhibit the clearance of a P. aeruginosa lung infection, likely due in part to decreased 
oxidative burst from pulmonary neutrophils.65 
Nitric oxide concentrations during infection were similar between the rapamycin-
treated and burn groups. Some studies have indicated that all isoforms of NOS are 
upregulated during severe infection and sepsis,66,67 but our studies suggest the iNOS is the  
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Figure 6.7 Percent change in NO relative to uninfected mice during Pseudomonas 
aeruginosa with and without 14 d prior burn injury and after rapamycin treatment. Each 
treatment group has a separate uninfected control group. For each treatment, n = 3–4 and 3–6 
for uninfected and infected groups, respectively.  
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major contributor to NO production. While the physiological response to burn trauma and the 
development of immune suppression are complex, modulation of NO release may be key in 
improving patient outcomes. Especially during CARS, supplementing endogenous NO 
production (via NO-release vehicles or modulation of physiological pathways to stimulate 
NO release) may prevent the spread of serious systemic infections. Diminishing the initial 
inflammatory burst that results in later immune suppression is likely of equal importance. 
 
6.4 Conclusions 
While increased levels of endogenous NO may indicate development of a severe 
infection and SIRS in otherwise healthy animals, the immune dysfunction during CARS 
caused by prior trauma (e.g., burn injury) will also significantly alter its production. As such, 
monitoring in vivo NO production may provide insight into emerging infection as well as 
immune dysfunction. As such, understanding normal circulating NO concentrations is vital to 
comprehending the immune response to infection. The clinical utility of blood NO 
measurements should be evaluated further by monitoring concentration changes at additional 
time points (i.e., more frequently) throughout the course of infection/sepsis and throughout 
the SIRS/CARS phase following trauma. Additionally, the effect of pathogenicity must be 
evaluated with the use of identical strains of varied virulence. 
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CHAPTER 7: SUMMARY AND FUTURE DIRECTIONS 
7.1 Summary of work 
 In the preceding chapters, the development of sensors for NO and nitrosothiol 
measurements was described, along with select biologically relevant applications. Most 
notably, they were used to measure the production of NO and nitrosothiols during the 
infection and inflammation associated with sepsis. Before such measurements were 
possible, it was necessary to understand the various techniques available for the 
measurement of NO and their caveats in complex biological environments. In Chapter 2, 
the three main analytical techniques for the measurement of NO (i.e., Griess assay, 
chemiluminescence, and electrochemistry) were evaluated for accuracy in variety of 
complex media, including cell/bacterial culture broths and blood (whole, serum, and 
plasma). This work was especially important given the relatively low physiological 
concentrations of NO. The Griess assay was quite useful for estimating total NO 
concentrations based on the buildup of its byproducts (i.e., nitrate and nitrite) in solution, 
but accuracy depended on the sample milieu. In addition, sample volume (and thus 
headspace within the sample vial) was important, as a large headspace volumes permitted 
the loss of NO and resulted in underestimations. A dependence on sample concentration 
was also observed. The chemiluminescence analyzer was especially useful for obtaining 
real-time kinetic information and totals. However, this technique required the use of very 
specialized equipment and was limited to non-proteinaceous media, as purging with 
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nitrogen was required to carry NO to the detector. As such, scavenging effects were 
minimized due to the lack of oxygen and the limited time allowed for NO to interact with 
media components. Electrochemical detection (i.e., constant potential amperometry) 
allowed for the greatest versatility, as it could be utilized in all types of media (including 
whole blood), whether they were deoxygenated or not. Due to the small electrode size (3 
mm diameter) relative to the large volume of media (~30 mL), overall totals calculated 
were low, as detection is limited to the NO oxidized at the surface of the electrode. 
Similar to the Griess assay, a dependence on concentration and headspace volume was 
observed for electrochemistry as well. When measuring from a NO-releasing surface 
(e.g., films or cells) a distance-dependence also existed. Despite what seem like 
numerous disadvantages, electrochemical techniques provide unparalleled versatility and 
as such are ideal for measuring NO from biological samples, including cells and whole 
blood. 
 The advantages of electrochemical NO detection were exploited to develop a 
microfluidic amperometric sensor for the measurement of small volumes of biological 
fluids (e.g., blood). The fabrication and utilization of this device was described in 
Chapter 3. Standard photolithographic techniques were used to pattern working, counter, 
and reference electrodes onto glass slides. The microfluidic channels were formed using 
Kapton® tape to seal the slides together. The device was evaluated in phosphate buffered 
saline, wound fluid (10% v/v fetal bovine serum in water), and whole blood. While 
sensitivity was decreased in whole blood relative to phosphate buffered saline, limits of 
detection down to 400 nM were still achievable. Additionally, the device was selective 
against a number of important physiological interferents (i.e., nitrite, ascorbic acid, 
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acetaminophen, uric acid, hydrogen sulfide, ammonium, ammonia, and both protonated 
and deprotonated peroxynitrite). Blood samples as small as ~250 µL was measurable, 
which is especially necessary for collecting samples from small mammals (e.g., rodents). 
To demonstrate the clinical utility of the device, it was used to measure temporal changes 
in blood NO levels in a murine model of sepsis. For the lethal dose of bacteria 
administered, seven-fold increases in NO were observed over a period of 24 h. 
 In Chapter 4, the utility of the microfluidic sensor was expanded to incorperate 
the detection of S-nitrosothiols (i.e., S-nitrosoglutathione, S-nitrosocysteine, and S-
nitrosoalbumin) via visible photolysis and subsequent detection of NO. The device itself 
was identical to that detailed in Chapter 3, but with the addition of an external 530 nm 
LED. As nitrosothiols absorb light in this region of the spectrum, photolysis can be 
facilitated without interference from nitrite. The light source was tuned to achieve 
efficient nitrosothiol photolysis and detection. As expected, increased light intensity 
yielded improved sensitivity. Irradiation area was also tuned, but light intensity varied as 
the spot size was changed, and no change in sensitivity was noted due to irradiation area 
alone. Once the optimal LED arrangement was achieved, a significant improvement in 
sensitivity and limit of detection compared to previously reported results in bulk solution 
(~40 mL) was noted due to the small sample volume and cross-section of the device. 
Indeed, a 6–20× improvement in sensitivity (depending on nitrosothiol type) was noted in 
phosphate buffered saline when utilizing the microfluidic configuration. Additionally, 
minimal analysis time (i.e., <2 min for sample irradiation and detection) was required. 
While detection of RSNOs directly in blood was not realized, analysis in the serum 
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separated from whole blood was achieved. Using this device, basal nitrosothiol levels in 
healthy swine were quantified at 1.5 ± 1.0 µM, falling within previously reported ranges. 
 The application of the microfluidic amperometric NO and nitrosothiol sensors for 
numerous animal models was described in Chapter 5. Both murine and porcine models 
for sepsis were utilized to determine the link between NO and this disease state and 
evaluate its potential as a prognostic and/or diagnostic biomarker. In order to monitor 
disease progression longitudinally, a porcine cecal ligation and puncture model for sepsis 
was chosen. Utilizing large animals allowed for the hourly collection of blood and the use 
of traditional intensive care unit monitoring (i.e., heart rate, blood pressure, body 
temperature, blood gasses, and blood cell counts). Hemodynamic trends were as 
expected, with steadily increased heart rate and decreased mean arterial pressure 
observed. In the preliminary porcine study, NO levels increased in conjunction with other 
potential indicators (e.g., lactate), but the percent change from basal levels was 
significantly more dramatic for NO. A large rise in NO concentration was observed at 
~4–5 h post-surgery. Significant increases (up to 800%) were also observed at much later 
time points, especially in animals where the model was lethal prior to 24 h. Surprising, 
circulating white blood cells counts were significantly diminished within a few hours 
following the surgery in the septic animals. A follow-up study allowed for some 
modifications, including continuous (rather than bolus) administration of lower levels of 
buprenorphine and the detection of nitrosothiols in addition to NO. The swine were also 
changed from a mixed breed to a more standardized breed, in the hopes of reducing 
variability between animals. While this breed appeared to be much more robust and 
tolerant of the procedure, the additional measurement of nitrosothiols proved promising, 
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as significant changes were noticed in septic versus control animals at ~8 h post-surgery. 
Overall, changes in lactate and NO were less dramatic relative to the first group of swine, 
with significant increases not occurring until 19 and 20 h for NO and lactate, 
respectively. This study highlighted the link between circulating NO concentrations and 
other physiological changes (e.g., blood lactate), but also indicated that metabolites of 
NO (i.e., nitrosothiols) may accumulate early in sepsis. 
 Unlike the porcine model, a murine model of sepsis is particularly useful for 
studying mechanistic details of the role of NO in sepsis and general inflammation. Thus 
far, work in this model has focused solely on the measurement of NO. The murine model 
involved the intratracheal administration of pure strains of bacteria at known 
concentrations. Initial experiments monitored NO changes over a multi-day period to 
determine its role as infection developed and resolved. This was carried out for two 
separate strains of bacteria, Pseudomona aeruginosa and Klebsiella pneumoniae, to 
determine if strain virulence had an effect on NO levels. Indeed, mice easily clear the 
dose of P. aeruginosa administered in <1 wk, while mice infected with K. pneumoniae 
usually do not recover. As such, mice infected with P. aeruginosa had increased 
concentrations of NO at 72 h following infection (91 ± 50% increase relative to controls), 
but returned to basal levels by 1 wk, indicating their ability to recover from this infection. 
Conversely, during an infection with K. pneumoniae, NO levels were increased much 
more dramatically at 72 h (600 ± 110% increase relative to controls). This infection is 
fatal, and these increases in NO are similar to those observed during a high dose P. 
aeruginosa infection (lethal within 48 h). Finally, as patients with prior trauma are 
especially prone to nosocomial infection,1,2 we sought to evaluate the effect of burn 
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injury on NO levels in this murine model of infection. As expected, an infection that 
occurred 14 d following a burn injury yielded no detectable increase in NO relative to 
uninfected animals, demonstrating the significant immunosuppressive effect of CARS 
following burn injury. While this may limit to ability to “track” the progression of an 
infection in burn patients, it does offer insight into the immune suppression that is 
occurring which must also be controlled.  
 At a more fundamental level, electrochemical sensors can also be used to measure 
NO from various cell systems. Chapter 6 detailed the use of microelectrodes to probe NO 
and CO release from cultured macrophage cells as well as snail buccal ganglia. Increases 
in NO and CO generation from RAW 264.7 macrophage cells was noted following 
stimulation with lipopolysaccharide/interferon-gamma and hemin/NADPH, respectively. 
Promotion of increased CO generation prior to iNOS stimulation resulted in reduced NO 
production, with higher hemin concentrations resulting in lower amounts of NO release. 
The cross talk between NO and CO was also obvious in snail buccal ganglia, as inhibited 
CO generation led to a significant increase in the production of NO. 
 
7.2 Future studies 
 Initial results from animal models of infection and sepsis have indicated the 
pivotal role of NO in inflammation. Monitoring of endogenous NO production may 
eventually prove to be of diagnostic and/or prognostic value to patients in the intensive 
care unit, but more systematic studies in animal models must first be carried out. In 
particular, mouse models will allow for the study of fundamental roles of NO during 
infection and following treatment. To build on the work completed thus far, future studies 
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must assess whether infection with different types of bacteria has an effect on NO 
production or its duration and rate of release. For example, more virulent strains may 
induce more rapid NO release or higher concentrations, as these strains are more 
challenging to clear.3 For example, Matsumoto et al. discovered that a virulence 
regulatory factor CvfB (common in some strains of Staphylococcus aureus and 
Streptococcus pneumonia) binds RNA and plays a role in infection severity.4 
Additionally, Gram-positive bacteria must be evaluated as they induce an immune 
response via different receptors on innate immune cells.5 In particular, infections by 
Staphylococcus aureus are especially common in hospital patients.1,6 While we have 
observed that NO levels in mice decrease once the infection has been eradicated, there is 
also an interest in understanding whether antibiotic administration will produce a similar 
effect. In particular, it is necessary to understand if the use of bactericidal versus 
bacteriostatic antibiotics will produce differential effects. While bacteriostatic antibiotics 
keep bacteria in the stationary phase of growth, bactericidal agents kill >99.9% of the 
inoculum. However, the lytic action of bactericidal agents may cause an intensified 
immune response,7 thus altering NO release.  
The effect of physical trauma such as burn injury, with or without infection, is 
also of immense interest as these patients are particuarly prone to nosocomial infection. 
Even without a subsequent infection, the inflammation caused by injury may result in 
changing in NO levels over the course of many weeks following trauma.8 Indeed, while 
the SIRS/CARS phenomenon following trauma has been elucidated at discrete time 
points, it still poorly understood overall.9 The physiological response to infection 
following injury will also vary significantly depending on when exposure to bacteria 
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occurs (i.e., early or late after trauma).10,11 As such, NO levels should be monitored in 
infections that begin at varying time points following a burn or other traumatic injury. 
To date, it is unclear whether NO produced during inflammation is due solely to 
iNOS or also originates from endothelial NOS and/or neuronal NOS. While our studies 
involving rapamycin treatment revealed the ability of this drug to inhibit NO production 
via iNOS during infection, NO release was not completely diminished. In the future, the 
study of NO concentrations in iNOS knockout mice with and without infection could be 
directly compared to rapamycin treatment. Additionally, nNOS and eNOS knockout mice 
(and/or drugs to inhibit these enzymes) should be utilized to understand the role of each 
enzyme in inflammation due to infection and trauma. 
While ventilator-associated infection (pneumonia) is common in hospital patients, 
other types of infection also persist.12,13 Utilizing alternative models of sepsis in rodents, 
especially cecal ligation and puncture, will provide additional information on the role of 
NO in multiple routes of infection, as septic peritonitis and polymicrobial infections are 
common.14 Additionally, a two-hit model of sepsis may provide relevant information, as 
sepsis often occurs after bacteria exposure that follows another type of injury and/or 
inflammation.15 
In addition to building upon previous animal studies, future work will also require 
refinement of the measurement device. Most importantly, the device must be 
miniaturized in order to accommodate smaller sample volumes. The current minimum 
volume (~250 µL) prevents serial measurements in a single mouse, as drawing a large 
volume such as this induces hypovolemic shock.16 Ideally, a single drop of blood (<50 
µL) could be used for future measurements. Further tuning of selectivity and sensitivity 
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will also be important. Enhanced sensitivity would allow for detection of much smaller 
changes in NO concentrations and is most easily achieved by tuning electrode surface 
area. For example, platinization of the working electrode (with lead acetate and platinum 
black) has been utilized on disk-type microelectrodes, but not planar electrodes within a 
microfluidic device. Thickness of this platinization layer will be important, as a layer that 
is too thick may impede flow through the device. This modification may necessitate 
recessing the working electrode so it does not significantly protrude into the channel. 
Further tuning of the composition and application of the selective xerogel membrane may 
allow for a simultaneous improvement in selectivity and sensitivity. In particular, spray-
coating procedures should be evaluated, as they will allow for more even and 
reproducible coatings. 
While NO and nitrosothiol detection are currently carried out in separate devices, 
it is possible to eventually incorporate both into a single platform. The current challenge 
in achieving this lies in the inability to detect nitrosothiols in whole blood, resulting from 
significant light absorbance/scattering by red blood cells. The two main options that exist 
for addressing this problem are 1) the use of a much more intense light source and 2) the 
removal of red blood cells from the measurement entirely. While a more intense light 
source may help overcome the poor transmittance of blood, there is also a risk of sample 
heating, which will initiate non-specific nitrosothiol degradation. It is also 
disadvantageous to remove red blood cells from both the NO and nitrosothiol 
measurement, as they play an important role in NO regeneration from nitrite. A useful 
alternative would be the creation of a device that allows for detection of NO from whole 
blood with subsequent exclusion of red blood cells to allow for photolysis and detection 
 209 
of nitrosothiols. This would be possible with the incorporation of a filter or a narrowing 
channel. Numerous examples that utilize both currently exist in the literature.17-20 Having 
a single device to make both measurements simultaneously will significantly decrease 
analysis time and increase the feasibility of future clinical implementation. 
Finally, there are a number of studies outside the scope of animal models that can 
help further elucidate the physiological roles of NO. Related to the murine sepsis studies 
that have been carried out, it is also of interest to study NO in inflammation at the cellular 
level. During in vivo studies, immune cells are routinely harvested, sorted, and analyzed 
to determine release of expression of various markers, cytokines, and other mediators. 
These cells could be cultured and monitored electrochemically to determine their NO 
release profiles or their ability to be stimulated by lipopolysaccharide or peptidoglycan. 
The study of CO release would also be possible using the dual microelectrodes pioneered 
by the Lee lab.21,22  
As our lab also designs nanomaterials for clinical applications, there is interest in 
characterizing their immune stimulation characteristics in addition to cytotoxicity. While 
many of the materials generated in the lab have proven non-cytotoxic, they may still 
generate a host immune response. While this response is normal, a prolonged or 
overzealous response—possibly elicited by certain types of materials or functional 
groups—will create a risk of chronic inflammation. Both types of NO sensors developed 
in our lab (i.e., microfluidic devices and disk-type microelectrodes) coupled with more 
traditional assays (e.g., cytotoxicity and cytokine profiling) could be used to assess this 
response in cultured macrophage cells. While scanning electrochemical microscopy is 
useful for spatial resolution of NO release from individual cells, these cells can also be 
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cultured within the channel of our microfluidic device. This setup would facilitate 
incubation with different types of nanomaterials to assess their biocompatibility. The 
measurement of NO in addition to pro-inflammatory cytokines (e.g., tumor necrosis 
factor and interferon gamma) will provide insight into macrophage phenotype, with 
increased concentrations indicating a shift toward the M1 (pro-inflammatory) phenotype. 
Assessment of cytotoxicity is possible using a lactate dehydrogenase assay.23 As 
transition to the M1 phenotype requires a significant increase in metabolic activity, the 
MTT/MTS assay can be used to monitor mitochondrial activity.24 In particular, changes 
in macrophage phenotype as a function of exposure time, material type or 
functionalization, and concentration can be determined. For nanoparticles, assessment as 
a function of size is also important.  
 
7.3 Conclusions 
 Electrochemical devices are well-suited for tuning to specific biological systems 
and as such, will help to elucidate the complex physiological roles of NO and 
nitrosothiols, potentially providing new diagnostic tools. Induced NO release from 
immune and other cells types is especially of interest, as various triggers and complex 
pathways are involved. Despite knowing little about the exact mechanism of action, many 
hypothesize that NO plays a vital role in disease states related to severe infection and 
inflammation, such as sepsis. Our research provides the first example of direct 
monitoring of endogenous NO levels during the progression of sepsis in two separate 
animal models. The ability to measure NO directly, rather than its metabolites and/or 
byproducts, provides unique real-time information about the circulation of NO, whether 
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via its direct production from cells or recycling in the blood and tissues. As previous 
indirect assays have indicated, NO levels do increase quite significantly in sepsis, and it 
seems that other physiological changes also play an important role in its generation, 
scavenging, recycling, and circulation. Future devices will expand on the versatility of 
such measurements and further enhance the understanding of NO’s role in biology, in 
areas including wound healing, organ transplant, cystic fibrosis, and neurological 
diseases.   
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APPENDIX: CELLULAR NITRIC OXIDE AND CARBON MONOXIDE—
UNDERSTANDING RELEASE FROM PHAGOCYTES AND NEURONS 
 
A.1 Introduction 
Since the realization that the endothelial derived relaxation factor was likely to be 
nitric oxide (NO),1 the pivotal role of this gaseous free radical species has been 
recognized in a number of biological processes including the immune response to 
infection,2-4 vasodilation,5 would healing,6,7 and cancer biology.8 Other biological gasses 
have also been recognized as significant, including oxygen (O2), hydrogen sulfide (H2S), 
and carbon monoxide (CO).9 Much interest in how these gasses interact with one another 
while exerting their individual physiological roles now exists, particularly with respect to 
certain diseases. Both NO and CO are known to impart physiological activity through 
binding to the heme center of soluble guanylyl cyclase (sGC), an enzyme involved in the 
formation of the second messenger cyclic guanosine monophosphate (cGMP). This 
shared target means NO and CO serve similar physiological roles (i.e., vasodilation,10,11 
inflammation,12,13 and neurotransmission14,15). 
Within the innate immune system, NO is produced by specific cells (i.e., 
monocytes/macrophages, neutrophils, eosinophils) via the inducible isoform of nitric 
oxide synthase (iNOS), an enzyme whose expression is regulated by complex cascades of 
cytokines from immune cells.4,16 All isoforms of NOS (i.e., inducible, endothelial, and 
neuronal) produce NO from L-arginine, which is oxidized to produce N-hydroxy-L-
arginine. Further oxidation of this intermediate yields both L-citrulline and NO. 
Stimulation of iNOS by cytokines or components of the bacterial cell wall (e.g., 
lipopolysaccharide or peptidoglycan) initiates NO release for up to 5 d as long as the 
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stimuli remains present and the intracellular L-arginine supply is not depleted.4 When 
released by these cells, NO acts as a signaling molecule and may also have pro-
inflammatory activity or immunosuppressive (i.e., anti-inflammatory) effects, depending 
on the concentration. For example, the presence of bacteria within the body will 
upregulate iNOS production by immune cells, with the NO release killing nearby 
microbial organisms.3,4,17-19 The bactericidal properties of NO are attributed to both 
nitrosative and oxidative stress, caused by toxic byproducts such as dinitrogen trioxide, 
which initiates nitrosation of protein thiols and DNA deamination.20 Nitric oxide may 
also react with superoxide (a radical product of normal cell respiration) to yield 
peroxynitrite, the buildup of which results in lipid peroxidation and membrane damage.21-
23  
Nitric oxide also serves as an anti-inflammatory molecule or immune suppressant, 
providing a mechanism to defend the host from itself. For example, NO has been shown 
to suppress T-helper cell proliferation and cytokine production, thus limiting the chronic 
immune response.24 While neutrophils are stimulated by low NO concentrations, they 
may experience inhibited adhesion to endothelial cells in the presence of elevated NO 
levels, thus hindering their ability to traverse the vascular wall and migrate to local sites 
of infection.25 Further, NO has been observed to inhibit mast cell degranulation.26  
Carbon monoxide, in addition to ferrous iron and biliverdin, is produced by cells 
by the degradation of free heme via heme oxygenase (HO) in the presence of O2 and 
nicotinamide adenine dinucleotide phosphate (NADPH).9 Similar to NOS, three isoforms 
of HO exist, including an inducible form (HO-1) linked to the immune response.27 Unlike 
NO, CO serves a protective role in the immune system as both an anti-inflammatory and 
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anti-oxidative molecule.28 Up-regulation of HO-1 occurs during oxidative stress,29 
suggesting coordinating functions of NO and CO. Additionally, HO-1 is associated with 
the production of superoxide dismutase, which will limit the cytotoxic effects of NO by 
decreasing peroxynitrite formation.30 Increased CO generation can also down regulate 
NO production as CO can bind to and/or degrade the heme active site of NOS.31 
In contrast to the immune system, NO in the nervous system is not produced by 
an inducible NOS isoform. Rather, it is generated by neuronal nitric oxide synthase 
(nNOS), which is triggered by increases in intracellular calcium.32-34 Small, transient 
increases in intracellular calcium concentrations will thus cause short-lived production of 
NO (nM amounts for <10 min).35 Within the central nervous system, NO is involved in 
general neurotransmission, thermal regulation, hormone release, and sleep cycles.36-39 
Nitric oxide is also plays a role in long-term potentiation (i.e., memory formation).40 
Rehder et al. reported the importance of NO in neuronal development, as it regulates the 
extension of neuronal growth cone filopodia.41,42 Nitric oxide produced by nNOS within 
the peripheral nervous system is involved in smooth muscle relaxation.34 Similar to the 
cardiovascular and immune systems, dysfunctional NO production within the nervous 
system can contribute to disease. Inflammation and resulting NO production contributes 
to numerous neurodegenerative diseases, including Alzheimer’s, Parkinson’s, 
amyotrophic lateral sclerosis, and multiple sclerosis.43 
Heme oxygenase-2 is concentrated in the brain and produces CO as a neuronal 
messenger with functions comparable to NO.38 For example, CO is involved with long 
term potentiation in the brain.44 Verma et al. demonstrated the ability of CO to inhibit the 
release of certain endocrine factors, including oxytocin and arginine vasopressin.14 
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Additionally, CO may be linked to circadian rhythm regulation.45 While NO is implicated 
in vasodilation, CO can function as a vasoconstrictor or vasodilator, depending on the 
presence of reactive oxygen species.46 Carbon monoxide has recently been implicated in 
neurological disease, including stroke.47 Cross-talk between NO and CO can occur in the 
same manner as in the immune system and remains misunderstood to date. 
The most common detection strategies for NO and CO analysis from cells and 
tissues involves the measurement of their byproducts. The accumulation of nitrate and 
nitrite from NO released into solution (i.e., culture medium or blood plasma) is easily 
measured using the Griess assay.48 Carbon monoxide production is quantified via 
detection of biliverdin, a byproduct of CO generation by heme oxygenase.49 
Immunohistochemical staining has been used to quantify the upregulation of NOS or HO 
within tissues.50 While only recently gaining in popularity, electrochemical methods offer 
the unique advantage of allowing for the detection of NO and CO directly from its source 
in real time. The first microelectrode for the simultaneous measurement of NO and CO 
was reported by Lee et al. in 2007.51,52 These sensors were used to measure NO and CO 
from brain and kidney tissue. A final goal of my thesis was to measure NO release from 
snail buccal ganglia and quantify both NO and CO simultaneously from cultured 
macrophage cells, further expanding the knowledge of the in vivo relationship between 
NO and CO generation.  
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A.2 Materials and Methods 
A.2.1 Sensor fabrication and characterization 
 A dual amperometric sensor for the simultaneous measurement of NO and CO 
was prepared as described previously.51 Briefly, two platinum (Pt) wires (25 and 75 µm) 
were inserted into the openings of a pulled dual barrel capillary. The tapered region of the 
capillary was then thermally fused. The end of the electrode was polished using 3.0, 1.0, 
0.05 µm diamond paper and then electrochemically cleaned in 0.5 M sulfuring acid using 
cyclic voltammetry (+1.2 to −0.3 V vs. Ag/AgCl). The 75 µm (NO/CO) working 
electrode was platinized in a 1% (v/v) chloroplatinic acid aqueous solution using 
chronocoulometry at −0.1 V vs. Ag/AgCl (2 C cm-2). The surface was further modified 
with the addition of a tin layer, deposited electrochemically at −0.6 V vs. Ag/AgCl in a 
stirred aqueous solution containing 0.01 M tin chloride and 3 M sulfuric acid for 1 h. The 
25 µm (NO) working electrode was platinized in a 3% (v/v) chloroplatinic acid aqueous 
solution using cyclic voltammetry (+0.6 to −0.35 V vs. Ag/AgCl) at a scan rate of 20 mV 
s-1. Single microelectrodes for the measurement of NO alone were fabricated in a similar 
manner utilizing a 50 µm Pt wire. To impart selectivity against common interferents, the 
microsensors were dip-coated sequentially into a (3-aminopropyl)triethoxysilane solution 
(1% v/v in ethanol) and a fluorosilane-based sol, prepared as described previously.53,54 
Briefly, 600 µL absolute ethanol, 120 µL methyltrimethoxysilane, 30 µL 
(heptadecafluoro-1,1,2,2-tetrahydrodecyl)trimethoxysilane, 160 µL distilled water, and 
10 µL 0.5 M hydrochloric acid were added sequentially to a 1.5 mL microcentrifuge tube 
with vigorous mixing between the addition of each component. The sol was then 
vortexed for 1 h prior to use. 
 220 
Sensors were calibrated before and after each measurement using saturated NO 
(1.9 mM) and CO (0.9 mM) solutions, prepared by the deoxygenation of phosphate 
buffered saline (pH 7.4) using argon gas for 30 min, with subsequent purging using either 
NO or CO for another 30 min. All the electrochemical experiments were carried out 
using a scanning electrochemical microscope (SECM, model 900C, CH Instruments; 
Austin, TX). For measurements from cells (cultured macrophages or snail buccal ganglia) 
the electrode was positioned ~50 µm above the surface of the cells. Prior to measurement, 
the electrode was polarized for >1 h (+0.8 and +0.6 V vs. Ag/AgCl for NO and CO 
electrodes, respectively). 
A.2.2 Macrophage cell culture 
  RAW 264.7 murine macrophages (American Type Culture Collection, TIB-71) 
was used for the macrophage experiments. Cells were cultured in 60 × 15 mm 
CellBIND® dishes (Corning Life Sciences; Cornina, NY) at 37  °C under 5% carbon 
dioxide atmosphere in Dulbecco's modified Eagle's medium (DMEM) containing 1.0 
g  L−1 D-glucose and L-glutamine, and supplemented with 10% (v/v) fetal bovine serum, 
100 units mL−1 penicillin, and 100 µg·mL−1 streptomycin. All stimulants were added 
following the growth of a confluent monolayer of cells (~24 h). The addition of 
interferon gamma (IFN-γ, 20 units  mL−1) and lipopolysaccharide (LPS, 50 ng  mL−1) was 
required to induce NO release. For combined NO and CO generation, hemin (20–100 
µM) and NADPH (80 µM) were added 2 h before IFN-γ and LPS. Prior to 
electrochemical measurement, the RAW 264.7 cells were mechanically removed from 
half the culture dish. For lateral scanning experiments, the sensor was traversed from the 
blank side of the dish to the side containing cells. For long-term measurements, the 
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electrode was positioned directly above cells to facilitate continuous measurement from a 
single group of cells. 
A.2.3 Preparation of ganglia and neurons 
 The buccal ganglion from Helisoma trivolvis was dissected as described by Cohan 
et al.55 The snail was deshelled and then anesthetized in a 25% v/v solution of Listerine® 
in saline. After 20 min in the anesthetic solution, the snail was pinned onto a dissecting 
dish. An incision was made on the dorsal side of the snail, from the mid-back region to 
the top between the antennae. Following this incision, the penis was pinned to the side 
and the esophagus cut to expose the buccal mass. The buccal ganglion was then detached 
from the attaching nerves and muscles, and pinned in a separate dish containing saline. 
 
A.3 Results and Discussion 
A.3.1 Nitric oxide and carbon monoxide from macrophages 
 As NO and CO both serve important roles in the immune response, cultured 
macrophage cells were used to study the dynamics of their release following stimulation 
with LPS and IFN-γ or hemin. To establish the time course of NO and CO release, the 
dual electrochemical microelectrode was positioned ~50 µm above a confluent 
monolayer of cells for 18 h. As shown in Figure A.1, NO production peaked ~13 h 
following stimulation with LPS and IFN-γ, increasing 170 nM from baseline 
concentrations. A lateral scan of blank and LPS/IFN-γ stimulated macrophage cells   
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Figure A.1 Release profiles of NO (black) and CO (blue) following stimulation with 
LPS/ IFN-γ and hemin/NADPH, respectively. Basal concentrations of NO and CO prior 
to stimulation were below the limit of detection. 
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revealed similarly elevated NO concentrations following a 15 h incubation period (Figure 
A.2). Carbon monoxide levels did not increase after stimulation with LPS and IFN-γ, as a 
source of heme is required and was not present in the media. In the presence of hemin (20 
µM) and NADPH (80 µM), CO generation was promoted, peaking much earlier than NO, 
with an increase of 580 nM relative to baseline levels observed at ~5 h (Figure A.1). 
Carbon monoxide generation from macrophage cells was also examined as a 
function of hemin concentration. Cells were incubated overnight (~18 h), with 20, 50, 
and 100 µM hemin (and 80 µM NADPH) in DMEM with LPS/IFN-γ. Following the 
incubation period, the media was replaced with fresh PBS and a constant-distance lateral 
scan was performed across the cell dish. While the increase in CO generation between 20 
and 50 µM hemin was minimal (Figure A.3), 100 µM hemin caused CO levels to increase 
by ~1 µM. In all cases, NO generation was suppressed to non-detectable levels. Others 
have observed similar decreases in NO generation upon upregulation of HO-1, although 
via indirect measurement of these analytes (i.e., nitrite and biliverdin for NO and CO, 
respectively).56 
 These results demonstrate the cross-talk phenomena between NO and CO. 
Common immune stimulants, such as LPS and IFN-γ, seemed to shift the macrophages 
toward a pro-inflammatory (M1) phenotype, resulting in the generation of large quantities 
of NO over many hours. Amatore et al. have demonstrated that these cells also release 
other reactive oxygen and nitrogen species.57-60 While in this pro-inflammatory state and 
without a source of heme, CO generation was extremely limited due to down-regulation 
of HO-1. Conversely, the presence of hemin resulted in enhanced CO production with 
concomitant suppression of NO generation. In addition to its involvement in the   
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Figure A.2 Nitric oxide release from unstimulated (black) macrophage cells and those 
stimulated with LPS and IFN-γ (red). Nitric oxide concentrations from unstimulated cells 
were undetectable and thus considered to be zero. Dashed red line indicates barrier 
between blank dish and cultured cells. 
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Figure A.3 Carbon monoxide release from macrophage cells incubated with 20 
(black), 50 (red) and 100 µM (blue) hemin and LPS/IFN-γ for ~18 h. Dashed red line 
indicates barrier between blank dish and cultured cells. Release of CO was not measured 
from the blank side of the dish. 
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production of superoxide dismutase,30 HO plays a role in the degradation of free heme 
(often from lysed red blood cells).61 During a severe bacterial infection (sepsis) where 
hemolysis and extreme upregulation of NO are common,62 the down-regulation of heme 
oxygenase may prove detrimental. Indeed, increased concentrations of free heme in the 
blood have been associated with poor patient outcomes.63 Future experiments should 
include the study of NO release as a function of duration of CO upregulation (i.e., 
preincubation with hemin/NADPH at varied intervals prior to iNOS stimulation to 
determine if extended exposure to CO will inhibit immune stimulation of NO to a greater 
extent. In addition, HO and NOS inhibitors (e.g., zinc deuteroporphyrin 2,4-bis 
glycol and 1400-W, respectively) should be utilized. 
A.3.2 Nitric oxide release from buccal ganglia 
 Helisoma trivolvis snail ganglia and neurons were utilized in a subsequent study 
due to their size (up to 100 µm) and the ease at which they can be cultured.55 Little is 
known about rate and concentration of NO released from these cell bodies and how NO 
rates/levels may affect neighboring neurons. Microelectrodes offer the spatial and 
temporal resolution required to examine NO release from such systems. As nNOS is 
dependent on transient increases in intracellular calcium, potassium chloride (KCl, 17 
mM) was added to the surgically extracted ganglia at varying intervals to cause 
membrane depolarization. As shown in Figure A.4, the subsequent calcium influx 
resulted in rapid and short-lived NO release. The addition of sodium chloride (17 mM) 
resulted in no detectable signal change, indicating that this effect is not the result of a 
change in ionic strength. The use of a selective nNOS inhibitor (7-nitroindazole (7-NI),   
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Figure A.4 Nitric oxide release from a H. trivolvis buccal ganglia following 
stimulation with 17 mM KCl. Nitric oxide concentrations prior to stimulation were 
undetectable. Signal returns to baseline after ~10 min. 
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400 µM, 30 min incubation), resulted in a significant reduction (of ~40%) in NO 
generation following stimulation with KCl (Table A.1). 
To date, dual NO/CO measurements from ganglia have been challenging due to 
irreproducible placement of the dual electrode system. Buccal ganglia are bundles of 
nerve cells with specific locations, so care must be taken to place the electrodes in an 
identical manner across experiments. While this problem may be minimized by using 
SECM to scan the entire ganglia, the transient release of NO and CO following 
stimulation would make timing of the measurement challenging. We predict that the 
cross-talk between NO and CO in this system would be similar to macrophage cells, with 
inhibition of one resulting in the upregulated production of the other. Future experiments 
should study the effects of specific inhibitors such as 7-nitroindazole (a nNOS inhibitor) 
and zinc deuteroporphyrin 2,4-bis glycol (ZnBG, a HO inhibitor). 
 
A.4 Summary 
 The spatial and temporal resolution enabled by using microelectrodes allows for 
the measurement of NO and CO from cell systems. The results presented herein represent 
the first simultaneous direct measurement of NO and CO from cultured macrophage 
cells, and suggest that upregulation of CO generation may prevent pro-inflammatory 
macrophage polarization. In addition, a NO sensor was used to determine NO-release 
kinetics and concentration from extracted snail buccal ganglia, indicating the transient 
release of NO from nNOS relative to iNOS.  
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Table A.1 Nitric oxide concentrations released from H. trivolvis buccal ganglia 
following stimulation with 17 mM KCl with and without 7-nitroindazole inhibition. Data 
are presented as average ± standard error of the mean. 
 
 
Stimulation NO concentration (nM) n 
KCl 435 ± 77 8 
NaCl no detectable signal 8 
KCl after 7-NI incubation 272 ± 91 4 
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